var title_f39_3_39984="Fistulotomy";
var content_f39_3_39984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fistulotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The treatment for a mammary duct fistula is surgical, by means of excising or unroofing the fistula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39984=[""].join("\n");
var outline_f39_3_39984=null;
var title_f39_3_39985="Robot-assisted rad hyst 2";
var content_f39_3_39985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/71473/Div_right_uter_art_conv.mp4?title=Robot-assisted+rad+hyst+2\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Division of the right uterine artery during robot-assisted radical hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Colleen M Feltmate, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39985=[""].join("\n");
var outline_f39_3_39985=null;
var title_f39_3_39986="HAT in endemic and nonendemic populations";
var content_f39_3_39986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    HAT in endemic and non-endemic populations (traveler)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 572px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In 14 patients, more than one country was estimated to be country of infection: Kenya or Tanzania: 7; Cameroon or Congo: 2; Nigeria or Gabon: 1; Zambia or Botswana: 1; Zambia, Zimbabwe, or Tanzania: 1; Namibia, Mozambique, or Malawi: 1; East Africa: 1 (these patients are not counted in the figure). The black line divides the endemic regions of T.b. gambiense and T.b. rhodesiense HAT.",
"    <div class=\"footnotes\">",
"     HAT: human African trypanosomiasis.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - Do they really sleep? PLoS Negl Trop Dis 2011; 5:e1358. Copyright &copy; 2011 Public Library of Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39986=[""].join("\n");
var outline_f39_3_39986=null;
var title_f39_3_39987="Nepafenac: Drug information";
var content_f39_3_39987=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nepafenac: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/5/26708?source=see_link\">",
"    see \"Nepafenac: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1615798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ilevro&trade;;",
"     </li>",
"     <li>",
"      Nevanac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6859683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nevanac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F1615821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F1615844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pain, inflammation associated with cataract surgery:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ilevro&trade;: Instill 1 drop into affected eye(s) once daily, beginning 1 day prior to surgery, the day of surgery, and through the first 2 weeks of the postoperative period. Instill 1 additional drop  30-120 minutes prior to surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevanac&reg;: Instill 1 drop into affected eye(s) 3 times/day, beginning 1 day prior to surgery, the day of surgery, and through the first 2 weeks of the postoperative period",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F1615843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pain, inflammation associated with cataract surgery:",
"     </b>",
"     Ophthalmic: Children &ge;10 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F1671877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16055899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16055900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1615847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ilevro&trade;: 0.3% (1.7 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nevanac&reg;: 0.1% (3 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1615799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15853319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ilevro&trade; 0.3% ophthalmic suspension: FDA approved December 2012; availability anticipated in January 2013. Consult prescribing information for additional detail.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1615845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical ophthalmic use only; shake well prior to use. Remove contact lenses prior to using solutions containing benzalkonium chloride. To avoid contamination, do not touch tip of container to any surface. May be administered with other eye drops; wait at least 5 minutes before administering other eye drops.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1615822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pain and inflammation associated with cataract surgery",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F1615832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Hypertension (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea (1% to 4%), vomiting (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Capsular opacity (5% to 10%), foreign body sensation (5% to 10%), intraocular pressure increased (5% to 10%), sticky sensation (5% to 10%), visual acuity decreased (5% to 10%), conjunctival edema (1% to 5%), corneal edema (1% to 5%), dry eye (1% to 5%), lid margin crusting (1% to 5%), ocular discomfort (1% to 5%), ocular hyperemia (1% to 5%), ocular pain (1% to 5%), ocular pruritus (1% to 5%), photophobia (1% to 5%), tearing (1% to 5%), vitreous detachment (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Sinusitis (1% to 4%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1615827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nepafenac, other NSAIDs, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1615828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin/NSAID sensitivity: Use with caution in patients with previous sensitivity to acetylsalicylic acid and phenylacetic acid derivatives, including patients who experience bronchospasm, asthma, rhinitis, or urticaria following NSAID or aspirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Keratitis: May cause keratitis; continued use in a patient with keratitis may cause severe corneal adverse reactions, potentially resulting in loss of vision. Immediately discontinue use in patients with evidence of corneal epithelial damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a predisposition to bleeding (bleeding tendencies or medications which interfere with coagulation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may be at risk of corneal adverse events, potentially resulting in loss of vision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, ocular surface disease, or repeat ocular surgeries (within a short timeframe); may be at risk of corneal adverse events, potentially resulting in loss of vision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may be at risk of corneal adverse events, potentially resulting in loss of vision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery patients: May slow/delay healing or prolong bleeding time following surgery. Increased intraocular bleeding (including hyphema) has been reported. To minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lenses: May contain benzalkonium chloride which may be absorbed by soft contact lenses; contact lenses should not be worn during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: Use for more than 1 day prior to surgery or for 14 days beyond surgery may increase risk and severity of corneal adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Latanoprost: NSAID (Ophthalmic) may diminish the therapeutic effect of Latanoprost.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F1615823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1615824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events were not observed in animal reproduction studies. Exposure to nonsteroidal anti-inflammatory drugs late in pregnancy may lead to premature closure of the ductus arteriosus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F1615826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16055552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     It is not known if nepafenac is excreted in breast milk; the manufacturer recommends that caution be exercised when administering to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Ilevro Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3% (1.7 mL): $173.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Nevanac Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (3 mL): $173.40",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Nevanac (AR, BR, CH, CN, CO, CR, CZ, DK, EE, GB, GR, GT, HK, HN, IE, IL, IN, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, SE, SG, SV, TH, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1615837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nepafenac is a prodrug which once converted to amfenac inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1615839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Low levels (0.2-0.5 ng/mL [Nevanac&reg;]; 0.6-1.6 ng/mL [Ilevro&trade;]) of nepafenac and amfenac are detected in the plasma following ophthalmic administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hydrolyzed in ocular tissue to amfenac (active)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9468 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39987=[""].join("\n");
var outline_f39_3_39987=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615798\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6859683\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615821\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615844\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615843\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1671877\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055899\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055900\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615847\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615799\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15853319\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615845\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615822\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615832\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615827\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615828\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299757\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221887\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615823\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615824\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615826\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16055552\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422161\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539961\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615837\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615839\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9468\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9468|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/5/26708?source=related_link\">",
"      Nepafenac: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_3_39988="Longitudinal view";
var content_f39_3_39988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Longitudinal view of a second metacarpophalangeal joint showing various anatomical structures in a standard scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5p1qR/wC2b752/wBe/f8A2jVLzH/vt+dWtb/5DN9/13f/ANCNU6AHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTaKAHeY/99vzo8x/77fnTa7Xwh8Nde8WaIuqaU2nrbyXp06Jbm6WFprjYHEaBupKnjnsaAOM8x/77fnR5j/32/OtG50DV7WOaS40u9SKJnR5DA2xSjbGG7GOGIB9zipbrwvr9pcwW93oeqwXE6GWKKW0kVpEAyWUEZIA5yKAMnzH/AL7fnR5j/wB9vzrXsfDd/dWF3ePG9tBBam7RpoZcToGC/IVQjqepIX3zxUkXg/xNKsLReHdZdZnEcRWxlIkYruCr8vJ284HbmgDE8x/77fnR5j/32/Otaz8LeIL22u7iz0LVbi3tHaO5lis5HWFl5ZXIGFI7g9Kk8QeGb3Q7PQ7m6eCVdYtBeW6wliyoXZcMCB82VPAz9aAMXzH/AL7fnR5j/wB9vzrptY8AeKdJ1uDSLnQ799RniE0UMELStIpUN8u0HOAwzjoeDWA9heJqP2BrS4W/8zyfsxjIk8zONm3Gd2eMdaAIPMf++350eY/99vzrVuPDGvW01rFcaJqkUt0GaBHtJFaYKMsUBHzAAHOOlFv4Y165N0LfRNUlNoiyXHl2kjeSpG4M+B8oI5BPbmgDK8x/77fnR5j/AN9vzrp7jwHr0fhLS/EdvZyXmm38U8261ikkNskUhjYzELhASDg5PHpWSfD+sjSE1U6TqA0t2CLeG2fyWYnGA+NpOeMZoAzvMf8Avt+dHmP/AH2/OppbC7hvzYzWtxHehxH9naMiTcei7cZzz0rSvfCniKxvYrO90DVra7mVnjgms5Ed1XliFIyQO5HSgDH8x/77fnR5j/32/Ouo034e+LNQub62h0HUI7mys/t0sM8DRP5WcAqrAFiT0A5ODjoayG0DWV0dtWbSdQGlK2w3htn8kNnGN+Nuc8YzQBneY/8Afb86PMf++351u23hLVnW+N5az6f9ktpbki7tpl8wRlAyrhDhvnX72FGeSMjNO48Pa1bWtlc3GkajFbXpC2sr2zqlwT0CEjDE+2aAM7zH/vt+dHmP/fb86sahp17p0ix6hZ3NpI2cLPE0ZOCQeCOxBH1FbHiTwfqmgXhtLlUuLqK1juruK2V3NkHAIWY7QFYArnBIGQM54oA5/wAx/wC+350eY/8Afb861bTwvr95cTQWeh6pPPDGJpY4rSR2RCMhmAGQpHIJ4q9H4K1mfQdG1SxgN6NWuJ7a2tLVHkuC8QBfKBemDngnoc4oA5zzH/vt+dHmP/fb861JvDOvQ3s1nNomqR3kIVpYHtJBIgY4UsuMjJ4GetTah4YvbLwxZ66ZIJbKe5ks5Fj3eZbToAfLlDKMEqcjGQQDzkEUAYvmP/fb86PMf++3502igB3mP/fb86PMf++3502igB3mP/fb86PMf++3502igB3mP/fb86PMf++3502igB3mP/fb86PMf++3502igB3mP/fb86PMf++3502igB3mP/fb86PMf++3502igB3mP/fb86PMf++3502igB3mP/fb86PMf++3502igCSOR/MX526jvX37k+pr8/4/9Yv1FfoBQB8Fa3/yGb7/AK7v/wChGqdXNb/5DN9/13f/ANCNU6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooIx1oAK9M8IfFB/Cfw2GiaVaRtraa2dUiurm3SaOFfIEYKBukgYZBxjGa8zooA9KHxPuYfD/g20ga9kuNI1C41DUI5JcQ37POkyBgD83KtncP4uK3734q6JJqulSW8Wvi1t9cn1+aWSZDcCR1GLeNs4EWRyTyQTxXi1FAHr2v/FLTNXuvEd99hvoLjWtCTTDaqVMFrIjoR5XOREQmduMhieua0L740QyprCWw1eJLoaQtuolAEItf9cOG439sde9eI0UAfQPhv40+GNK8SX2sPo2orPPq9zfkpHDIZYpQAFJfPlkYGdmN2OT2ryrxp4mt9d0rwpbWsM0Umj6aLKVnxh3EjtuXB6fMOtcnRQB7VqPxY0fUr+9luodcSPVdHi028aOVN9s8fl/NASeVYxncDjOR6VgN4ytPEPx30LxJMn2CwTU7Dc9xICyxQtGvmSP0Jwm4n/CvNKKAPfpfi5omheLLZdOj1W/srPV9R1KW6llRnaSaGSFVgwcCMbg2Scnriuc8B/FaDSNNs08QrrF5fWGq/wBrQzwXIzdP5SxiOctztAUDdzxkYrySigD2nQfi1pGm6BoRkstUOr6RBqMcdtCyJZTNdSSH5xncVUP0x1FM1H4t2GoeC4dM+z6hZXg0yDTJo7eK3MUqxY2t5jLvXpnaOh6GvGaKAOsvPEGmy/Eoa9JFqWoaYL5Llo724/0mZFIJDSL/ABHHUV6lc/GnQkvNEksLDUkj00aiExDBAVFxFsQKIyB8p6k5J65JrwGigD2fQ/i5Zw6bp9lqo1p8aBc6NdXMMqmXfJMJElQs3O0DbyRjJxTL/wCLNheeA00hbe/tL1NIGjsIord4p0X7rs7LvXPBIHfkEZzXjdFAHsGv/FqHVvGPjfU5V1STTtZ0ibTrC2lkDfZWk8nJxuwq/ujnb7Vc1j4w6XezTXUWnaiLjUdQ069vIZZVaG1Frj5bYdfmx3xgcV4nRQB0vjnxTP4m8balrUkt1Nby3ss9rFdyFzFE0hdY+pAABxgceld9qXjLSdG+MGp+IjJ/a/hrxHay/bLaCUeb5M6fPC4z8ro4HB7KCOteOUUAe02XxgsrnV9WudbtdSjjm1yDWrVtPlVHxCpSO3kz/Bs2jI6EcCobD4qaJLJpkms6LcSeTqGp30scJXZGbsfLsBIDheQVbAI/KvG6WgD27xJ8ZLO8i1I6RHqlpdz6BbaTDcoI4GWSK4aRnxEQFUq2MKB6YxXFzahbWXwiewlvY7rVdY1Zb1oVkDtBFDG67n9HdpDwecLnvXC0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUALH/rF+or9AK/P+P/WL9RX6AUAfL+q/Czfql05F+A0rsfmT1PtVN/hYBgomosO+GTj9K7ibxFd/aLgLqceRKw2v160weK7mAqDOjY6gGgbVmef33wyuI0H2S2v3bPO90xj8qrw/DLUjJmW3uBF6Bl3V6NP44k2bRhTnjLVA/i69YFnG4HujdaBHDp8NZtrB7TUd/wDDh0wf0qxb/DFjbqZ7bU1mxyqtHgH8q6VvHF7BLukVRBju3zfzpp8fb5FkjmuVx+IoA5qz+GMhjb7Zb6kHzx5bJjH4imy/DdFJ2wao3/Ao/wDCuxl8dahJGslvNtQdmHWpIfHOqXIIjMQPc4oA4eT4cHCiK01Vmzz80fT8qgm+HFyXAitb9B/00KHP5Cu/i8X3qTMsjuzY6U5vFN4TvkmkYD+EDkUAeeH4a6h5gH2a629zlamsPhpePOy3tnfpH1V0dOR+IrvV8eNHGB9pUEdnHNMHxBuI3DRyiZjz5Z7j2oA5ab4Y2iRMyjVSwHA3R/8AxNUY/hyjt/qtTUehKZ/lXbt8VbsbvL0klz3K8VFB8Q9Tkk3yWiFT2H8qAONn+GkpC/ZINQcnruZMD9Ki/wCFYaj5gBgudnc5WvQh44u5W/fWssCjoyDpUE3i2dmxFekE/wAL8UAcI/w1ulD4hvGYfdAK/rxV1fhkjWMBW21b7UWbzfmj2be2OM59c11f9t3iLvGrwqzcle9SR+ItSmAEOoIB3zxxQBxcnwxmDgJa6lj1Lx/4VCvw1uFl/fWt+IvUOmR+ld1c+JdShKgamrZ7DmoNO8Sag128U1wHXGQSaAOUi+HNqwbeuqcHs0f+FVz8P4PNdBHqnHTlOf0rs5/ENyXkWG7CYySKw4fGeoeYd8rnccZAoAwZ/hze9YLS9Kd9zJn+VRv4GWIqs8d+pPuh/pXV3Pi7VvlEdxmIjBGPmoh1iaVEUX7s5PccigDlT8Pbx5tkFpesCNwYug/pVq2+G05YLc2moDPdHTH8q6Zte1K1i2LeuzE8N6VYsPE2sW4YyTJcSH7oPSgDE/4VlpsaZnfVlbqQDGeP++ao3PgPRhLEILjUyhHzl9nB9vlrtbnxLq5A863VlxkmLnj0qK01aS9LB5IYUHG1gNwoA48/DeCdR9ilvN2efMK9PwFQwfDS5NwyzJcGIdCjpk/pXUXk17aSK1lqWYyfu1INZvg2LmcKvZkOKAObPwyZlYRxagr9t7Jj+VQr8K9TUkSRSn02uvSunh8R6gsgEFzlCcZkPX6Vfk16+XY32gM5H3Q1AHFj4aTdGtdRDf78eD+lMj+FupySZW3nEXqZEzXZprOsF8tfRJE3ARm5FPS+vbcl5NRdd3cNxQBy5+FMog3iO+dh94Bk/wAKh/4VNqUsW6C3ud3ZXkTp+AruItefbsm1jzPXyz0qnqniK2to8RateRy9mznNAHIx/Cy8iz9vtb5P7vluhz+lWYPhWJkHF+j56MydPyresfFWoOQv2/zoz/q8tlvxq5PrWoSZR7gpxkFW5BoA53/hUPX5r3Hb505/Ss+4+F1xDMUNvfn0+ZP8K7Gy1hxG7S6tM8o6qT0psviTVhIV06/WVzx856CgDmrb4TtNbqWW/SYE7svHtx2xxVW++FV9AuYILqQdB+8Qf0rrLnxBq0VvumvUWVeuG61FY+MWeTy7m/mU+npQByUfwwvdoMlvdhu6h0z/ACrStPhIZIwZ5LqN/QOnH6V0dz4gtoUZ/wC0p3YnI2tz+VRQ+J7ZmBuNQmWZv4QeKAMaX4RKgysl4/0dP8KhX4VRiQb3vmQ/3SmR+ldI/iBLciSO8llXOMbs1WuvFTRSKVkuAeoweDQBiXHwxsUjJjfUy3TLGPH8qpwfC64mchUusfwnenzfpXRzeJr1EDzuRETnGeaJfElxMm+1uHUL3BxQBjyfCdoo/wB4l+JfTcmP5VGvwtVjGA90CfvZdOP0rprLxHfyfcvWaQjGJTxVn+1r6TK3aRoO7xtQByz/AAqgRSTJfE+zJ/hVSf4XymNvsqXry54VmQZH5V3ces3KxfuL+DaOgkPQ1S+33zSNJLrcYDcsyHAX6UAciPhXOVUMLpX/AIslSB+lTD4S3GPu3RHqHT/CtmTXpI2LQ61NO3Q06z8SXylpftzrAODk5JNAHPR/C2dQTPBfEZ48t05/MVJL8LHMO62h1CST+4XjGP0roD4i1KaVVtbxpST27VLea3rIGJJpY1HVl6mgDmF+E98eTDcqP+uif4VAPhXqG7DRXCfV1OR+FdIPE80MLLJfXcr99v8ADTF8RzPDltQut3YN1oAwG+Fl2yP5Rm3fwhsc1WHw1vo8Ga0vCOh2OgP4cV0lv4tZQYjcXYPctxitK38ZTwqP9KWRB3c80AcqnwxaUKYbfUGJ+8PMjGP0q0vwmJjLH7cmP7zIf6VtXPi6SUl42fJ7o2KW38WPt2u1ynruOQaAOd/4VPd5R4nkZc/MNy5/CvsH+zG9H/MV8yv4y8gJuLMnqD0r6i+3D1NAHxzdW1nHqF35ZEkomfhj15NUp7mAy7dixueOp5rT1LSbw6heG5MEKmZyGHUDJrMeDyAd7wzQ9zj5h9KAM27urNZGja4g3jrl+h9KSzksmAafV4Y/RFfpXJajt+33Hl5KeYcZ9M1XoA7m5utGiGRcR3Td8yYzVV9QtpSBBcW8EX91n5FchRQB1x1cK25rqB9v8IPBqxDr0CRszSwoG/hRsmuJooA7ePXLOZ8faDEf77tUkeuQIzK2orn++OeK4SigDuUuNGeYy3GoJIP7pGKureaOyZOpWyAfd9VHpXnNHagD0GLxHaWyGGOaJsdJC3Bqu99ZzXImbVY4iOy1w1FAHfvqsCsXOtoynqgpU1fT3xm5tjzyZGwa8/ooA9GvNW0WOMbJbeWTHBUniq6atYzyB5r6JMdhxXA0UAegR6tA8rJZzQyyscKp5J+lTaWVMr3Fy2xx/BmuJ8PEjWrUqwU7jye3BruUht/OeViZZT27UATy3m6UmGBNhH3j1qrukmXPmrHg/wB0c1KbohhvjRFHYLT2gFyQYpURhyFIxQBlT3eJMSXCBh8oAXrTEka2y5ulUnrgdasmyu1uGM1vbEZ4bvS3cJimSWaGBoV5oAfBKceaJWY9g3Q1VS5k+0tOrsdv3l7UrXCSvutkby/RhjFLaq8ry4mhTPQGgC/Jr93FbAwH5ScYPNV4Y766LzCECR+Q5OKa2nXJxIkkG4Hj5qVtQmjUw3JJlPH7scUAWY4tQSJlmKKByWBHAqC4ytsWa7SXH3UU8mqgjnGWkkl2Hqu7qKWOTT8r5FrMsw4BfoaAI/tUiMPOhO0cqCavW7/bZFZHFvIvfPBpszCaPawhJ9O9ZsIxdiJgxj77aANa+V0lVZ1Eqn7sgbmrBXzIdi3W3H8D1jXXlrc4WRlT0c9K0bKFdufK+1g/xA9KAKVxburP5UaFz08s5zS26tbgPP8Avs9Y3XoavzQyR3Ea2lu8BPU9cVPKhjA3Hcf4s9c0AZhmtkuQ6wvbSdjng0lwbgS+e0jyMe6ngCtRHkbiO3juYh94MBkfSn+Tp7ffiuIJP+ea8igDIVUuWBluHU/7I5qNoEgf5bqeNj3x1rXh0xvtAntGESj+GQcmrskLqMX0QuSenlr0oAxTawLbl7gTzFvunNVROsB2pasrH+N+eK247aSWUxu7QQ9g3arElnDBbuXuBOpHKnrQBhwLaB/OeNi/d1+6KmiW03nA+0O3c8bas21pFOQrb4o+0Y71rLp8ToBFEMjoVHNAHN3D2FhFuhmVZGbnzDwDUEmv24cLNJDKPVG4FVvGtrJa2kSzBEYykhf4sY61yFAHYvf6fMjf6UFOeFZqWxurNm23GpxxbemDw1caRjGSOfQ0YzQB3p1axEv7y7hdRwMNili1Ww+cC+RQezSHFcDRQB2txrNqY9kT22AepfrVWTVrcOu2SN1/iGeK5SigDrn1u06xJFE3oDxUUGrJDIzi4jfPOw9K5aigDsrbxDtl3rcRQeu2rs3jCZSAl5DKvT5q4CigDvE8UmJd0c1puPJ4602Txc8i4kWzz2ZeorhaKAO6tdcsJpyb+ZHJ7ngUuoXWit80V3CP9lSTXCUUAdctzpm3P23B/u54pW1O1mIU3YCjuWrkKKAO3s7eG5ffbajGRuGR1xX2x5Z/56LXwf4XEZEhkgkl+cfc7V934X+41AHx7d4uNUu/td06EzP945B5NR3lnDbIzwyec/rjgVPdBl1O/iECohnf95Ie2e1U7qSKBPKt5FlT+IZoA4K+JN5OT13nOKhqe+x9tnwMDeagoA9Q8U/DWP8A4WfofhLwzIwfUrO2mD3b5Cs8e9ySB0GCcYzXR+G/hFolp4othr2tw3+kvp15fCONXikLQAblkVSWVcMGBBywBA5rgr/4p+Mb+GyS41ZN1m0TW8sdnBHLGY/uYkVA/Hpnnvmq918R/FFzefanv7dJ/Inty0NjbxbkmAEuQqAEsAPmPPvQBsfEvwl4e0Xwz4b1vQtSkeXWUknNkyOVjTzHHyMyg7VwE+YlieelaWnfCOU+HNC159RjvYr+S0JhggeSFRNKqeXJMh+RwG+YEDB4BJxngL7xPq9/4bsNBvLpZdLsXL20bQx74iSxIEm3ftyxO3dj24FdBJ418Z6f4d0lBfxQabIIzbGKC3DyC3cBBIyrvYKyjAkJBwOooA7fwt8JtMm8cxr4jvIbfTJ/EF1pNrp8CyO1x5LEPiTIKKOACSSf1rE/4VBcP4Wl1uTV7O0eS2nvrWzlB/eRRswCmQnAdtp2jBzxkjNc/pfxS8Y6XcXU9lq6rLcXr6i7SWkEm24f78ibkOwnPIXA9qXw54p8ZarHb+F9IuFvPtLSRW9vJbQSOpkyXWN3XdHnJ+6w60AN8D+B18R6Xc6nf6tDpWnRXcNgkrQtM0k8udq7V6AAEk9uwNdN4i8C6N4T+Ft9d6syXPin+159MGHkCQmJgCEwArZHzZbjDADBBrkPA+v+KdD1VtM8KzOt5ezxxfZfIjnEkqt8hCurAMCeGHI9ap+Ida157efQtZvDNHBfzXciMUkP2l+JHMgyWJx/eIoA6vwj8K38RaX4enXXLW1vNf8AtaafavA7eZJb9VZxwoPr9ODzh1l8KJby68L2UfiDTxqev2kd/DaNFLuigKyM8jNt24URNwDknt3qlbfFDWNO8D6N4e0MDT3sRdrLeKEeSVZ2BIQlN0WACCVbJz2xXPnxhr/9paLqC6lJHe6Nbx2thNGqo0MSFiq8AbvvN97JIODkUAeieGvhhpDwajf3uqJfaFceHbvUtPv1ikiMUsM8cTF4s5O0luMkHIqKz+CdzcXlzI2u2y6KlraXcN8IGLTJcgmP92SNuArFsnjHGc4rn4PHnjYef4hiv4PKSD+yXBtbbylidvMMYtyu0AlckhO3J5pfD/i/x3rXiS/k0q9a91G/gzcwSQQvDJFCpYAxOvl4RQSAF45xQBi+KPC8Xh9L6OXWbC5vrXUXsTbW7Fi8aqGE6t02HOPXIrmq63xPqfimTw9aRa24/sfVLl9Wt9kcQjll2iJmUoOCAoUpxt/uiuSoA0PD4jbWbUTf6st835GvRBKQSmnwAAfxN0rzXTC4v4TEu593A9eK6oz3Pmj7VDKqf3VyAaANKbVLm3nCiKCZ/wC8Oi+1WWuNQvUU+RbYzyAahhtjdKohhRYO4z81OuNMjZlCs0QU569aAGSFXPIRZk4IzVe9a3kUsGXzeyE1bdLSCMq0kaMe+eTVF7KB0ZhAz/8ATQHigCs15NG6tdWu2LGPl6Gnvd6U2PMgbI7A1B5d2rbCVMZ4AznFS/YbVIgbmcRuP1oALI2pkMywS7egUHNXJEinG9rgWyjoMc1nQSRw7jbTEn0I606ybzJ2M6ESnpkcUAJcN5cubaZ5W96Ibm6YkSI02egIq/IRG6tJsD9sVbezgmRZrm7cNj5ViHIoAw5ZHdAv2ERDP3z2oVbmHGAzIf44+a1ZdOvZkAtzvg/uvwTU9jbXVqCbWJo3H3o35GaAMuBkU5eJbpu6sORWtFb2Qi8wTPZE8kIeBUE091dXQhu4UtkPWRFx+tWWs9Mt4iI78u55IPNAFJ76AO0ceoT5H8WPv1at4yQHmRzEesjdatWV0sMQEb2Zb+ENjNRvJJeSlZJ4twPCqeKAJksNJnJP22SGQeneo9QtLy0jzY3YlHXLdaRofNPlXE1tbAfxk8mlg0mCBxJa6ilw45xuFAFKNXkWNp7mRbtum4cCtuO4ls4VWMPNLj+EcVXu5BwLjbHjuelVYtUdSUivYcdyOwoAkvtTvoxm4jiCHu3UVnJfNdXJ8sRoyjOR0rQS3Fx81xG8sZ/5aKMimQ2trFceXbwuwPIdhwaAIhPcXY2wTiOZeue9aEVwY40Vb5bZx1xzUVzpt7OQEe1gj9S2DWcluum3BMsyMD0brQBjeObqS88mSWQylWK78YzXJ12XjS9kudNt0aW3ZRISBH97p3rjSent7UAek/BHwXYeM77xBFqFtc3cljpzXVvbQXaWpmlDqoQyOCqg5xk1t+Lvhppun3/jmy0ENcHSF05VF3K3mwTTyqjRqVCo4y2NxGMdOea8w0PxDqmhQalDpV15EepWzWd0PLVvMiYglcsDjoORg+9bGrfEXxVq0F7FqGqmYXsEFvcv5ESySpA++Lc4UMSrc7s7j3JoA73Sfg9ZW3iexgvdZg1S2t9cttH1O3hiki2ySAllVyeQNpG7irGh/BzQ9S8UacP+EkE+h3tzf2p+ywvHLFNBG0nlgyKcjAzuI5CkdSKg1H4sa94wn0rR/COlSW+stqUV9HPLNDPNLPGpCc+VGp65JcMTgZNcUvirxn4bTS50v/soW7n1G1KrC5Ez5jlYgAnkArtbjHbmgCn4R8JReKPGo0Kx1i0jhYyGO8mUoJVUE/KjYJY44U4/Cu1l+EN1FDqWnQbZdRW/sLSGa8hltXQ3BYfcOVK8ct83TjvXB6frHiGwvLjxTaQ7Fmla3luvsEbWxkcbjFsKGIEgZCY6DgcVtaX4t8d+K9aTTNNv5rrUL2eCWKGKOKPD24Ji8vgCMINxCrge1AHYn4RabqWj6PZeHdUjvNTm1e8s7nUZI5Io1jghDsAhJzjDYI65HSvPviJ4N/4Q+8sY01KDUYLyDzkdF2OhBIKOmTtIx6nIIrTtvH/j3xJrmk21hqEkuqJeNNZpZ2sMLefINrN8iLncM7t3BySe9c54v1zV9Z1DZrklq09oWiC2tvBDGpz82BCoU89+c+tAHoA+DgttUW0vdegeWxvrKz1mGKBwbU3P3NjHiTn5ScDB9RWV4v8ACmlX3xnPhDwp5dnbfbhpqyM0jgSByrM2/nIPBxxxxWJefEbxXe29lDc6u8iWk0NxGfJjDPJFxG0jBcylQBjeWqtoHi260/4hWni3UI/t97HqH9ozrkRedIX3tyFwuST0GB6UAdlafB6TUJrD+zfENlPazyXlvNO8EkYgmtkLupBGWUr0YD8Kh0P4URazHaNaeKLFhqd1JZaU4tpgt3LHGGfO4AxrltoJGSe2OareIfG/jgPpPiGac2VhdpeLpYSGARiN2McwCKoBbkqXZdx65rO8H+IPGmleGNUk8N3ckOj2UqNcSbYj9mkmBjVkZxujZgpG5CDxyaAOr1L4YafeeHNFk0u+Sz1t/D8mrT2cqu/2kxO/mEP91DtXAHQkHOOtUfEvwfuPDugNf6hrtgl1B9mN3aspXy1mK4KNn94V3ruAAxzjOKyNc8W+ONB05vCmqXX2SCOzW08pbeAObZ/nCCZV3NGwbPDEEHvWdc/EPxPdadBZXOopNFAIlSSS0haYLGwZFMpTzCAVBwWI4oAwdas4dP1a8tLW9hvoIJWjS6hBCTAHhlzzg1S79Me1Xdb1S81vV7zU9Um8++u5Wmml2qu92OScKAB+AqlQB0Xhee7igmFoxUGQZOfavuvdL/er4V8KQwTRTLKkrPvG0p0H1r7r8se9AHxzq8fmapdrLDP5XnPyT/tVEJtJhO2W2Y+uCea3L3Tv+Jpdm6v2IMzfL26mq1wNLtWAkRp2zwqjNAHmOomNtQuDCpWMyHaPQZqvVrVirandFFKKZGIU9hnpVWgD6X+IOu+HdCS70zU7qzmNzBpEltpkVgQbRlETy3DSbADlARhSxOcEAVgj4iaJd+J/GYh1Sw0gTSqug6smkDZBAJi0iFEj35kUjllJ4wSM14NRQB7/AKH448BR+JPFF3c/ZoNLvdSEukWz6aZTYy+Ww+2MMY8vdg+UCScj5eOc/wAOeMvC2nad4c+13tnPqVlpmsR3MrWLyB7mWVmtyd0fzbhggkEDOGx0rxCigD3jxT8RPD2ueFNUsLq7tZJrvQtOZvL04I76mjr57bhGPmCjGSduOAa60/EfwFDc6Ay63Fcrp+sQXMU72U3nxW4hdX3kRBQdxX5IxjpjPb5aooA9E+D95bp8VoH89IJLsXdvZ3DnAjnlikSJvb52Ue2a2/CutWOg+DpNBm1aLwr4htdQmbUvtWmNcteR7QqxZCtjaQw2NtU5zmvIKKAPco/Hfh2Txv4bQ6jFZaBY6XEWnttOVGW9FqY28x/KMpXJIJAbHVeeRp+KfiL4WW51jUdDvdPfWJfD9pBFMmnOytfJcsZCPNj6+Xt+dvbnIr56ooA998T+M/A2qzTSi7RJLnWNLvJpbWwKyBEgxcOoZNvD9QR8x5w1bmqfEXwU2saHdLq9tPPaQ6pBLdR2lxuMcsO2AMzRhmJJPQYUk9BzXzNRQB6HraPp3wT8P2ep5W8vdWn1CyicfMlr5SIX9QruvHY7CRXnlFFAFvSNv9pW/mO0a7uWA5HFd6mmR3JDG+lZOw21wmhlV1a2MgJQNzgZ7Gu7W/QErayMJPRloAvrpcFso2XpRiOrCoGt2DhRqsT/AOyRVZ7wZH2vzJH9FHFRrqkDybZLALH6kYJoAde6VEzebcXsK49OaqxOIYmiN0HiPAPTNOnu7EShzbYX0Y5qCdrS9dCkQjQfwg9aAL1pYrCBOy+eOvytUV8bS9cGO3lDp1Ujir1mttbxgwTNCe4bkVFqV9dtGFheBkP8SLzQBkxQTmTMMABXkCtW2jv5TunEMaj1xmsyzllluNrTtH6nFX5dHWT942on1HNADmubeO8CbPPc8dOM066iEcgkn3QRHuvP6VW+3m2byLiJZkHR4x83502W7jZgTBcBezPzQBba5mZWWxuHlGOBtwR71d06e6gtWMlzG0vUq/FZMzz25E9pIFH8WRT4HtLwiTVLgDHOI+CaAL8epwXBK3zDr91FzTZ/sQPmWcMjnpgoat22r6NAmy2j5HdlzUEurRTT4jnaH3CcUAVE0oyMlw0BBzwrNg1fhfTwwjubRkkz94GlTToXk8+XUjLIei7sVeB8qPGxJD79aAIb+yS6h/0e0TA6NI2KrQ6YAQZSny/88WqGUtLck31z/o//ADzQ4K/WrtjJZo5FiGCDq7nigCCSJvPzFYT3aD7ytwDS3wsDB8ujfYj/ABFmrSudV1RVEdjNbGPucc1kXVykmW1MTS46hen4UAMbU1iiS2gu0SM8DA6Vr6TaX32cmO4ieI8ruFc1cSWbqPsmkT7M/earKSXdtbefBNiIDJiPWgDfuNJ35e/k3kf882rFNvbCVhHHLJbj1BrNm1a4n/eW4mjIGGUjg06wubq43D7S0Mf8QI5oAzfGf2H7JALS1MMm/wCZieoxXJV1PizyvsUXlCQkSEFnHXiuWoAKKKKAPdfgn438N+HNF0VLzWYdFubXVXuNSDWUkz30BQCMK6I2Apz8pI65GTT/AAz418JWV/4ane505JLbSryC5kuLSbKTSXO5CrpGzK+w8OFbAyOM8eD0UAe/eMfH/hvVvCXiTRtO8QXCQzatDdJ9osA0l1b+QEkRGWMANvGQz7CQOTkmusPxM8BQ6z4duTrkNwdP1szrdGyn86O0a1lU7j5SjPmFMogwOMDgmvlWigDvvgjKg8btbLKkF9fafeWVhMxwI7qWB0iOexLHaPdq39A17T9K8BRaGurxeGdctLm6GqxXOmNcPfggBEBCHG3DLtYqMnOa8iooA+itV8d+Bl8HW1lHqKakbSfS57WKazk+0II3X7QpJjWJTtBGFOCO5JpYPFPw00vVjP8A2lbapBc+K31cqNLkT7NbvBMFGGUbhHI8ZKjrt4Br50ooA+i18eeGpbrwr/a3i/7Zfabp+opJfxWU0cTXEkwaIOPK3hCuQSi7uB0yayfiF418K6po/ji30W7he61iHR/KSC0ljE80JfzzyowRleW69s14VRQB6F8YFa1/4RHSrw51fTdDhgvVP3omLyOkTf7SxugPp07V57RRQAUUUUAb3hmd0WSJZRGrODX3fk/3q+EvC9gt2krswUK4Ffdvkj1oA+XdYe0F5dR3CyFvNblVPqaxJr+2t/liYAg9WXmutv7KQ31yTdKE8xjtxz1NcvrenJdOBbROZv8Ano3AoA4vUNNtpLmWZrxt8jFsCPPX8abY+HTdSY82QRn+IIP8a35NDMC5IM83dVrX0SFVj2mzlRu+48UAc6/glRHuW8kY+nlj/GsubQYon2NNcK/vEMfzr0pLK4LlomjRP7rdawtdsZlkEhmDsD/qs9aAOc03wrHeIZHu3iQdTsB/rTrnwxZxMAl/cOp7+R0/Wtm0ts4kSTy3HVCavaZfXEM8gtoDceu4cLQByT+HrTOEvZ2PvBj+tJH4dtif3uoGMf8AXP8A+vXZ6lfG4jZWUJKvOFXpXMz3ay5jaNWk9elAGfPoenxAj+0pHbsFh/8Ar1f0/wAIQXMO6TU/JB5AZB/jVixtGktMosRPYdxTJbLyxi4cA+maAKy+EY5bmSG3vWkKfxeWAD+tWB4JiOF/tEiT0aMAfzq0lzepAIYmiVOgx1NbFi17PCES3iDd3c8UAchqHhT7H968VwehUf8A16W08MW0q5l1HYewCZP866o2UjTbbl4JSf4IeTVZ9IeOYyRxGBcdXNAFG2+Hktyu6G+TZ2LAD+tZl94Rls3dHuUZwMgKM5/WujeKAx/vr5y391O9TWtlCISy3BiY9GegDltM0y2sp4bp7vM8Zz5Jj4/Otl7SXUCZ4jFE/YDvVqfTPNA3XltKPyJqfT7SS2kBRYHj7gNzQBzc8VxFKVuvOV88FeQatxW6yRj7XdFU7A9a6bUbi3dAkP7uY9N44rMmtbhYzJdwQzx/7DUARfZLJIRtiEnHBJ61QubR4AJ5Io4VHIANRO8LzEwWswUdRnIBqaeBDbrI4lZ16A0AOg1Z58QQ2kTHplhVm2tbx5AttFCSfvLnpTNMs3v1+UxQsON2cYou9LexYumpxK5+9hjmgC3e2mqW8eY7OF/XGM1iZYXP/ExDwDPbpT5ruWJgDds5AzvBqRb2KaMCVGlJ9aALsd1CibbdVcH+PHNQSI0W6QSySbv4ccCoYpALgCOHyCO7dKtT689upjCKx6ZA4oAzrjy1YedcyHPVAKtC3W6tcoiRRjoT941Xe5e5G6G1IPdiKqzxXLHKh2P+zQBYmeSCLa0aLGOhA5NXrRLZ4g8dyQ+OUK1hNFc9ZVkCj1qaKOVSHgkG76UAaqre+cJYrcMq/wATcCrEkj35H2m6itivdGrJfUdQlxBJIzr0KgYq3FPpMaD7Vpk5fHJB60ATusKSq0EguXTrz9761ovqUDRASW6N6onFYEssMp/0KzkjjHvzUMcaSEkloiKANeW7gclUha3Hop61Q1B9pVUu5cn+E9qS1WASZN4T7EU+7NizfvPNc+qigCW1e4iUFdQJJHCnpWjZKS4luWBYn8KzbZ7QR4ikVfZ+tIbOaVw8EnmAHOwGgDrLeeC15uvJZCeG2jiszxDLZzGP7GglYnnyhjFUFntivkz2zxy9Dk8VnTAW0jC3mEXrjvQBavdPm1e1jtpJBCI23DgVk3HhZYCQ14SfZP8A69XI7xiQUYnA6N3NbGlXzy4SWSBXP8LUAc9D4Vg27rm+eJD0Plg/1pYfCSS3BRb1jH/C4jHP611d7Ywom5lMhPXB4FOs4CuVsAu7vk0AczP4IMJBa8Yp3IQZH4ZpP+EU03b/AMhabf8A3Rb/AP166S6sr9GM07BJAOgPUVmpe3iygQMiDuGXk0Ac/P4bWI83LhD0Lx4z+tWbLwraTDM+oyRf9scj+dbt3crKyfbAXGeO1Tvdy4Cxx/ue/FAGE/hXR+keuSu390W3/wBeqk/hQrMgimleI/xmLGPwzXW2l+AcWVpEZR1DDFJe69PjFxA8DD+6Mg0AYI8DoUyLybOM48kf41np4UeSV1S5GF6kgZ/nW+t/q962It6Wx4yVon0Wd1LI+w9SSetAHKzaLDBJtlum+qoD/WnyaNYrGGTUHbPbyuf51cvbOSGTYg3kdW9aRIzGAZbRjQBmLpUW757h1Xsdmc/rU66LasMLevu9DH/9etPcu3JlRAf4T1FWreMRRb7ZPPY89KAMUeHcLueaQL6hB/jUsfhmOT7tzKP96MD+tXZNQmMoE6SEj+ADFPudQiljH7iVdvYmgB+m6UdNjZEn8xnYHp0r7Xw1fE1tfs7IlrF8xI5btX2zmT2oA+P7rVtQtr+8acbo/OfBJ9zRb+IpbhwqwEqerE4xWNrqbdVvBDd+YDM/Hp8xqqIpCq4EsyDsvGKAN7U7+GMhlkMc3+zzWYmpzTyAm4lUr3Hes6V0ikGyBkf/AGzmpEkkncI0saD1xQBtDVruOMtDIZT7mqjaldagCs0RJXuvWoktfLwRewqfTPWpPPvIX3QNEy/3hQBuaPOYYy408sR/FJS3mvx/MHiMDjoIx1rI/tLUZ1zdODCP4VqrLdo2R54HttyRQBPdag06kvP5LH+EDn8aLSytXUPLMpkPc1SzZqQXiklY9zxUwjgkG+G32sOg3UAXDDFaxMzyZT1SsuJBc3DeRISvo5qys0pyktq5+g4p8UMGdxsLrd1yDgfyoASOEWzbpmDD27VK7XU8gW3d/KxkkNinwwxyttS3lTPXfVpfDruu5JJV+nSgCtZ3DQylIZBbP3c8k1oCOeR/Ma8FyQOjNgVl3dhIjrHIu0Dq7GmutrakFg7Njqp4oA2o7i4VuLG3kA6+1aMcpuGX7RDCsY/gHNc8mo2whAkZ2B6IvU0pmjdNkKtAp9eTQB2LSaSkOGsowf71c5fahp5ci2tyJl6FDgVSFrAV/fzTyD0xjNJ5lrbtiKwlcnvmgC3Cbi7jPmRj6Vi3m+Gd49k30B4rZhVSP9bcQbv4QuatppszqTbW9xKT/EwxmgDmbZZ0BaCfYeuw1NNd3xhO9eB7da3o9J1cZ8myiQ92arUWm6mkeZp4AfcUAcVawXErEoJTk/dTitK30+/X5vscb/8AXRq6CLTrwk+dqVvEP9kY/rUNxZWcZ/0jWjI/91KAMeS1vMES6bCW7YPAp9vomozoWRYIPUFulXI4IlfbDNPKvqaka0jPJjnlPpnFAFA+HrzPz39uQOxaoL2zMKbZJIJW9I+ta40+ADd/Zjg+pfrSNeCyx5Ghlz6rzj9KAMKK0vp48W6yL/s1Zj03W4oeIgD79a6K01G9n6adNF/wGpJ7nVTIscFuyZ6u44FAHJyWGonm5Ln2xUkUN2qjyrNuO5HWumkif713rUMb/wBzb0/WqxmjV9r6s7j/AGEoAxBb6hI2RYbW7NipmfVo12z2MRjHUkc1uR3MMa5S+mcehGKdBqmnyy+Xl2fvu6GgDJiuIlUFokHsBTln80kWlihPqwro0bTnxi0Vm+tWY4J5vltoljHrigDkilz/AB6db5PfH/1qfExVthjgVvQrXWjRb0Hc8iNmoZ9P2f66IE+uKAOTn023uW+aNDJ/scULpM6DEUvkgdMGt+RLdc/Iyj1XrVb7NpkhPmXM4J9TigDGube7tYy58uc+/WsxYzLKHngcY9BxXVrpNm5zbXT57ZOalOnXi8R3AZf92gDmdQa1dEzbsp9VFTWMdtgH7ASOzk81tSWD5/e3kMbehxUY0RXYv9sWQnsOBQBiSx36zN5EW+M9Az9Kcpv7VNy25R/UPWvLZW8P+sgnf3RqfB/ZydY7tf8AeoAgsre5ljE13cNLIeQpPAqrexXq3QkS0jYD3rb32+3FvvH1qneRzTJsUlc9WzQBlSJPe5FwsUbduelNhe7sQyL5dwOx3ZxUn9irHkmbzG9M1BLokzBmhfZn+H1oAqXd3PcNiKIJIOpQ1CsepswIYv3wxzWvYaI7Da0UinuwqZtCv7WXzLMlx/dagBLbVLyGMLcRR4A5Aqhe64kkmEMi+prWEWqH/XabGfU02S1nEbf8S+JM+tAGG11DJgvJ9CKjeSFyVW7k57YpbqB4pSzW6IKeH/dkPJb7cdB1oAg+w4UtCRP9aqC6uYMokhjHoD0qykFu5LC4K+oFO+zQkHY5ZqAM955HfcZGL+tWVvmaHZJEHPZjUYtf3h8yOQL6gVaWC1KhR5v5UAJYxFpFZ5AgJ5ANfcO0etfEsWmRl1aO4CDPRq+2fLH98UAfHOvNpZ1e7ECsZfOfOBx1NU2cxL0ZR22Vryy79WvFt7Fo385+SvHU1ob7+2QMlmkvsFoA4qa4geTa0ch9S1XobLT5EBAct6ZrpP7XeUbbzQdhH8W3FIWtZj/x5rGKAMm3stPcgNbE++c1pwaNZypiOE49M04Q2Abd9qEZH8NJPFZzrhZLgn+9GDQA1vDrRsGhj+XurNTn02aLmO3skb/bpI7e0tl3RpfufctUMl/EjE/2TdNju2TQA9oZyMSiwqnPpqFtzzwwn/YNaNteRTEA6aE/3xin3EyIwAsoH9s0AYuZLYYgvBIvoRT7PUriSYrKQMcdOta0V2MjOjvj1UVbWW3I3NZbG9COaAK6PDMAHl8s+oFH9n24O5NbmVe8Y/8A1VLLewop22efc1WPm3mRC1vDnsRyKAB9I0qRv9KububvkH/61SwaJpe7Nr5rY7SdKZDptzE43amnP8O0YqzPpklzGEa/Cn1XAzQA5YtNtm/e2luGHpViKS0Izb2UJPqwrLOj21r89wTIR/Fk5q1b3OnIoLWdwVHoDzQBdeaPbmdIEUdlFUnntpGxbAl/93iraarpSEBLCXd/tA1OuqRdYrUIP92gCkn9osRtWFR6laSZNQC83kn+6owKuHUpWPyHb9RVW51Xblbi9iiHvigCjImqSHCzyIvrVVrVg48w3Vy/oW4qzPqVkR82qFj2CjrWXM09xIPsd3JF7mgC7LY37keVZIi+rNTBaPDJukghB7nrRY2d2hzcahJKT2WtJbESdIJZG9TmgCrbXkZYhLaRgOu0cVM2oRrwlhPkdatHTdRC/uFMI9MVXl0TWZwc3yRj3wKAJbTVLQHMkMmO4NX016EEi0sUJHQsK5xvCErkmfU03+zUf8I3JGuI9TAI96AOrXVtQfGyO3j/AAqK5ub2dcXMyKn+yK5U6LfIw/4ma7fXNWvKhiQJPqJ3dzQBea301pMzRCV/VqmRrCFcLGqj/cpthFZhQy38D/Uii7urOPhr6AewxQAj3Olk4NrLM3oq4pU+zYzDo/PYtwaoz3Fntyk8uT3jFQRTwyHBe7I9eRQBtIZv+WdjFD9TUqzXqDG+NR7Gs21gsc7mlkz/ALb1dWOBj+6ZSP8AeoAmbV0tyPOmbP55p51hJEysXmD6VkajbEJuKK6+xqhZahcBzHaW7IRxl+lAF27vp5pf9GtHV/ccVcitpbuMfa0WM99oqETa3IuGnt419sZqMQXRYNcXrNn+FaALI0Wzibf9tmT2qWTTo7iIxW2pMjHuWxVKX90mQjyH07mq6zWr/NdaVcL/ALSkjNAFg+Erpzlrlbn/AGi9RzeF7lVKvO0af7B5poutIGds1zbezE0sN7B/yy1c4HQNigBw0yaCLZBqDgj/AJ6VTeLXkb5HhnT8K1YriCQE/NcH1pJJ2HEf7lfrQBlNLqKjEsSg98CnR6h5YxcRsD64rTjvccMgk98057uAj95ECPQUAYdxqlrg+R/rfcVVTxFdW4w1sjejYroC9ietnz7Cqk97AjbYdOdz7jigCrba3fXIDYjWP0A5qeTVdg/eNKPoKfHqF0n+p0tM0kms32cS6SFHqBQBXOt2oGXa5f8ACoG1Y3TGO1Vlz/FJWgt5O/ObSIehAqpezwSIRcKh/wBpOlAFVvDl7dt5sk8cmedoekbwnc9Ujj+u+qX2TTt5J1CSP/Z54qeKytyd1rqrkjsWoAsDw5qUf3IrfH1qeDSdQh5dbcVCupSQHYZmbFXILppx+8usL6CgCXZe7NpjgP0qo2n3LtmRo1HtV5lBXEM5JqkUvw/ytuHvQBWn0hCwJlJOexr7H8ketfHxl1QOBJECmewr7Dy392gD531TRL6W+uSJ4oQZG4AHrVVvDk8i/Pqro3tVzVNTmS+uT5DPiRsD8agi1SaVfmtfLPuRQBCPDroP3uoSSr3zUMmh6Wp/eXkwbuKuveTFSD932xWRqE0e3LxyM3bFAFxLawtDuSEXA7EjrVj+0mRR5WnKq9sJXLC41dpB9gTy4vVwKsyHxBuQi8iCdxgf4UAbh1sxsA1jIx9loj1zMuIbQBj/AH14rBZNRYgyapCp9P8AIqcOduLm9hY/7JoA6OS4inUfaIIRn0GKyrxLGMgpIkR65YVSK3EwC2i+aT3JqH+xvEMkg8y2hkhPUHFAE51dYW2rdxOP9gVOl/bum6SVc/SrFposkCZbT4UbHPIp81oBw1tEM+hoAppc2CNuy0x/u4PNMub6Rhi00mH2ZuKm+zqGwVjX6dql+xRycSu5HsaAM2O5vAw+1WMOD/dYcVdFzGFBeFFH1FPfSNPXJCTMfdz/AI1Uksd74gtGIH99qAJf7SlyfsaW0h9JKuQajq7riS0sV+hB/rWHfQx20Za6ijRB/cPNZr3unRxH7ILlnPqTQB1NyNSlTLfY4/cEZqitnJuzNeFz6JWFa6ULw+bPfTKD0QA8VoQ6UYyVs57gt6npQBoCxnbIQu4PrUEvh2CVt94QCOetH9n6oVwbzyh6mhdM2km61IOe4yaAEXTtJiOGeMkdqtRCxjUGNNw+lQPaaMB88nz+xNJHNFAAttC8g9xQBbkvHVD9lt4yewNZL3mvTSMN0dtCvdW5q44urgEqiQg9yelZtxo6s5a61hIvbmgCzGE/5ftclD/3VamyS6WjDzLq6mz3DGs9bHRIn/e3X2hvbNWBc6ZZgeXEWHpgmgCaSTQyp+e6/WqyNo4kyhvWYezEU/8At62Xn+zWA9cVesvEfmMFgsdvuVFAEcckfW2tp3/3lNVr2SeRgn2Bue5Sujh1Wd/vIF/3Vqz/AGg7DGQD/tLQBzWn6bFnc9q6k9RitRLGyUZNkXb/AHKsy6mY/vXMK+wX/wCtVaXxFLED5VzAT6YoAbJO0AxDprEf7uKoyao7NtlsnjTuQvSmzeKLssRLJGV9hTo/E4OENsz59uKAJFOmzLmVmU+4IqreR28K77WdSo7butaQuFvFG+xBHvUctirr8lgme3zUAGj3CyINyNn8xWo8unKP9MYJ9K5y7tNRVT+8itYR6HkVBpG0yEAm9OeSw4oA6RxpUgzBOTn0NUrmzgYcXssa+1Xbe2LDiyRfoaknt5kXCQxL7saAMWGy02U7YtXn83uGyKnOmsig/wBrR7R/ekFJLAd5+1WsUidzGcGg6fpJ+ZrQg98sf8aAIJtPmZSEuLS49CSKrhDajF9DZhPVCM1fWHw8vD70PopNL9n8OFgDBczk+5xQBkzzadOmIdQ8hvRciqyXlxbnCOtyvq3ety40bQ5VJFq0Q9Sx4rMuLeysl/c36KvQAqTigBsWoGc7ZbUKf9k4psmN2WBQdvmqC1YCXzNjXkXrGMVrRvZTjB0q6J9//wBdAFWC+t4SBvZj6nmpjr9tH8ssRZfVetXPsVtKmItNlX6//rqmdCuN+6KMIPRqAJItV0m5barXCE+xGKhurK1mbdBqFwD6E8VKul6kBjEIH05qVdOuEGJERj7UAYz6NBI3726dj7VFPZx2mNkjsB2JrUnWaHJFtn6GsuQNdvtkhZAPegCu8tzIoWG0Qg/xEUtvpAmfMzmJ/wDZPFasNrEY9vn7T6E9Kmj0fjInyPY0AVoNEWLkXin/AHqke1aH/VXFux9yKSXQA7E/aZBT4vCtm4BkuJN31oAzbu6v4TiPyj/ukVENV1VRyI8e+K2J/DVpGvyXBX3JNY11oio5Iv4gB2JNAEZ1G5uXAkkYHPSOvtbn1aviiOBVZRDeRDnqAa+2MH/noKAPnPVdK1SS/uiLu2VfMbo3OMmsw6LarzqWryKR2SQ1S1KJ9R1S7RUubT96wL546mpbXwaJGWSfUVmxyFc0APnPh63XDardt7KSaiju9JTm3mnceslbMmk21lCSkVrNIo4Ujk1meer/APHzpsUIHAFAA2p2KjP2hv8AdUVF/aMUxzHb3Dr24qxFf6ZbA5t7dW916U+PUr25OLK7t44v7qjmgDOuY5ZYytvpLtIehao7PRrnduu7OJGPo3SteW4uI4z5motGfWqE+pQKh864mnb2oA2bOC3hXDyiHA/hNTi8sgwUalNuPQf5Nc1Bqyg82+U9WFWX1O3cYWBGPoFoA6XyreRcvqJ59TWfcW+mKx36hITns1YQmupG+5HHH6sKlQaaObmWJn/3aALssVvuPlXe70yact5Hb8TPGAO+6oN+jbcG2eTPTaKVI7MndDo6so5/etQBOdfsOFeQyegQc0j6jbyDKrLj34piO7HFvZWMB/2OTUb2t1K247Ub2oAr3G2Vsx2SzZ/vtUkUF9Jxb6faRn1IFOXTxuJkV3f/AGTxU9ylysBCSiAY6luRQA+DS9WHzXctui9ggp01kduHvXX/AHDisKG0vjMWOrM4PYngfrVs2zEfv7syH0HegCV2t7clWuJJz6M2aoz3kZJC22QPXmrIgiUj9wD7mrO5UX5IVoAqwSh1G22Qcd1olklQZddq99oqC6vwsmwlYz61SM7u37zUlC91HegCy9xYjmWadfxqCS/0UNgwSTt+dU5hbvICIWnbPVuBTipVjsjjhT2oA1be8scfubCJF9XAq0stvKudtoPwGaybeCBziVZZgfQVdj0PTn+YafNk980AQ318tqhZTAxHbANVrPxPEDidV+iIK1f7DgHMWjs/uxqQWE0a/JpVvHj160AFl4ls2wBE6+7JxWoupafL/riDn0GKw7q+ktflmtkYeiimxSi7TMOnA59aAOgMmjOuRHGT74qs9ppkx/dw2/4kVl/2ZcMctpQVP7xapk0i3cYkijU+meaAJpLWGAEx2NrJ+IqJNQmiGDpEar6qoNRPoSAHyY5VPYhqbHpesRcpeSCP+6aALP8AbMA4kt3j/CnrqWnSH5pnQ/XFRrHfgYlgjn9zTJLc9ZNIDH2FAElzBYTruF3uHYM1UGbUk+TTIbaROxAAqc/Ygds2nvCf93ikj0+xBMtvdy259uKAIFh8Qb91wuE9EJq6t7BAMXkdxn65ppuJbUHy9YVh3D1XfxJBEdt1ClyvqtAGgl1bTgC3C89yeapXumyTtujc7u2H4oj1PQJxuktvJ9+lXrOfw+f9ReDd3WgDNtLa5tj/AKRaxSA/xdTWkLi0K7ZHEB9AK1Y5dNI4kLD604nTCOYo3/3sUAYMkemvknUiw/u5qEQWIb9yiTf7wzW89vpjHixtxUTWloeI40QeimgCgl/BaDH2XZ/1zUVbh1QyjKjavutO/s+EdGYUCzAb72R6UAWUmdxlZMZ9BUwtZpBlZlyeetV1jIGAcfSoHtQc/v3X6GgC79jnUEvIp/Go5racjChc+tZ72RxxfSj8apSaM8hJGsSJ7H/9dAEmoWd8MtE8Rx/Cx61XivJoUAuLOAH1HemHSriP/V6kJB/tGmvp105w0kMp9c0ALLGboFltYwT0w2KxptP1KCYyW8pQf3S5rROkXecZ2D/ZamPpGpADZmQe7UAQrrV5bri7tgwHVlpy+IrJzhluVb0Aqymk6oo3Sw7k9PWptt5bj5NGjk98DNAEceoaZMo80T/jTzLondGJ9CKryatNE2LnQ+PYf/Wpy6zaOMnSSD9KALEctlvX7JZxnnuor66z/sD8q+Ov7dt0kXFhKnPavsL7Qv8AdNAHyx4i1+++3XUYijWIysBjlhz1rnJZoYyDM1zJM3TaDjNO1TSnh1m6eS8MZ81znr3NSGVF2l79GA9V5oAihbXNuYbcmMngt1FPSx1GZ9127K3pU6arAPkilkdwe3SmHX7hZdhtGkB6c0AWbfQZ5v8Aj4kDoewrZ0/wzHEoYFYx6lsVmR32pT42RCFSO5qcRyzAC5vWB9FNAGrLoVhvH2i/iBB6GQVZjtdMhGFlD/Tmucm0qxKhndy46MWojnt7UbRPuxxxyaAOriWyVvkgZz6EVYZig/c2lun+8RXHtqAb/VtOfoDUeZZWDC2uZD6l8UAdDfXExb5o7UewrGum1Bsm3gtQPVqqtZXrkmOIQt23SZrLvtPvwrb9RBb+6O1AE7y6wjlftdmGP8II4qCUXbH/AE2QPx1jPFVLWySMMZQ8kg5zTIr28LlIjHEgP8dAE8dzHbuAhkRh0OCavR6xf9FYbezMMVBDKFwbm7ilY/wquamF7DMTHFbtK3TngUAPF7POG+0ajDF7KeRVWa0sZW3nUJXlHvxSHSpVkMtyba3Q8gFgTSGKNpNkN3AW+mM0AMNrBwXumkA7LUn9pQ2QwFdxT/Ktbcr506Bj6c02SewQjzH+bthc0ACeIpX4jRI1z95xVkXcV0P9Iv1JxysdZz6pp8ZKi2E57Liki1ISSAQWENvnoepoA1Y7Gyc5AlkPqR1q1Dp0eBiFVX1NRQ3N55QKzQrjswxmkuL+IwFbqKaIj+JORQBZks7JB/pMwUegNT2KWIyLMec3oap6Dq+luTDcQs0hPDODW5LYWlwQyy+Sv/TIYoARLtVl8vYsMnbAyKS8vL635iljl/2R1pmdPs8os4Pqz9a53UTbTXwks71sj7wHSgDok1CaZMTuyH2qpNcvBJuVZHTuxrIh1ZbSTbcL5yd39K1n1K0mtdyzoUI+73oAtWupWV0v7tkd+/PSiaSCNWeGNzPjjb0rmTdWULALpjqSeGVuD71eW+uxHvtYlIH8OcmgCF2upXaS9ebr/ql6Yq5FcaM0Y8wmKQddz4rPuL+O6jIu2ks5O525qpZ6Pa3rtJLchgD8v+1QBv8A9poiH+z5TKewp1jeatcPm5MSp2QdawLyNrNlTzFjgHdOTVzRxIbhZbeV5IvRqANrUdUuLJMwwO0h6YXNP0/WtTZQQVZj1UjpT7jUYLaPNwyg+mM1gTa4JCW06Mhwf4hjNAHUzeKWtUIvbYBuzbOKqxa0L4l5oYkTtgVjwanJeR+TeW43e9Y01rOly0anELdBuoA7Vv7PkBMqwMD7io1tNEcny2j3eisDXG3GlXSxjyUcA9TuqK1s5xIDaZMg+981AHaTW2kRffeNf941RntdByHaNZSP+eLcmsmchQBfwbj6Zqo62k7bbVhbOPQ5oA63Tk0K4cRxeZFJ/dc4raOg2bx5STP0avL/AD1s5v30clw3aQHBrRtfEyxKqLHOv1NAHS32gWiMd7yKOx34FY0vhuORy1tfMn/A81Qn1SWeTMkc8iE4xnpU1tYzzyE6dM8Uvo/SgCwPCt83+q1Fz9TTR4a1hSRFfF/xNbdrbaxbRL/aEiZPTZyTWzZWN9Mm5LaVh65xQBxo0DX48lpMj1L9aVLW9iOLoSZ/2TmvRYvDUs4BvZJIV64FWh4OjmdV066WWTHRzigDzZLedsYjuD+FPl02Vh+8guj9Aa9fsvh5qrRhmu7eAH6GrT+Br2IfvNds1HuBQB4JdaeYclba5z9KzZVkyf8AQ7vPsDivfrzweQpL6lbyY54xVSDwxHK2yO6ty3pQB4PGLjkiK6CDqOc1ZjuLNQN15eRN6EV7tceAL/yjJF5BX8Oa5LUvCTPP5U5t4weN2O9AHAx30IHyX18//AM1Ib6NTiSe/b6LXZyfD+5gjLw6oiJ14TrVF/C+q4P2S4FxjjO0UAc3/aNmBkNf/wDAlqvLciY5iNwAeMstat1o/iC1c+dsVfdRVOfTtacbknXHoABQBmttSUeZcT9f7tfaGV/vNXxylhfow86ZGOeVI6V9k7W9qAPjG/jebVLzz3MSec+Nx/2jUIs7J2xJdZH+z2q9fyQXGp3qnMp85wB0/iNEMN1GMw6dBGOzMck0AU1fT7bi386RvXFKmoQb8N5qN64rVW3QgNdyRwn+6oq2otFXKxRuR3YUAYTTSs3+imaU+p6U6R9UbapiVR6gc1c1G+MQIV4oRjgLisNdVv5mMSSqF6Bm4oAS5jugcMZD75qxpq3iHMEDIR3cZBqsxu4FHziXJ65q3bX7lcXd1IgHYLQBrkamV5eLnso6U6DSFnIea8u1b0RqoR6tboSLcySt71Kuv3KA7YADQBtQ6Q6AC3nk+spNR3GlTjJuby2C+x5Fc3ca7eTf8tiq91xzTUaCZQz3zpIf4W6UAbEyWEAInv2Y+kYqjI1lnNrazzt238A1XuZHjTCeW4P8WKXSobm7kAimaTnsMAUAW4ftu0eRa2sH+9yaZ5F5cS/6RDKP9qMYFdRp3g97hkmu7pkI5ABrck8NsiZhvZJSBwgHBoA8+NnAj4WKeZj3kycUTaaWIM1nKE9YxzXaizukyLizMaj+I1MsUezCXalv7mKAPPRb26kpbwOxPUv1Fbml+E7eWAyR3aOTyd3b2rS1Dw/NeEyRsIXH8S45rJFhcaeCjXbrFnkqOaAJl8JXocvavbZH96rNr4ckZwbiyfzh/EPu1Ct1mArp80ryDj5+Oav6VqN6P3d9dgP6Ag0AXpNNhS323cAPpjisO7srbYQRP5f92ti/uflykzSN2ptt5ssH+kJsY+tAGHa219PA0VvZJHAeNzD5sVeg026ggETOQv61Ru5rrRkkMdw9yzHIBPArMXxHOVLXVwQ/90DgUAaWojS7Nc3cUjsf1rJiu7SSUi0tfLGeN5qlfahLPMuydXB7MOB71Yso7OPLX06OT/doA3fNsFtv9KijII5EfJqBLfSphmy0e9Y+rDimWeraXAcWcQdwf4gTWp/wmLxIcKkYHoooAx7qYWzLFNpl0EJxnHAqOeK3li3WspgkHI571dufGiSHEgWQehFVf+Ep03+KxQn1waAMr7fd+cYrx45UHbZ96pLZbfzC0kb2+egJ4NX/APhI9NlfnT1x6+lOuNZ0ieLbLCfQDB4oApzTw7toTK/3gc1chkEMYcXSqnoRil09NORC8LEE87TWfq9ws0hjSFWx36UAaP8AaSOR5NsLmTtnpUV1DqF4yG5toolHIWPg/jWRHcRRrtbzIm7FOtWYru6tR58cbyJ6yt1oA0LtJEg2yTRRsBgc81iQ2Rlu8XMsuD0dTxV43a38fmPbp5noT0pFF20eHeKKL14JFADrrSvJjBgv5QT2duKZbaPdRx7orxMHk4NOuI5JLcJHMsxHqaktZL6FVjS1Qqe+aAIfKvQWSSaOUdOTzVFZksyYpUDS55b0raudPkeMvKpUnn5TzWDdwsG2iFmA7tQBJLIAQ0cy89qtLdxpGGaPzTj04rKia3jDfuzv9+1aWlo85AlZfJ9h0oA1dHsLrUm37TCh4ArtdKsLbSYNtxI8h9Stc7Dd2OnQqY7yQOOgIqy2p311EW8+OSM9BigC3e6tBa3ongdnA42scgVr2niu4aMGCeFPxFcBdukrmOQhFPUg1GkelWkbYnkJ9s0Aem/8JgYyEvJYyx4HPWq0usCG6FzbuQx5Kg9a8kuVklY+RKJI85Us2CKktby4t3GL4mX6ZAoA9rg8Z3M6CNiyjuCcU2bxTZwxk34wOxJ615bHJqVyPMkvEXHQgCor77S8RW5lEyjnpQB6Sviy3kkJtrCXb2LHg1rWPim3+XzbKNG7NXi+na1qMJ8qOVHUdj2q3f6/exxZCKWP6UAe2SeIQ4yJWCnnCvxWLrHiW2SFxNA0i4PI615ZperarNjbHuJ9elbjyav5RZ0gPHI4oA29L8V27BkeYiE8AP1Fbdh4htreNvskuSe1eaJcPJMfMs4lYdealluJ1ZTDGgHtQB6bp2swXVwWvyj4P3M10669o3k+WumIxIwDxXh20yjeomjkPUg8GrFtrF3YShZHBh7etAHq0ttol5N5k8AiJOQFxXuflW9fIyeIzLMq4JUnrX1V5tAHxFqjD+17uaFo4cSvnHXqaZHrMe4CTzX+hqhq0Bl1i+C4yZn6f7xqBrV4yqjLn0XrQBszatZNgGCQt9aibV4VBAR3B7DtUcOj3c8ebeBlz/eoTS7izdXljAYHoe9AFScwXDF381SemakhsX2CSbDRemcGtxftF4qxxWEQfoHqSXQI7WPztYnfHonQUAc3C26ci3fYB0DHNWLlLoqPMkRvRVXk11Onabol7/x6wuCP4iKmi0g2t5utJI29TIOlAHIW4gHy3UM8T/3kU1Kiq58mGZi7fdJHNdxNfNBGUnFs+PbNUIFmun8620yPcp4bGM0AZWn6Oi/8fwLt6itNdH0tlyI2VvU1oS3ogi3XVuQ30qWCY3UW6NY9h7ZoAz4tH0+b5IpwHHqeBWpBplnbxmOG8jQ92TjmoJNPtJUJuXNsT1KUunaKhfbZJ5sJ6sxxmgDa8O/ZUuDGZ2uWHfdmuknkEa7rNdsmO5rmU0h4FP2OAW0ndwetNml+zr/p5nLf3l5oAsXra1dF1uXjMR4Cp1qLT9NvrZWK20X1PJqGGZ50LWt4oHYM3NU3bV/O+XUY9g7FqAItaW+V90kzI2ei9KrafetDLi5R7mL1K5qDVtUvo38qdop890OcUmhXBVWWS8DOx4Ur0oA277UtKMBL2pi46qAD+lZludMZDNZ2Vw8n95z/APXpl3cWkV6qzzI7nnJHApsniKzR2gAJZR95BxQBXee6nnP2VRb7Tg+Z0qe6aKe3MbajiQDkq+Kw77Vo55igMkqnsOoqolhYXG0BniYnkmgCpdwzxzMq3bOnUksTmpdN0+7u4yLW2Vw38T8k11Wh6Ppkcqbn80Z5Z+1ej29p4bt7RZIp/LnHTaoxmgDyO38EatcceSxz6Ka07b4Y6vMpEdrIWPQkHAr1rSfGsdsjRoIhsONzDBNXW+I0nJiuIiB1UdaAPKYPhPrccZNzJBFx2yP6VFa/DTUUlcXG24XttJxXomoePxdKwVQX9CawYvGV+ZSvleXGf4lY0AZsXwyVRultWc+gJrPvvh9MziK206WFif8AWMDiuquvGMscBaO4kVh0bd0rLt/iVfxORLcTzoO4zgUAc7efDPU4ot2WL9gAcVzOp+GdT01wZrdnz6KeK9fsvGdzq0oVL4iLuB1/Guhm1ayjtSLiPzyR6UAfNvkXUM2AG91GeKYWmjlJeNwvevb5rHS7tTM0MdgPU4zXM3/hm0d2lS8MsZP3QOtAHmjzSSY8oFcdM1KHu2x5rFk+tbOuaXZRMViE5fPyqq8VivHFAcP9oL4zgjpQBdQ2sqFJN6MPQ4qJbaXOEk3RHsTniqEkgZfuHb2q5ZTtDCSTlewzzQBp2sNtGMZZT3Oa1Ea3MWIr1Vftk1yzXV1MT5cZ21WMQPzsjY7gdqAOo/tO8gmMTwrMvZlNZt7qb3DGN7dopOwx1qtaXFvbMrh58jotW3vbWeTfdGQehAyaAM/7NclvmKJnsetaunaasW1zc+XnqM9au2Fr9qlDxW++P+/KeRV260tB80rYHoOgoAp3gsmKxtHJKR3FRzO6AJA4VfT0ouGWOEpDdqPcdq524keKQlZmkY9STQBdu2iWT95uZvY1NBNBEv8Ax77s+tYwmMrZL7SO5pTOynIcH6UAaVwbCRs/ZZwe4UkCo4Qkj+XFstl/vScmqyajNGBgfL71JJqcEy4ltw3vQBoSQQwAEaku70BqRJTKAon3jucVm289iMYtwW7Z5FS3M87J8hihQdAtAF46bZyNvNyqP6A4oms1dQi3JUDuR1rBgLyy8H5/U1rK90i4d1f2FAGhZ2d5EmIrlQv61ZFxNCds7Ow9Qay7e/njPEfAqxNrDOhQxrk8cmgBby3SQeck7Ljtuqol9DC2TKdy+/Wsi7cedlnIHcLUErQsPkDA+poA66DXjJHtWBzjvWTc3bPeB7xWEeeNtRadMYkDef8AKP4TWnFrVow2PbBj3OOKAJBqVkFUxB2cegr7G84ehr470XVodO8Q2t7BZ2U4jcEwXEIkjcZHUH+favtn+1l/58rX/vmgD4ivNKjn1a8GGhk85zjP+0as22iLCwd7hsjuBTdZvlm1S68q3kTEzfOO/Jq7Y3DMgWRCox95j1oAvWF5ZxyiP7TI5HUCrl6mj3BVjBdTSjpjoKS0ns4P9VBEznqcUDXrmK+jt4zaBHOMgcpQBRbydIjBgV1aVuN56Zq7cRiW1JuZBK2M9OM1Z1Q2RVXup0lY98cCsPVCrQEw3QK+gPNAD9MhuQ5llaOKIcCMd6sXM0dyTHKgjQdXJ61g6fDa3cZ3XM0UmcfM3FWZIbG2UCWeW6bp8tAGtFZQhQtlHHI/95jmnOPFFsh+zJC6f3VHSpbLSUngXYZrdDyCOta9pY+Su2PUiT/tGgDi71dSnLNewzqx6hV4rPgkgtGbzI7oV2urXVzaofPvFMf0zms3zZ72Ai2WGVTxkjkUAcrcavM+fJjcp2Lmrlh4mvoFw0kUWPSi68MXcHM2/Y/p0Wo28IORmGdZD7t0oA1LfxjO8vlyTZB7in3GtXztuj1GBI/7rgGsVPC9xBIPMaNifRulSXPhxANzSYcc/ezQBFeXcbybnuA8pPJTirkGnWFzH5kt1K7EcqhxVbS2t4naOSGF9vBZhzWlMiAB9PSMOOo9aALVpElrAVsYSo/vPzWFqOp3SSPFdQoQP441xV/+1wMRSxuJO4U8Vm6hqZVSFgVQe7DJoAyGvHLbSnmIT93vVuJYEBaRXhB6mkt4ZrkiS2WPjrnitSDBwk9hJMOnA4oAwp5IFl/0SR9/971q5ptvJNN5jxtJIOx4rqI9NtGiDNZ+TxkYHIqxZTW0ZMU0bL6MVxmgDNaZ1i2XFusEfTdms2W6jtZ1+xXm92PK9RWtrVlbg+asrEf3CeKzIrOCU4WGNB3IHNAEzyxNIk9zfLFIOq9qs/2vpKoWjkzL/eA60iWOnQLmeESe7c1Suru0aTyhaR28PTzFWgBX1tSfmt2kJPykcVqWep3yJ89sCvYVhtZyD95ZXazJ1wRzU0La04IUxgf7VAFmfWhczeRc2DD3U0k6yQIJNPcL/wBMiM5qNH1GEnzXttx7k1PHPcEbnaB/92gClbDVXuvOEK2792Axuroo75xBi6uRFJjrXPT3kskpVm2jtg1Xm8+RgscfmjuSaANK4v4Bugv5ZLmM9JENXbXWreKNY9PhdwBgB6xo7hbFPnsN/wCGalF/G8ZlW2QJj7oGKAOiiN3PiZmih9iM1nXUb7ZDO0bynhWxgCqmhzvcXDyNKEiP3Y2bpXRS2MN2gWQjb/sGgDj5dHmnAH2hGkPREHSs+60qez4fLfQV6Bb2FvaIVgBB9TzXPa9AHYiO8YS5+6OgoA5yFriPgXAj9FaieOcne8qnP92oXQQyk3IeQ/3hTZ5FkVViY5oAfbzx2rlmG8nv6Vbl1lnXbFFGPcis+S3EUYZm3nuoNIqxt8wR9nf2oA1bLUrwnKyxog61Jd389wuxbxPcVStm04/Iwk5q09jp2zcrlKAKD25CkkBj7HrVJgA2DlTU1wERmEMrtjvmq+S33jz70AAyOhBpCRnIGDQcUqEg5wMUASNIWUbz9Kaq4ORzTsg84GPSlEeejhT6UAWYruFEw1uQR3FJJdRH7kDZ9zUO6VRtyh+tHlueSw+goARZW3ZTap9DVtdRuUBGEI+lVGUD7yAn1FR+ZtPyfrQBYlubmXk5x7CmqYXH75pFekS9mX7u2o5J3kPz4/AUANkRQ3ysWFCbM/PkfSlO0DIzSBs/dXNAEybWBABKU5Jnt2/dr8vuKijlaI9BSs+/5i+PagCZr6WR1+UJyORX3FuPrXwrHy4J5Ga+6aAPjzW4ll1+6Fm0u3zXySOPvGrMWlXEhDKxmHcA8VNrmrR22rXlvOFZWlcbou3J9Kk02GGSHba3jxg88GgDQXTrn7IVFuw46CqWnWtrG7JcWZWQdWYnJq7b200BzJqEzx+g5p8tzaKf42b+84IoApT3traFkgthK49TwKwbm4Go3IP7m3CnkK1WtVhivJ8efsT/AGDSnQ9N8gE3BVwODnrQBoaXFp8zKblo2A4JziuysG0mGJTbNbggdc5ryPctjdH5hOvovStaDW7Ty9pi2eoANAHotxqMDNtN+sY9ABzVS4SZRvs1Ew67nGBXnzajbSyZgco+ejVsWOoQ7R9svn/3AeKAOitJ7RJC2o7JZv7ingVHc3lpHNs0cJBcOcsuc5rEuLq3kuIwu1YQcl16mrE99psK5hwZf72DmgDYltbqWLM0kpiI+YEcVSt9N0vedlwQ3dQ3esCfVZkUv9skZj/yz6ioLfVmmYk2jb/74BFAGzr+nwLbsbG3n84/x5Jrm7ySONFjmklR8clvWpru8vWysNxICP4DWYsl0rs1zA0x/wBocUAMjuEttxTbOezE9KuRagksR851RfRTzVDEs8v7u0zz90DitSLTgw3y23lN+lAFMz2ocmBJmPck9adJNCy5MEpz3NW2WKJvnhd1HdVqW3uLY3IDpIkZ6blxQBl2MTXNwI4XaNc81uzXN1pUkMcd2X3nG09q1o7NCha1t1yejYxVf+x72d8tZrK+eDu6UAXrXWpxiPZlyOoGRUsgv7jLXDxmLsu3GKXTfD2r2x3yRKsJ6g4JFTXsIRCHLg+5xQBhX0wGUVVdh78CsGW+v4ZdsbxKPQVLrVoglZluuf7oNZMG2KX96cg0Aatxq93FFiWON896qW10biU+Z0P8OKZeTQsoCR7veqsUTOcq/ljvmgC/eKIcGCQxMagikkL/AL+5JB7g0147YD97dO59AM0y3t97kxK7L2yKAL66fFK+55WZe3NJcaesab0mMajtmmFLxMBMBagmkQ8XDsQOuKAIFkIk/dEsw/iNX4NVnGI8BT61T3QY/dZA96rzbXPykk0AbEtxkYubovnslVUt2Yl4ZCiejVnKGQ54z69a0UmVods7ke4oARbVHcs9wF9TnrW1Z38NgAI5zIPrXMygB/3LFge1XtMgcsWCc+9AHQXWr3M0e2A7Q3cVTsob1WLSKWBP92opLiW0PzxKy+3artjrzBgAuR6EUAVryzuZpV2wSbO67etRX2liKDesLI/uK6GfWsRZZhGcdhWGL4TzETXQZPQ8UAc/ISF2MAG9c06G7kVdmcAdqv6hZpIxkt8N6jcKzJYzGeVA+nNADvmclg4Htip4p1jUrLF5nvUljazspkiMfXo/FSX09yg2TQRJ/tLzQBn3EqSfcTYPSoCV9Oacwbrximlsj0oAQEA+1SRqrZy2PrTOvOMUHnk4oAc6KORzT4pUXhow3vUe87cU6OPd3x70AWRPbgc2uT9aeJLZhxGU/GqTDbn5s0gPORQBcZoQPkyagcbvupilWZuAVUY9BUnn8cgYoAqZAPK0hx2zVh5UbjGPfFVz7UAKBkYzzTlypwaYAP4qU7cfLnNAFgxhwAuc0PbhAOcn0qBN5ICk1I8br8zOc+1AChAHX5SozX3PXwzFO29QwDcjrX3Rn2FAHxxqotBqd6sCyKhmfczLnuadp17BZIUgieYjvjGa7DUTcQ3dyos7UL5rctj1NYWoo8i78xREdoxQBWttXvLmYpGyWvoriotVM0aFr+Yyr2CcVTms2L77mVl9G6GmMlvLiN7yZ09hnFABpwRGMhtZDnplqW9uH3YEGIu69TUyaVbBQYtRlU+jcVbsraNWw92HA6EjrQAmkpDcQ/u7Hb7tSXPh++unISKOKH1HWtaz0eZp/Nt7tZFxxHnArUS1vQ+0qyH1ByKAORtNDs4JPL1KOYns69K1P+EcsSP9DRyT3Yk12dnYylP9NaJl/WrSNYW/AnRMeoFAHF2/hmWNf9GVmf0YcVbl8NX7QgNboSepUciurXVIN22C+jcjsozVW51u7WYRWtyhkP8AeGBQBz9t4AuChe3nAc9d/aqt74N1qLO29hCj0GK6m/1B7WHfdXrF8fdh71zV34nn6SW8xi6bjQBlRaJc20mbi9hLe4oukuowFhnhlHcKK1LS8s7/ACJIC7Dk5FSTnS7RGcKiEDJAPNAFHTluVUlYV3fhzVhvPuUP2qAxLUFrqE12f9Dsw0RPDFsGtS2tddDB4reF4/7rvmgDmrp2S4EdoJFYHoV4NWriwu7jyWKI6od20ACt68fULePdPYwA/wCzWBe63KQEVPs7HjIoAv8A9pmz2pPayRL7GtGy1e2UB44pmfrnPFcrJcKqCS8lnlPpjioodRvvMAtnjEB7P2oA7O/8UTRRDbJt+o6VzN9fS34LSXyNnsvFV9RnMkOHkib1xWIJ4LdCqLzQBbnSG2G9trE981mz+RO2S6x1WupllOSW+lRxNEH+dGb2oAuKlqgOZGdu2KYdzdiq0kc0IbhQnsRVw3kDLtc/pQBTEph5jjQj1IzUqajN/dwPamzPbjlT1qo2GJKB8UAaD3Kzj5pihqFraI8mXJqCEx4xIjfXFJOIwMxk4oAY4VWwCTSbST8v5VHnml3EdCc0AXbcRR4MiZ+pp11PbOmEjwao5BALEmp4ZoVHMdAEeXUZTgVNFezoMJJt/CopnVvuZx71Dj3FAGvCgkBea6BY9RVcEQXOYpAwqqjBec80MVY55U0Abzo86Dywu7tk05vDeo+cPttu8St0Yisa32CSMmdjhgdo+teqxSfaX+1XXIAwqevtTSbdkTKSirs42TwhMsIkSV1U9yDg1Xt9Iu7KcE2b3KnrgV3MsrzPuc/RR0FNr0qWAurzdjgnjnf3UYk1vBLbYOmTh8fwjGP1rDbSbuVmDWs6x9gRmu3orT+zod2R9fn2R55caHfKSIrOZh9Kr/2HqY/5cZvyFelUUf2dDuw+vz7I81/sPU/+fGfP0FMl0fUIkLy2UyqO5Ar06ub1Sd57x03Hy14C1z4nC06Mb3dzehiJ1pWsrHIwaZeztiK3kc+gFXh4Z1sj/kG3P5D/ABreso3j+aPPFatzq99EsUSOE35BIHIrzr9j0lBL4jz6bS76C5+zy20iz/3DyavReF9dnx5OmXLg9NoH+Ndbo1tDPfNKr+Yyn5m68/WvStCg2su0cCqM35HjNt4A8Xz4+z+H7+Q+yj/Gro+F3jxuf+EU1Mj2Rf8AGvqTwwMbfXNd5bf6ofSgR8FXXgzxLbD/AEjRLyPnb8yjr+dUZvDusQECbTrhCeRuFfT7XC3bXSXCqql2AOfesjWtIElru69xxUc7vY1cEfPEPhvWp2xDptw7DsAP8amn8Ka9AA0+k3SA9CQP8a9n0u28i646MO46/Srt0Wa+RVAVIV65A5PaujDU/b1FDoY137GN2eDf8I7rIBI065x34H+NWR4S8SMM/wBkXePoP8a9fs7X7Vq4XG5Yzn1DGupmg8u4EIOTwD9a9X+zKbejZ51THOLtZHgVt4F8UHY40G9ZSc5AH+NfZ32G5/595K5aBFjjRBnC4Feocetc2KwUaNrN6kYPMJ4jmulofC3iOKVdUuhfSzr+9fBB46msOSUW8q/6Q0n93HavQ9QsTLd3RvJFbMjcN9TXLSy29tetFJHabD0YYrzj1Sq8dreRBrm6Z2x/qx1ojurezXbFbPtHcjNa0UOjK3nI6Gb2Ix+VUNU1VUPlsgMJ7heRQBW8+3uznaM+/FNe5t0Gx5kX2AqnOunSITbyyLIezcCqgsZMbhtb6mgDftYraYb4rmbzB02dK27HUrmyjAuJmZPc81yVpBcxjK3EUXfGcUOrTvi4uy3srdaAOp1TxKqJhFYMeA+aqTa3bXNsI5nUysMZPGawWtp5MGCCVlXpuHFLFKzybZ9PV2U/3cUAdVp2n3cEIe0eCIHnkZJqK6vbiCcf2lIm3oDGnNV7fV5beHmyVQPU1nXmrTXD75IhHCO4WgDT3O1wkkF9HsznYwramlmNuTIUC469q4hNRtwx8yHzUPQ4wRVpdVe4It7dCykdGP6UAKJhFdOy3/DHlEFWrWxs76bdO5jkPA3HrUa6W8ro8xt7Ur0XPJrUhMKYiuog5HSRVzQBoWugwQASPOxXt5bYp0yooItbi6jfsS2axp7s21yv2eaUoTypORRc6i1ypQXccA7880ATXs08i+XPq2zHqKxLxYRIjG++1yg/KFHANLeSWkUe0t57nqzGss/MflhZY/VRzQB1NtLM8WbkJt+nSsbU90kypGP3ZPzFazDePG+I5JNo7P3qcarKBhbcH3IzQBPLbWcUJCzEN3zWLMI1bKvu96sXE73B/eIkYqo6oOj59qAButKsUrH5VJJ6VHg9qljaVT8sm2gCWO0ldsSRso9TVxLGEDDuo/GoA+8/6Tdnb6Kakb+zAv8ArJ3b36UAONtaqc+ZyO1SpcOOIUXPbiooYrZhkMT6c04zR256tt9MUAR3huHGZUAA7is58Z4OTWrNqEDR7QCSay3YMxKYFADNp9OKBkHhSaUlgeTQWPqaAA5P8NBGMYFJk+poJz2NABnnOKliiD8n5ai6UAkDqc0AWjbjbkOA3pUfKEh8MKakoH3lJpHcOflGMUATxeS7oD8p3D+denQLtjUAk8dTXlUJ/fR5/vD+desL90fSvRy+Kbcux52PfwodSUUV6x5wtFITSFgKmU4x1bCwtFRlvSmkk1zSxcVsVykoPOB1rm7gg3so7E/1rfDYz61zl0St8+fUiuHF1vaRR34BWkzcso1W3+7yRWNqUmW2qM9R9K29FmWTMbZHHWq+qWot9QTIyrnjPrXno9aV7s0fCloILVABz1Nek6ZZtFaRy5AdxkA9hXIaLABGvHWvR3jA021ulI8rywjHP3WAxg1aMje8JTGdBuG10JVhXeWxxB+BrgPB0bBJJiMCVsr9Old2GEdlIxPARj+lIDxHWbWQ3W23YtIGL7Rx3oXUZViMNwm1umSa5eXxYiareSxjedxjjUHOcd60LOG7v089urc4x0rNo6bJqz0RZiRi4bG1R830FVpJQ0k021GVmyAD6etWoSRBN5py2NuSazzCzSfZU2AsAWx2HtXsZZC0XUfoebjJe9yGv4Xt1jE15OgCj5gOg9qvW5knvQ8agvu3Ypsg8i1itgf9pue9aOgwBt8jDJztFexHRpHgVp/FUfXY2whEase5r0qvOnwq4J4AzxXom4V5+Pd+X5/obZdDlckvL9T4dvn1UaheFj9pi85+N2O5rIv1WfObLy39Q2atatb6lPqN55TCKHzn6tjuaz1tr63yIm3t6k5rwz6Iz2t2hOWkMZ7Ckd9y/vJ2z9OtXJob4fNOibhzk1mzSM0n7wZ+goAnBAiIdUYdiOtTaeY0O53Zh/dqgwjyMbvpUhO0jaNo9aANwy20rgNaTfUVYI0+HaWtXB/vHoKz7RhLhBqOxj/eXir82m3Ji3fborqMfwKeTQBpwB3iXybsY7ACrSQ3WNxgR8fxd6523uHYeXEv2Zl9RWrby3G3m7AP6GgB05slYtf28uR/dGRWa08NzdD7FFI8S8eW4wKs3uoXkHCNFI394jIqqbyeXb5m3cRyYxxQBokWmwb7RSe4UVWaK1vMx2UPkN696z/tE73JjtCS46k9DV2S5voWV5bdDgdV60AT22mC2kEl6zXJHTJ6VtRXsZTbHGsaD1rGXVLtkylqG9jWLd3l1NN+9TyRQBv6jqNpAduFaQ9BisWa7JJklsIyB/EDzVWW4iHDDzCfSqs0km3KLIv+9QBNc3NrOP8AVPGwqSG+jVQqZ49RVAXErrtYqAPakkCkjc6/hQBee+jc4aNW/Cqk1w+cR/IvpTESJTkEk05wh7H8aAK7S7h8y5PrTS3GNvNSs6j+DFQZoAcTRyB1pB1pTg8igBTkjOBT1YgYdMj6VGDgZzT/ADHPy7uKALEM6REMq4qeRzdrgbR9azyhXnNPBBXAJ3UANmQRtjIJphYH+EA0/aMH5Tn1qPA60AJk5zS5yegoGDSUALg4oUkdKBRQAElupopCBS9sdqAEpeRSY7d6WgB0J/fR/wC8P516wD8o+leTxAebH1+8P516kkgKjBB4rswlZU1I4MdFy5WiUtTSx6U3rRWkq8pdTgSFyaQn1pGZVBJOAKiE6s+1ck+1ZNvdlxg5bImqnc3RD7ISGPf2q15UsqlRxxzxSQaYQScH6ms3US2OyjhXvMpmdkHXLHqazr355N2Mk9a3bmxCxn5efYVzpd1u5IiSduCM1jKTe5206Si/dRb05WWVd8jJu6Fea6y8tfP02J5MGWNlIYdxmuXsQbl/LjAaXqAOprqdJg1B2IvIhFAn3F5Jb3NSaJ20ZuaYm1UHtXXWGRhSflJGR2rndNgOEBBOOprpLJDuXjvVIk7XSCNq9K0fFt8mm+DNWupGChLVwuTjLEYAHvk1l6PklQByaz/ixqMEegw6VuV7i4cOU64Ve5/HFJu2o6cXJqKPA/CPhyW4XzrsspPzAA8j616Do8clopRnLIOPSrVrpzWNvDLOqsjnkgdKsX4gCN5YAwM5qeti5O10noZN8jC5jjTud7Z/lUVhia7knx8inaB64qNJEj812mZ85wDx83tVrT4vJtUQ5z1OfWvpaNL2NOMDwq9Xnk5IuKGml56nrXVaHb+Tbrx23GsHRo99yWP3QMV1dpwgGMAcV07Qv1PNnK9RQ7Db3C28rDGQDXe7jXnurPt0+Y9z8v613/415+N2j8/0PRwKV5P0/U+A9enf+17z95Lt858DOP4jVOKeYHKyyL7iun1vULWfU7tf7O3ESvzjHc1zkzqk+5EaEeh5rwz2hHa8k+95rr70wKy9Ym/GrjXi7RiaRz6KtV5HuJOV3lfcUAVn2k52nd6URhyeASfSphMqcBDu96jdjv3Lu3+3SgCYxyFeIN3qelTaeY0lzJI0K98GoI5pHGJZsL6VM0lqpU+QZB6Z60AaF9qEAj220hkb1K0+w1Z/IMcdosjfxFjUC348sJDpxQngErRFA9rJ9ouyMnnYpoAEu4luG+0wHnquTitW2uNH480PF9CaaNYTyhvsYsdgQNxpjypMhaTSH2dcigCzLb6LIDJa32xvbisl4Lxpx9md5k7HNOGlQ3SmWNPJX+7nms6XfbT+WtxJEPXJoA6RPtghCzRMpx1FZd3bRStmWRgw7GqX2q7UYju5HFVpZ7h/vnJ96AJJ0WJv3DgH35qvNcTMm13LD6VGzv3IzTSXx1oAj/CnZ544oIJ60hGO9AEnmk8AfjTCSeppACR1FHHTmgBDRS4pKAFI9aTjtRj0o9M0ALgnoKkCnZ2A9ajBIPFGTjk0AOwT/F0poPpSUUAPZ8qAMim9+tC9OTSH2oAD70DFGc9TRQAv0pKXGB1o7UAAGaOM8Uho4oAUj3o4oo7dKAHRACVOf4h/OvSAmVGepHTFebw/62P03D+depqoKDO7GMUmBUCsB8jEZoMkqnOQ2PUVeSBWycDb656VEyKWPZR/KqUmiZU4y3RnzyM3DRqc9jV/SrXe44AHfFCQGaX92pKDoCP1rptI05oUUsOvtRKbejKp0orbQtWmnqIwQnGODipVteMbeO/FalvGywnYMrnkf4VYEahemAeOKkZzV5Zq8ZyPmI4rz7X7KS2nMsSEkcN7ivW7iEhG+VmAOOmKxdU0cXKEtGwLcZNBS1OQ8DRxrqzSsSxMeVNekxOsq4bBz3rzsWkmg6pbSb0NruKnnkA13MVwk2x42UnGCVPBoV+op2v7puWkKLwP1roNMt1JViMk1zFrNkdeR61sWV60TDk49Kok7W0AhiLIPnxXini68upfG9wbgkDAAB9AK9a0/U1bHK/Q1ZuvDmheIrqKbU7c+ag4kifYce9S1cqnLkkmcNr9/HHoscR5eRVwAOlczPdSsshZmjAAwT1/CrfiF4rrXbn7ANlokpjiUueFAwM/WoUhDRqsoVwpB4P+Ne7h8vhBKdTVnlV8dJ3hDYpxw7zCNoyW3FjnPHGT2rZLqFUr8y5xkc1kyo8JlmTk42gDIyTVzTZhK+wlcjGM4/yK7pbnE9Vc6/RIiLc7gBk55Fb8AYopyMd6yLEFLdIsqSeMY6mtuNQiKPQUS0VjjprmqORl65xp+ATy3NejcV5h4mfZDBGONzZIr06uHHSVor1/Q9PL1ZSv5Hwfqd5INUvVERX98/I/3jWbO0knMicetSaw6Lq9587nEz5H/AjUDXELJgNID2rwz2RI53h/1AH4ikkvrhvvt+AqB5OfWhAW52igCSMxynM7EVJNJHjZECFHcCq6ReYSM8+lXIba8C4iVSpoAghCKxZ13r70qOPtAaKPavapRFtYi7icHsR0qWIkN8iLt9TQBYudRlMQjMjAdMDtVJZlWQNK7v6bjU08bscmVcHt6ULaRxjcX3mgC4YxMokj+Zh0OelOGo3kCbJbh1HQCsx7yWL5FUKPaoVlkkk3SEn2oAmluHSUvDO/zdRnikdpZjlirfWptuV3bVyOlUbiR844AoAl86SLCgDFRyyu9V93tR5h7cUAKSe4/OkyT9aM5+8aRvagBR7mnGM4yvNM6D3oDHGBQAhBzzxS9OhpOSeaCR6UAKc0mMUd6KAFI5ooJJoHHagA2k9KB1waQ9aBQAp5NGPzpB1pQxHSgBKXpzilJY8GkoAOp4AoGADkHNGfajOfWgBKKM+1FACkHAJ70lH0pcUAFJ3opaAHR58yPIx8w/nXqUJynPXFeWxn94n+8P516VDMNoPfAoAvTOI4QF6uefcVSklzJsXGF+97mlmkDKpHYVTzsdiR94g0ncuPKtzrdJRE25Az16V1VjIgU8DOOK4K2vBuXGa6fTroSAc80CumjYbdH/qyef1qOaZwCudx9qngMboRn/GopoedyBvrmgVyFYXYbmfAPc9KpXA2lljbzGPqOKnmZYULzuQg6Duaq5e6UlMxp7feNJmkH3M77Er3OZ8SOPTotbNho9pcvtA2uOcqdpH5VFa2TFtpBX612Ol2apCoONxHU1k5u9luayUbKMTGvNIns7ZpbO5D7RnZN3/Ec1iWutTBys9vNEVOCR86/pzXUeJ1H2YRmXbj5jsbk+lcbY2UvnAC5dix43AVUZNbh7KLV1sjrNN1WOfBjkVm9AefyrcvdcOn6RJsfbd3ClUz2Xua5K506QQGTy7e4kQZz9xh+NYk2rF5m+0RTxv3LAnj61tCooyUrXsczp865b2ua0SAJtjYE5yceppY4B5hjhUZAwFPc9qptfwm2zDKgOQvvWxpjyCJmOxnI5IxXtUszhJ2mrfkeVVy+pBc0Hf8yrcwpbQv5xJAT5yOef8AGqHh8H7YHXG3dnGMn8as6wG2xwBGWSQ56cY70tmotYlZ0cA8LyP5V3cylZrY4rNJp7neaZ+9mVyo2jn8a2XPyHGfSsrw6Q9mrEda1H5TjP4US3OeCtFnN+KHzdQJnO1a9WryHxCxbVCD2UCvXq8/HfZ/rselgdmfnzrF5GNWvQWjP75+/wDtGqT3MRX78Y+hqlrf/IZvv+u7/wDoRqnXjHrmsJYiv+tTP1pwuEGP3qfnWPRQBsrdRI2Q6k/WrkWogr/x8Ig/3q5qigDrPt8DD57mNvqwp0Oo2RJV3iX33VyNFAHUTXVsJDi5Rh7Gopbq36x3Ck+hNc5SUAdAmoqmcmJz6k1HLexyH7yL9DWJRQBtLeIBxID+NMeeNuTKn51kUUAaomiz/rF/OgzRn/lon51lUUAapmiwMSJ+dHnR/wDPRfzrKooA1fOi/wCei/nR50f/AD0X86yhyQB3o780Aa3nx9BIv50gnj7yJ+dZVFAGqZov76/nSedH/wA9E/OsuigDV86Mf8tE/Ojz4z/y0T86yqKANbzov+ei/nSCaMf8tF/OsqigDVE0f/PRPzpftEXZ0/OsmigDWM8bEZkT86GmizxKn51k0UAaomi/56L+dKJ4xnEifnWTRQBqebH/AM9EP40vnRf89F/Osqg8YJ79KANUzR9pF/Ojzo8/6xfzrKooA1fPjH/LRMfWgTR/89F/OsqigDWjmQuoEiZJHeuxxeRjBfB90rzu3/4+Iv8AfH869tWMbF47V14aj7W+hzYiv7Jo5Rri7UdUb25FNS/lBxLCw46g10l1arPIq7AFXqfX2qrdaWoRVgGW/iLGqnhVutCYYuLsmVLHUoncIr4PUA9a6PT70qwwRz2rlptLkXnyxx3FJFcT2zAH58dm4IrnlRmjojUjLZnp9jfkqfm+vNbMF4HBZyoCivMLDW0GFdinbDf410NrfiQAK42k8kGsjS6e5vyQNeuZdvT7qjtWhotg0kuHU4XrVCyuMsAjAduDWyupLarsQKZe/PSpa00L576dDaktreGLzGKdMHisq81mK3RkgKsQO/rWRcJJdu5aVlDdQhIFZGp6VIke+1uD5nXbJ3qFBLUuLV9CzPbvfyb5bm4yx4wcj+VEttc6bmQMLhB6DDfl3qlaT6jbAGW3aT/aiYN+nWp7vW4JvKSRnSUZ3CQEc1XQeqlZPQlfX4lsnSVJIjwPmUg1QS5ilkLpLz0GTmrcIRlXY28HkkU+9srWWAl4Y2bGFIGD+dFg+BoYFWRACiPn+8AaltdyzkRNsUdh0qpbaeMBYZ5oyB67h+tT2+l6kgLxhbiLrlflb8qWu6NW4p8rVjoJ54JdOfzIne6jGUKrkN7ZrBsvNvElkmJLggBT0X8Kn0XUUe+CpNtcNh1PBz71vazbQQ31s0Tqsk6kFOu6vVwFdp+za0Z5GOoK3tE9UdL4dx/ZUTe1ahPA9OpIqnpcKwWiQoCR1JznNWp2CISfr9K9h7ngqS5XJHGao+/UpT/tYr2evEJW8y4dvVia9vrz8dvH5npYFWTXofm/rf8AyGb7/ru//oRqnVzW/wDkM33/AF3f/wBCNU68Y9YKKKKACiiigAooooAK9Hi+EWt3Gl6dcWmo6PcX2oaf/adrpaTSC6lhwSdoKBCwAPyhs8HGa84r2Gz+LunafF4c1Cy0G6/4SXQtJ/suzuZL1TbplWUymMR7mbDtgbsc0AcT/wAIJrVzc6bb6PZXmoTXmnJqJVLZ4xGjMwyS2AVyv3x8pzgVaufhf4ttfDMuuT6RcJbRXhsZIijeajjA3FcY27mC5z97iun0f4tW1ndaW0+m33kWmhW+jSxw3EJE/lyO5LJLE6MrbsYIyMZBqrdfEzR73Tru0ufCkUVv/b665a2lvchLdfkRGgkXZyhVD93by3QAYoAydH+FniW68UaZo2q2U2kNqCTtDPcxkxt5UTSMMjvhcY7ZFZPgjwPrnjVtUXw/am4fT7Y3MqgHLDIARcA5c84HfB9K9Nk+N2mx6lo01j4fuYrbTru8uVha5iAxPbtEEQJEoVV3ccE4HJzzXnHw58U2vhe81kalYzXtjqumTaZOkE4ikRZCh3KxVhkFB1HegCjN4P8AEUOgHW5dGvk0kdbloiEAztz9M8Z6Z4pvh7wl4g8SI0mhaPe38aSCJngiLKrkZAJ6AnHeu0ufijbSeG5LaPRZE1h9DTw6bg3YaAWiuGDeVsz5uABndjvjnFSfDzxV4d0P4dXttrkdzeXaa3a38FlbT+Q7+WjfMXKMNucAgYPPB4oA4j/hEPEZ0+e+Gh6l9jt3eOab7M+yNkIVwxxwQSAQe9bWlfDLxJceJtE0fVdPudIOrS+TBPdQsEDYyQfcDGR15rR8SfFS81m201ltBb3trrNzrDkOTFI0rq4Tb6KVxyTnNbo+MljBrdje2GgXEUP9vP4hvUmvRK0lwyFCkZ2LsQBiedx5HPFAHBXvgLxTZaxZ6dJoeoi8vN5tUELZmVT8xH06nPTviqeq+EvEGlNfjUdIvbf7Akcl00kRxEsh2oxPTDHgHoTXomnfGGz0WfS7XRtBm/sW1ivY54by7WWaY3RG8h/LCrjauBsI65zmsLxh49sfEFrqEItNWzJY21laPPfIBGIpmkO+OKONGXDbVUr8pGc+gBzHh7wl4g8SI0mhaPe38aSCJngiLKrkZAJ6AnHepLLwV4mvrK+u7TQtRlt7F3juHEDfu3T76kdcr3HbvXafDzxV4d0P4dXttrkdzeXaa3a38FlbT+Q7+WjfMXKMNucAgYPPB4q9ZfGofbINU1LQ/O1iwvr++094Lny4Ea7HzrKhQlwvUYZSehoA4fTfh74r1Gzsry20O9+xXjxpDO0ZCt5jhEb12liAGxg5q3ffC7xha+JL7Q00O7ub2zw0hgjJQqSVVgxAyGIO31wcV0M/xVs38FadpDaG93qFnHaxxXd7NFJ9nELK37orEsgDbcbWdgoOBxWjF8YtNj1fxFLHod7FZa1dR6i+26heeC5UsSyNJAybfmwAVyMZzzQB51Z+CvEdzEbj+xNSWzSZoZrj7K7LCysFcNgcEEgEdc8Vab4f+Ip9S1e20jStQ1GLTZ2gmljtXT5hk42sMhsDO3r7Vu+Ivia2r2ulxLaXUZtNYuNUlaS5DGcSOjBWwqgkbTzjBz0Fbdv8ZLP+17q+vdAnmMeuy6/p6xXoi8uZ1C7JfkO9OAeNp4xnBoA8yl8Ma5Doa6zLpF8mksAwvDAwhwW2j58Y+8CPwqxB4ZlbwZL4iuLhIYWuxZWkG0s91Jjc+30VQVyfVgK0fGnjWTxLoXh+wMD2502KZJSsnyTNJM0m4L2xuxjnpWhY+IrP/hXuiILiKLWvDWrPeW9tKrFbqKUxscEcZV4hkHGQ3FAEWo/C3xJpnhW31e/sbiC5udSj02DTmhbz5GeJnVgP+A4x1zWRdeBfFNrqqaZNoGoi/eFrhIFhLM8a/eZcdQO+OlejS/GmxtLyO90Tw/cxXTeIf+EguBeXwmR3aKSN40xGpVcScE5xjv0rNtvirY6b/Z9no+jXUOl6fp2oWduJ7wSTmS75Z2cIowpxhQO3XJoA45PAHi1rW9uP+Ee1JYbMsJ2eErsKjcwwecqOTjp3q1ZfDfxNJfaHFf6Zc2Fpq15BZRXc0ZMavKwC7sdODnBwTit7w18TrXSvAk2g6jpE2rSlJ1iF3NE8CPL/AMtAGiMqMOOEkUEjPWuguPjTpQt7SLTvDMllFFqVhqLW8dxGIUNuwZkjVYlIDYzuYscmgDzzUPBc1tpPiK8gvIriTQb/AOx3sAQqyoXKLMD3UuNvqCR61ydeip4k09fD3j7UTMq6n4kuBBb2IyzQxGfz3kc4Ax8qoO5JJwAOfOqACl3N6n0ptLQAUUUUAFFFFAD7f/j4i/3x/OvcBkqoHUjtXh9v/wAfEX++P517/pcEaRfarkgBcFV/vGvSy9N8yPOx+nKxhgjtrYb1zK3Y/wAP/wBequKluJWnkLuSWJyTTcfp1zXqWS0R5/qRlRnpUMtrFLw6A1a2fj647UuATliW9TUunF9CldbGRNpETD92WU/mKgj0u4gJaGba3oOBXQwxBpAG3BSO1O8pd5wCQBgcYyayeGhLc3jiKsepl29zq9tyjxP9RVmLXtQhY+fab+5ZTmr/ANlBwFZD2POKnj0wNyXYjjBAxms5YCmy1jai3IbbxQsa5mhlQe6GrltrtpfXChZkAH944zUDaU24p5iFjzt68U2Xw+JJVRY1bjlimMVjLLV0ZrHHtbo6S1kgdtzMCB0waW3toZnYuQQ5zgjNcnF4dmVi0BeIgnBjcitay0vU4VXF52ziQbsfjisZZdUW1jWOPhbqjorbw9a3UbiJTbTDoycZ/oa4vUrjUbG/ks5IvOMb7QyNjP4GutsbjU4Bh54HAHDKhyf1qCQGa+jZiZHb5nJAGK0o4B3bqoKmNXL+7Zzq60kTlbmCVSOpC5/lXV+Gdbs2RsXEYj6kE4IqqtvbzX90rpGyrtJBUcH1rNjEZj1GW3jBIYBcL2+laSy6n0ZnDMKnVGXrUUV1r91f2YeMPJlXQlc+9dfoNsyyrNeyvcSY+8xJyOwFc3DaE3VvEScSfMOwx3rvdJgLzQoDtwdwAGciu7D0op7bHFiqrs9dzqrCIJAp27SR09BTdUfy7KVh/dNWl4AFZviCURabISeTxWid5XZyOKjDlRyIAGGY4r3DI9a+e9VvNkB9TxiveN30/KuTMIK0WvP9DvwMubmt5H5163/yGb7/AK7v/wChGqdbusxp/a998i/69+3+0ap+Wn9xfyrwT2DOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgDOorR8tP7i/lR5af3F/KgClbY+0w55G9f517tPP523ACoFACjoK8agjTz4vkX747e9e1Ii7F+UdB2r1MudlL5HnY/wCyVsc88cZ5ozxjFXGRdq/KPypu1f7o/KvSOAg2ggcjA9BTlXI4PvkmrMargcD8qbtXc3yj8qL6lWViNXkBJDLknk9f1qzbkhJGYjai5Jzxn096CihEO1c59KvyRp9mh+ReSCePeq2HYqiRTCx+UsgG5iMgn3qdGXKpC3zf56VM0UYhhAjTBlAPA54q/p8UbwyF0ViQOoz3poEilCSUOwbuABn+dXwkgxuTJY52g44qby0VCVRQeOg96eAAnAHMnNJsztchjkEOfMwgJwpLZpyhny6ggycc9hVyONDLkopOD296fMAIXwAPlNFw5SswVYyCeDwP8KzftLx2tzKqeWdwSMNyavuo8uxOBnI/lWbfovlqu0bfPzjFS2aRiPjxb38q7R5j2+9znOCPWquhQs2mXbbdxkJCj1q7eqv269OBkW3HFXNDVf7Mh4HT0oF5lJIf+JpaIT80UJJwPwrvtCtIwPOC844NcbZgHVb4kAkbQPYYr0bSwPsEXA+7WidoswqLmkkyauc8XzYiiiBGSdxrp8DHSuQ8YAfaen8FTHcVXY8+1y6DTCJcfKRn619F183Xqqbn7o6+lfSeK5czdnGPb/gHfgI2i/kf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39988=[""].join("\n");
var outline_f39_3_39988=null;
var title_f39_3_39989="Ectopic ureter";
var content_f39_3_39989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ectopic ureter",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39989/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39989/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39989/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39989/contributors\">",
"     Duncan Wilcox, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39989/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39989/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/3/39989/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic ureter is diagnosed when the ureteral orifice is caudal to the normal insertion on the trigone of the bladder. In many instances, an ectopic ureter is not detected because the affected individual is asymptomatic. In other cases, especially in females, an ectopic ureter commonly presents with urinary continence; in both sexes, it may present as an antenatal diagnosis, urinary tract infection, or rarely urinary obstruction.",
"   </p>",
"   <p>",
"    Ectopic ureter including its pathophysiology, clinical presentation, diagnosis, evaluation, and management will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ectopic ureter forms when the origin of the ureteral bud from the mesonephric duct is abnormally high, and separation of the bud from the duct is delayed or does not occur (",
"    <a class=\"graphic graphic_figure graphicRef68944 \" href=\"mobipreview.htm?27/49/28433\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/1\">",
"     1",
"    </a>",
"    ]. Ectopic ureters are commonly associated with a double collecting (duplex) system. In these cases, the double collecting system is thought to result from duplication of the ureteric bud. The cranial or superior ureteral bud is associated with the lower renal pole, and the caudal or inferior ureteral bud with the upper renal pole (",
"    <a class=\"graphic graphic_figure graphicRef68944 \" href=\"mobipreview.htm?27/49/28433\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef86773 \" href=\"mobipreview.htm?2/32/2567\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22472?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Anomalies of the collecting system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ureteral orifice site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ectopic orifice is always found along the pathway of the developing mesonephric system.",
"   </p>",
"   <p>",
"    In the male, the most common site is the posterior urethra, occurring in approximately 50 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/1\">",
"     1",
"    </a>",
"    ]. Other sites include the seminal vesicle (approximately one-third), vas deferens, bladder neck, prostate to the level of the ejaculatory duct orifice, and epididymis (",
"    <a class=\"graphic graphic_figure graphicRef78218 \" href=\"mobipreview.htm?27/9/27798\">",
"     figure 2",
"    </a>",
"    ). The ectopic ureter is always above the external urinary sphincter. Therefore, males with an ectopic ureter do not have urinary incontinence but typically present secondary to a prenatal diagnosis of hydroureteronephrosis or symptomatic urinary tract infection.",
"   </p>",
"   <p>",
"    In contrast, most females present postnatally with a history of urinary incontinence, because their ectopic ureters terminate at sites that bypass the urethral external sphincter. The incontinence is typically characterized by persistent spotting or moisture, requiring the use of a pad within their underwear. Since the upper pole renal unit subtending the ectopic ureter is often dysplastic or poorly functioning, the amount of urine draining ectopically past the urinary sphincter is not voluminous. In addition, these patients void normally, since the ipsilateral lower pole unit drains normally into the bladder as well as the contralateral kidney. Some patients are unaware that they have an abnormality, and think that the constant low-level moisture from the urinary incontinence is normal.",
"   </p>",
"   <p>",
"    The following are the most common terminal sites of female ureteric ectopy including their relative frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/1\">",
"     1",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef65413 \" href=\"mobipreview.htm?41/1/42002\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bladder neck and upper urethra &ndash; 33 percent",
"     </li>",
"     <li>",
"      Vaginal vestibule between the urethra and vaginal opening &ndash; 33 percent (",
"      <a class=\"graphic graphic_picture graphicRef61532 \" href=\"mobipreview.htm?43/1/44063\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vagina &ndash; 25 percent",
"     </li>",
"     <li>",
"      Cervix and uterus &ndash; Less than five percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only girls with a ureteral orifice site at or above the bladder neck and upper urethra will be continent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Single versus duplex system",
"    </span>",
"    &nbsp;&mdash;&nbsp;In published case series from the United States and Great Britain, the majority of ectopic ureters are associated with a duplex kidney with rates that vary from 75 to 90 percent (",
"    <a class=\"graphic graphic_figure graphicRef50628 \" href=\"mobipreview.htm?27/4/27713\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56184 \" href=\"mobipreview.htm?43/38/44643\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In these reports, ectopic ureters in duplex kidneys occur eight to nine times more frequently in girls than boys.",
"   </p>",
"   <p>",
"    In contrast, ectopic ureters associated with a single kidney system appear to be more common in India and Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In one study from India, 75 percent of the ectopic ureters were associated with a single kidney system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/4\">",
"     4",
"    </a>",
"    ]. In these case series, there was a strong female predominance. However, in reports from the United States and Great Britain, single system ectopia is either equally or more likely to occur in males than in females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/1,3,7,8\">",
"     1,3,7,8",
"    </a>",
"    ]. It remains unknown why there is this geographical difference in the incidence of single system ectopia and the gender variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/5\">",
"     5",
"    </a>",
"    ]. It may be related to genetic differences in the study population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ectopic ureters may be underestimated because many affected individuals are asymptomatic. The condition is found in autopsy series in 1 in 1900 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/1\">",
"     1",
"    </a>",
"    ]. Ectopic ureters occur approximately six times more commonly in females than in males. Approximately 10 percent of ectopic ureters are bilateral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prenatal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic ureter is increasingly being diagnosed by antenatal ultrasonography. In these cases, hydronephrosis is the usual presenting finding, most likely due to obstructed flow from narrowing of the ureter or bladder neck obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Postnatal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic ureters present differently in toilet-trained males and females, primarily because in two-thirds of affected females, they bypass the external sphincter, resulting in incontinence; whereas, the orifice of ectopic ureters in males is always proximal to the urinary sphincter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Males",
"    </span>",
"    &nbsp;&mdash;&nbsp;In males, an ectopic ureter usually is detected during an evaluation for anatomic abnormalities following a urinary tract infection (UTI). If the ureter enters the genital ducts, patients may present with epididymoorchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/9\">",
"     9",
"    </a>",
"    ]. Males never present with incontinence because the ectopic ureter is always proximal to the external urethral sphincter (",
"    <a class=\"graphic graphic_figure graphicRef78218 \" href=\"mobipreview.htm?27/9/27798\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other presentations for boys with ectopic ureters include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flank pain",
"     </li>",
"     <li>",
"      Sense of urgency or frequency in patients with ureteric termination in the posterior urethra",
"     </li>",
"     <li>",
"      In rare cases, newborn males with bladder outlet obstruction due to a dilated prostatic ectopic ureter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Females",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infancy, girls usually present with UTI. However, after toilet training, girls generally present with incontinence because, in most cases, the site of insertion of the ectopic ureter is distal to or bypasses the external sphincter (",
"    <a class=\"graphic graphic_figure graphicRef65413 \" href=\"mobipreview.htm?41/1/42002\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56184 \" href=\"mobipreview.htm?43/38/44643\">",
"     image 1",
"    </a>",
"    ). The parents typically report that the girl has normal voiding habits but is always wet. She may become wetter when she is sitting on the parent's lap because of urine pooling in the dilated ureter or vagina.",
"   </p>",
"   <p>",
"    Some older girls may present with pyelonephritis, which more likely occurs in patients with a dysplastic kidney and dilated ectopic ureter. Infection results from urinary stasis and obstruction. In addition, girls may present with flank pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other anomalies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Genitourinary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common anomaly associated with an ectopic ureter is renal hypoplasia or dysplasia in patients with a single collecting system, and",
"    <span class=\"nowrap\">",
"     hypoplasia/dysplasia",
"    </span>",
"    of the affected pole of the kidney in patients with a duplex system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/1\">",
"     1",
"    </a>",
"    ]. In one series, 25 of 33 ectopic ureters were associated with a poorly functioning or nonfunctional renal moiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/3\">",
"     3",
"    </a>",
"    ]. The presence of a poorly functioning renal moiety may impact on the surgical decisions. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other reported genitourinary anomalies include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urethral duplication",
"     </li>",
"     <li>",
"      Hypospadias (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26280?source=see_link\">",
"       \"Hypospadias\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cloacal abnormalities",
"     </li>",
"     <li>",
"      In patients with ectopy associated with duplex system, 80 percent of the contralateral system is also duplicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Impalpable testes",
"     </li>",
"     <li>",
"      Ureterovaginal duplication",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nongenitourinary anomalies in patients with ectopic ureters include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anorectal malformations",
"     </li>",
"     <li>",
"      Tracheoesophageal fistula",
"     </li>",
"     <li>",
"      Congenital cardiac lesions",
"     </li>",
"     <li>",
"      Conductive hearing loss",
"     </li>",
"     <li>",
"      Spinal cord defects including meningomyelocele",
"     </li>",
"     <li>",
"      M&uuml;llerian abnormalities including uterine didelphys and vaginal duplication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In particular, females with alleged unilateral renal agenesis appear to be at risk for M&uuml;llerian abnormalities (eg, vaginal duplication with obstructed hemi-vagina). These abnormalities often present during puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. An ectopic ureter from a minimally functioning hypoplastic renal nubbin is associated with obstructed hemi-vagina. It generally is not detected by a",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/22/8548?source=see_link\">",
"     dimercaptosuccinic acid",
"    </a>",
"    (DMSA) renal scan and can also be difficult to localize on magnetic resonance imaging (MRI). As a result, increased clinical awareness of possible M&uuml;llerian abnormalities is needed in female patients with alleged renal agenesis (",
"    <a class=\"graphic graphic_figure graphicRef86776 \" href=\"mobipreview.htm?40/61/41936\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is made by imaging studies that identify the ectopic ureter.",
"   </p>",
"   <p>",
"    Renal ultrasound is the initial diagnostic test (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86775 \" href=\"mobipreview.htm?27/18/27941\">",
"     image 2",
"    </a>",
"    ). The ureter is often dilated down to its abnormally low position. In many cases, the ureter may be followed proximally to a dysplastic or normal upper segment moiety of a duplex system. In single system ectopia, the kidney may be dysplastic and difficult to visualize.",
"   </p>",
"   <p>",
"    Computed tomography (CT) and magnetic resonance imaging (MRI) with contrast is helpful in suspected cases of ectopic ureters and a normal ultrasound. For example, a nondilated ectopic ureter associated with the upper pole of a duplex renal system may drain into a normal caliber ureter, which is not visible on renal ultrasound. In this case, the only ultrasound finding may be a discrepancy in renal length. In these patients, MRI and CT generally will pinpoint the location of the ureter, and confirm the diagnosis of a nondilated upper pole ureter draining ectopically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A voiding cystourethrogram (VCUG) should be performed when the diagnosis of an ectopic ureter is considered. We recommend the use of cyclic VCUG, which more reliably detects reflux into the ectopic ureter compared to a standard VCUG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A renal scan is used to assess renal function prior to surgery, as the function of the renal moiety associated with the ectopic ureter will impact on surgical decisions. In patients with dysplastic kidneys that have little function, a static renal scan that uses the isotope",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/22/8548?source=see_link\">",
"     dimercaptosuccinic acid",
"    </a>",
"    (DMSA) may be more helpful to locate a poorly functioning ectopic kidney than the dynamic scan that uses technetium-99m-mercaptoacetyltriglycine (Tc99mMAG3). In patients with hydronephrosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dilated ureter, diuretic renography (renal scan and the administration of a diuretic) is performed to diagnose urinary obstruction. Diuretic renography is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34119?source=see_link&amp;anchor=H7#H7\">",
"     \"Postnatal management of antenatal hydronephrosis\", section on 'Diuretic renography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/30/32231?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Dynamic renal scan'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/30/32231?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Static renal scan'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management consists of surgical reconstruction. The approach depends upon whether the system is duplex or single, and the extent of function of the involved kidney moiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Duplex system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of ectopic ureter in a duplex system are associated with a dysplastic upper pole renal segment. Excision of this segment along with the proximal ureter is usually curative. When the upper pole has good function, the ectopic ureter is reimplanted into the bladder or anastomosed outside the bladder to the normal pole ureter (ureteroureterostomy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Single system",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with an ectopic ureter in a single system, the affected kidney is usually small and poorly functional, and the base of the bladder (hemitrigone) is poorly developed. Management usually consists of nephrourecterectomy. If the kidney is functional, the treatment is resection of the distal ectopic ureter and reimplantation into the bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with ectopic ureters, long-term surgical outcome is excellent with resolution of incontinence in almost all affected patients, and decrease rates of urinary tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/2,4,8\">",
"     2,4,8",
"    </a>",
"    ]. However, patients with either bladder outlet obstruction or bilateral single system ectopic ureter may have voiding dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    small bladders with inadequate capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39989/abstract/8,14,15\">",
"     8,14,15",
"    </a>",
"    ]. These patients are less likely to achieve continence. In some cases, bladder augmentation has been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic ureter is diagnosed when the ureteral orifice is caudal to the normal insertion on the trigone of the bladder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ectopic orifice is always found along the pathway of the developing mesonephric system. In affected males, the ectopic ureteral orifice is proximal to the external sphincter (",
"      <a class=\"graphic graphic_figure graphicRef78218 \" href=\"mobipreview.htm?27/9/27798\">",
"       figure 2",
"      </a>",
"      ), but in female patients, the ureteral orifice bypasses the external sphincter in two-thirds of the cases (",
"      <a class=\"graphic graphic_figure graphicRef65413 \" href=\"mobipreview.htm?41/1/42002\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef61532 \" href=\"mobipreview.htm?43/1/44063\">",
"       picture 2",
"      </a>",
"      ). This variation in anatomic sites explains the gender difference in presentation. In females, incontinence is the predominant complaint, and in males, incontinence is not seen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ureteral orifice site'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Postnatal presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ectopic ureters are associated with both single and duplex (double) renal collecting systems (",
"      <a class=\"graphic graphic_picture graphicRef86773 \" href=\"mobipreview.htm?2/32/2567\">",
"       picture 1",
"      </a>",
"      ). Renal hypoplasia or dysplasia is a common finding in patients with a single collecting system, and",
"      <span class=\"nowrap\">",
"       hypoplasia/dysplasia",
"      </span>",
"      of the affected pole of the kidney in patients with a duplex system. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Single versus duplex system'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Genitourinary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ectopic ureters are six times more likely to occur in females than males. Approximately 10 percent of ectopic ureters are bilateral. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ectopic ureter is increasingly being diagnosed by antenatal ultrasonography. In infants, urinary tract infection is the most common presenting sign for both sexes, but after toilet training, the presentation differs between boys and girls. In toilet-trained boys, urinary tract infections remains the most common finding followed by flank pain, sense of urgency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      frequency, and epididymoorchitis. In toilet-trained girls, the most common presentation is continuous wetness in a child with normal voiding habits. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ectopic ureter is usually made by ultrasound (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86775 \" href=\"mobipreview.htm?27/18/27941\">",
"       image 2",
"      </a>",
"      ). Computed tomography or magnetic resonance imaging may be helpful in cases of suspected ureteral ectopy with a normal ultrasound. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further imaging studies include voiding cystourethrogram to detect the presence or absence of reflux, and renal scan to evaluate the function of the renal moiety associated with the ectopic ureter. These results help guide surgical management. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Further evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend surgery for patients with ectopic ureters (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The approach depends upon whether the renal system is duplex or single, and the extent of function of the involved kidney. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical outcome for ectopic ureter is excellent with resolution of symptoms in most cases. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Cooper CS, Snyder HM. The ureter. In: Adult and Pediatric Urology, 4th ed, Gillenwater JY, Grayhack JT, Howards SS, Mitchell ME (Eds), Lippincott Williams and Wilkins, Philadelphia 2002. p.2155.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/2\">",
"      Chowdhary SK, Lander A, Parashar K, Corkery JJ. Single-system ectopic ureter: a 15-year review. Pediatr Surg Int 2001; 17:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/3\">",
"      Plaire JC, Pope JC 4th, Kropp BP, et al. Management of ectopic ureters: experience with the upper tract approach. J Urol 1997; 158:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/4\">",
"      Roy Choudhury S, Chadha R, Bagga D, et al. Spectrum of ectopic ureters in children. Pediatr Surg Int 2008; 24:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/5\">",
"      Wakhlu A, Dalela D, Tandon RK, et al. The single ectopic ureter. Br J Urol 1998; 82:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/6\">",
"      Gotoh T, Morita H, Tokunaka S, et al. Single ectopic ureter. J Urol 1983; 129:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/7\">",
"      Ahmed S, Barker A. Single-system ectopic ureters: a review of 12 cases. J Pediatr Surg 1992; 27:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/8\">",
"      Mathews R, Jeffs RD, Maizels M, et al. Single system ureteral ectopia in boys associated with bladder outlet obstruction. J Urol 1999; 161:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/9\">",
"      Siegel A, Snyder H, Duckett JW. Epididymitis in infants and boys: underlying urogenital anomalies and efficacy of imaging modalities. J Urol 1987; 138:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/10\">",
"      Malek RS, Kelalis PP, Stickler GB, Burke EC. Observations on ureteral ectopy in children. J Urol 1972; 107:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/11\">",
"      Herlyn U, Werner H. [Simultaneous occurrence of an open Gartner-duct cyst, a homolateral aplasia of the kidney and a double uterus as a typical syndrome of abnormalities]. Geburtshilfe Frauenheilkd 1971; 31:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/12\">",
"      Wunderlich M. [Unusual form of genital malformation with aplasia of the right kidney]. Zentralbl Gynakol 1976; 98:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/13\">",
"      Son le T, Thang le C, Hung le T, Tram NT. Single ectopic ureter: diagnostic value of contrast vaginography. Urology 2009; 74:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/14\">",
"      Jayanthi VR, Churchill BM, Khoury AE, McLorie GA. Bilateral single ureteral ectopia: difficulty attaining continence using standard bladder neck repair. J Urol 1997; 158:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39989/abstract/15\">",
"      Podest&agrave; E, Scarsi PL, Di Rovasenda E, et al. Vesical continence in bilateral ectopic single ureters. J Urol 2001; 165:2363.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6584 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-5203FA14AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39989=[""].join("\n");
var outline_f39_3_39989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ureteral orifice site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Single versus duplex system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prenatal presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Postnatal presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Males",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Females",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other anomalies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Genitourinary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Duplex system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Single system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6584\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6584|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/38/44643\" title=\"diagnostic image 1\">",
"      Ectopic ureter MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/18/27941\" title=\"diagnostic image 2\">",
"      Ultrasound of renal duplex system and ectopic ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6584|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/49/28433\" title=\"figure 1\">",
"      Ectopic ureter pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/9/27798\" title=\"figure 2\">",
"      Ectopic ureter male",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/1/42002\" title=\"figure 3\">",
"      Ectopic ureter female",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/4/27713\" title=\"figure 4\">",
"      Ectopic ureter duplex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/61/41936\" title=\"figure 5\">",
"      Alleged renal agenesis ectopic ureter and Mullerian defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6584|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/32/2567\" title=\"picture 1\">",
"      Intraoperative duplex renal system and ectopic ureter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/1/44063\" title=\"picture 2\">",
"      Female ectopic ureter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/30/32231?source=related_link\">",
"      Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26280?source=related_link\">",
"      Hypospadias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34119?source=related_link\">",
"      Postnatal management of antenatal hydronephrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_3_39990="Overview of vitamin D";
var content_f39_3_39990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of vitamin D",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39990/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39990/contributors\">",
"     Sassan Pazirandeh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39990/contributors\">",
"     David L Burns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39990/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39990/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39990/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39990/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39990/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/3/39990/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamins are chemically unrelated families of organic compounds that are essential in small amounts for normal metabolism. Because vitamins (with the exception of vitamin D) cannot be synthesized by humans, they need to be ingested in the diet to prevent disorders of metabolism. They are divided into water-soluble and fat-soluble (",
"    <a class=\"graphic graphic_table graphicRef63827 \" href=\"mobipreview.htm?12/15/12541\">",
"     table 1",
"    </a>",
"    ). Vitamin D is a fat-soluble vitamin.",
"   </p>",
"   <p>",
"    Deficiency of vitamin D (commonly referred to as \"rickets\" when it occurs in children) is of unique historical value. Rickets was first described in the mid 1600s by Whistler and Glisson [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/1\">",
"     1",
"    </a>",
"    ] but for decades thereafter, no progress was made in identifying the cause. In 1918, Sir Edward Mellanby described the deficiency of a fat-soluble nutrient as the cause for rickets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/2\">",
"     2",
"    </a>",
"    ]. Shortly thereafter, Goldblatt and Soames demonstrated that skin exposed to sunlight or ultraviolet light produced a substance with similar properties to this fat-soluble nutrient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/3\">",
"     3",
"    </a>",
"    ]. This ultimately led to the discovery of the chemical structure of vitamin D by Windaus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin D and its metabolites have a significant clinical role because of their interrelationship with calcium homeostasis and bone metabolism. Rickets due to vitamin D deficiency is now rare except in populations with unusually low sun exposure and lack of vitamin D in fortified foods. Subclinical vitamin D deficiency, as measured by low levels of 25OHD, has been described among adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/5,6\">",
"     5,6",
"    </a>",
"    ] and the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and may contribute to the development of osteoporosis and an increased risk of fractures and falls in the elderly. In addition to its role in calcium and bone homeostasis, vitamin D potentially regulates many other cellular functions.",
"   </p>",
"   <p>",
"    This topic review provides an overview of vitamin D. Other reviews discuss specific issues related to vitamin D. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=see_link\">",
"     \"Causes of vitamin D deficiency and resistance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=see_link\">",
"     \"Vitamin D and extraskeletal health\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHEMISTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D, or calciferol, is a generic term and refers to a group of lipid soluble compounds with a four-ringed cholesterol backbone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sunlight and ultraviolet light photoisomerize provitamin D to vitamin D3 (cholecalciferol) in the skin; they are then bound by the vitamin D binding proteins (DBP) and transported via blood to target organs for metabolism and activity (",
"    <a class=\"graphic graphic_figure graphicRef65360 \" href=\"mobipreview.htm?20/23/20862\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intestinal absorption is the other major source of vitamin D. As part of the diet, vitamin D is found in fortified milk, fatty fish, cod-liver oil and, to a lesser extent, eggs. In the United States, milk fortified with vitamin D2 (ergocalciferol, a plant steroid) or vitamin D3 (cholecalciferol) is the principal source of dietary vitamin D. In other parts of the world, cereals and bread products are often fortified with vitamin D.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ABSORPTION AND METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary vitamin D is incorporated into micelles, absorbed by enterocytes, and then packaged into chylomicrons. Disorders associated with fat malabsorption, such as celiac disease, Crohn disease, pancreatic insufficiency, cystic fibrosis, and cholestatic liver disease, are associated with low serum 25-hydroxyvitamin D levels. Chylomicrons are transported to the liver via the portal circulation where vitamin D undergoes a hydroxylation process by 25-hydroxylase to form 25-hydroxyvitamin D (25OHD). Further hydroxylation of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (1,25OHD) occurs in the mitochondria of the proximal tubules of the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/9\">",
"     9",
"    </a>",
"    ]. 1,25OHD is the physiologically active form of vitamin D, with more than 25 metabolites identified, each with different biologic activities.",
"   </p>",
"   <p>",
"    The synthesis of vitamin D and its metabolism to 1,25OHD is closely coupled to calcium homeostasis, and is modulated by parathyroid hormone, serum calcium, and phosphorus levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/10\">",
"     10",
"    </a>",
"    ]. When hypocalcemia occurs, serum PTH concentration increases and enhances tubular reabsorption of calcium, as well as the activity of alpha-1-hydroxylase in the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/11\">",
"     11",
"    </a>",
"    ]. This results in increased 1,25OHD production and, in turn, intestinal calcium absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/12\">",
"     12",
"    </a>",
"    ]. PTH also stimulates bone osteoclast activity to mobilize bone calcium stores, thereby increasing serum calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/13\">",
"     13",
"    </a>",
"    ]. Estrogen, placental growth hormone, and prolactin may also regulate vitamin D metabolism, playing a role during pregnancy to meet increased calcium demands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DEFICIENCY AND RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency or resistance is caused by one of four mechanisms (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=see_link\">",
"     \"Causes of vitamin D deficiency and resistance\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired availability of vitamin D, secondary to inadequate dietary vitamin D, fat malabsorptive disorders,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lack of photoisomerization",
"     </li>",
"     <li>",
"      Impaired hydroxylation by the liver to produce 25-hydroxyvitamin D",
"     </li>",
"     <li>",
"      Impaired hydroxylation by the kidneys to produce 1,25-dihydroxyvitamin D",
"     </li>",
"     <li>",
"      End organ insensitivity to vitamin D metabolites (hereditary vitamin D resistant rickets)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lack of vitamin D activity leads to reduced intestinal absorption of calcium and phosphorus. Early in vitamin D deficiency, hypophosphatemia is more marked than hypocalcemia. With persistent vitamin D deficiency, hypocalcemia occurs and causes secondary hyperparathyroidism, which leads to phosphaturia, demineralization of bones and, when prolonged, to osteomalacia in adults and rickets in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Nutritional rickets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids, when used chronically in high doses, inhibit intestinal vitamin D-dependent calcium absorption and therefore can cause osteomalacia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D stores decline with age, especially in the winter. Controlled trials have demonstrated that vitamin D and calcium supplementation can reduce the risk of falls and fractures in the elderly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Benefits of vitamin D repletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have shown suboptimal serum levels of 25OHD and vitamin D intake in children in the United States and other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/5,15-19\">",
"     5,15-19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Requirements'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=see_link\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EXCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1940s and 1950s, a number of children developed hypercalcemia, sometimes associated with brain injury, thought to be a result of high concentrations of vitamin D in fortified milk products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/20\">",
"     20",
"    </a>",
"    ]. Symptoms of acute intoxication are due to hypercalcemia and include confusion, polyuria, polydipsia, anorexia, vomiting, and muscle weakness. Chronic intoxication may cause bone demineralization and pain. Vitamin D intoxication may occur in fad dieters who consume \"megadoses\" of supplements or in patients who take vitamin D replacement therapy for malabsorption, renal osteodystrophy, osteoporosis, or psoriasis. Vitamin D intoxication has been documented in adults taking more than 60,000 international units per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/20\">",
"     20",
"    </a>",
"    ]. The diagnosis and treatment of vitamin D toxicity are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intake at which the dose of vitamin D becomes toxic is not clear. The Institute of Medicine has defined the \"tolerable upper intake level\" (UL) for vitamin D as 100 micrograms (4000 international units) daily for healthy adults and children 9 to 18 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/21\">",
"     21",
"    </a>",
"    ]. This is also the UL for pregnant and lactating women. The UL for infants and children up to nine years old is lower (",
"    <a class=\"graphic graphic_table graphicRef81151 \" href=\"mobipreview.htm?19/31/19967\">",
"     table 2",
"    </a>",
"    ). Indications for high dose vitamin D supplementation and the UL for vitamin D supplementation are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Institute of Medicine (IOM) released a report on dietary intake requirements for calcium and vitamin D in 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/21\">",
"     21",
"    </a>",
"    ]. The dietary reference intakes were based upon the beneficial effects of calcium and vitamin D on skeletal health. The evidence supporting a benefit of vitamin D on extraskeletal outcomes was inconsistent, inconclusive as to causality, and insufficient, and therefore could not serve as a basis for dietary reference intake development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=see_link\">",
"     \"Vitamin D and extraskeletal health\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estimates of vitamin D requirements vary and depend in part upon sun exposure and the standards used to define a deficient state. The Institute of Medicine (IOM) committee assumed minimal sun exposure when establishing the dietary reference intakes for vitamin D. The committee also concluded that a serum 25-hydroxyvitamin D concentration of 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    was sufficient for most individuals.",
"   </p>",
"   <p>",
"    The Recommended Dietary Allowance (RDA) of vitamin D for children 1 to 18 years and adults through age 70 years is 600 international units (15 mcg) with the RDA increasing to 800 international units (20 mcg) after age 71 (",
"    <a class=\"graphic graphic_table graphicRef81151 \" href=\"mobipreview.htm?19/31/19967\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/21\">",
"     21",
"    </a>",
"    ]. For pregnant and lactating mothers, intake of 600 international units (15 mcg) is recommended. However, some studies suggest that higher intakes may be necessary to maintain normal levels of 25OHD during pregnancy and lactation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin D supplementation should be given to infants who are exclusively breast fed because the vitamin D content of human milk is low. The Lawson Wilkins Pediatric Endocrine Society recommends supplementation with 400 international units (units) daily of vitamin D beginning within days of birth for infants who are exclusively breast-fed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/19\">",
"     19",
"    </a>",
"    ]. Most infant formulas contain at least 400",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    of vitamin D, so formula-fed infants will also require supplementation to meet this goal unless they consume at least 1000 mL daily of formula. Vitamin D intake of at least 400",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    also recommended for children who do not consume at least one liter of vitamin D fortified milk daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=see_link&amp;anchor=H722827#H722827\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Casual exposure to sunlight provides amounts of vitamin D that are adequate to prevent rickets in many people, but is influenced by geographic location, season, use of sun block lotion, and skin pigmentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/12\">",
"     12",
"    </a>",
"    ]. As an example, a Caucasian infant's vitamin D requirements are met by exposure to sunlight for 30 minutes per week, clothed only in a diaper, or two hours per week fully clothed with no hat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/25\">",
"     25",
"    </a>",
"    ]. African-American individuals require approximately threefold longer periods of sunlight exposure because of the protective pigmentation in their skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/26\">",
"     26",
"    </a>",
"    ]. Currently recommended sun exposure for infants is insufficient to maintain vitamin D levels in the recommended range for dark-skinned infants and children, particularly at high latitudes and during the winter months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=see_link&amp;anchor=H23365767#H23365767\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Decreased synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D requirements also may depend on disease states and concomitant medications. As an example, patients undergoing long-term treatment with steroids may benefit from higher levels of supplementation of vitamin D and calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best laboratory indicator of vitamin D adequacy is the serum 25-hydroxyvitamin D (25OHD) concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/28\">",
"     28",
"    </a>",
"    ]. The lower limit of normal for 25OHD levels varies depending on the geographic location and sunlight exposure of the reference population (range 8 to 15",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    However, there is no consensus on the optimal 25OHD concentration for skeletal or extraskeletal health. The IOM suggests that a level of 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    is adequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39990/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Biochemical criteria'",
"    </a>",
"    .) The serum parathyroid hormone (PTH) level typically is inversely related to 25-OH vitamin D levels in adults, and may be a useful secondary indicator of vitamin D insufficiency. In general, this relation is weak for children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/45/10962?source=see_link\">",
"       \"Patient information: Vitamin D deficiency (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/57/13202?source=see_link\">",
"       \"Patient information: Vitamin D for babies and children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/62/15331?source=see_link\">",
"       \"Patient information: Vitamin D deficiency (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Very few foods contain vitamin D; fatty fish and eggs are the exceptions. Dermal synthesis and foods fortified with vitamin D are the major sources of the vitamin. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Absorption and metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin D3 (cholecalciferol) is synthesized nonenzymatically in skin from 7-dehydrocholesterol during exposure to the ultraviolet rays in sunlight. Cholecalciferol from the skin or diet must be 25-hydroxylated in the liver, then 1-hydroxylated in the kidneys to the active form, 1,25-dihydroxycholecalciferol (calcitriol) (",
"      <a class=\"graphic graphic_figure graphicRef65360 \" href=\"mobipreview.htm?20/23/20862\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Absorption and metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin D deficiency can be caused by unusually low sun exposure combined with lack of vitamin D fortified foods or malabsorption. Alternatively, impaired hydroxylation of vitamin D in liver or kidney can prevent metabolism into the physiologically active form. Rarely, genetic defects may cause the end organs to be unresponsive to vitamin D, as in hereditary vitamin D-resistant rickets (HVDRR). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Deficiency and resistance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=see_link\">",
"       \"Causes of vitamin D deficiency and resistance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Recommended Dietary Allowance for vitamin D is 600 international units (units) for adults through age 70 years and for children 1 to 18 years of age (",
"      <a class=\"graphic graphic_table graphicRef81151 \" href=\"mobipreview.htm?19/31/19967\">",
"       table 2",
"      </a>",
"      ). For adults 71 years and older, 800 units (20 micrograms) daily is recommended for the prevention and treatment of osteoporosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Requirements'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excessive doses of vitamin D supplements in adults can result in intoxication. Symptoms of acute intoxication are due to hypercalcemia and include confusion, polyuria, polydipsia, anorexia, vomiting, and muscle weakness. Long-term intoxication can cause bone demineralization and pain. In children, the hypercalcemia can cause brain injury. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Excess'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Institute of Medicine has defined the \"tolerable upper intake level\" (UL) for vitamin D as 100 micrograms (4000 units) daily for healthy adults and children 9 to 18 years (",
"      <a class=\"graphic graphic_table graphicRef81151 \" href=\"mobipreview.htm?19/31/19967\">",
"       table 2",
"      </a>",
"      ). The UL for infants and children up to nine years old is lower. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Excess'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Fraser D, Scriver CR. Hereditary disorders associated with vitamin D resistance or defective phosphate metabolism. In: Endocrinology, DeGroot  LJ (Ed), Grune and Stratton, New York 1979. p.797.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/2\">",
"      Mellanby, T. The part played by an \"accessory factor\" in the production of experimental rickets. A further demonstration of the part played by accessory food factors in the aetiology of rickets. J Physiology 1918; 52:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/3\">",
"      Goldblatt H, Soames KM. A Study of Rats on a Normal Diet Irradiated daily by the Mercury Vapour Quartz Lamp or kept in Darkness. Biochem J 1923; 17:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/4\">",
"      Windaus, A, Schenck, F, Von Werder, F. About the antirachitic irradiation product of 7-dehydrocholesterol. Hoppe Seylers Z Physiol Chem 1936; 241:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/5\">",
"      Gordon CM, DePeter KC, Feldman HA, et al. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004; 158:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/6\">",
"      Das G, Crocombe S, McGrath M, et al. Hypovitaminosis D among healthy adolescent girls attending an inner city school. Arch Dis Child 2006; 91:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/7\">",
"      Lips P, Hosking D, Lippuner K, et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 2006; 260:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/8\">",
"      Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/9\">",
"      Henry HL, Norman AW. Studies on calciferol metabolism. IX. Renal 25-hydroxy-vitamin D3-1 hydroxylase. Involvement of cytochrome P-450 and other properties. J Biol Chem 1974; 249:7529.",
"     </a>",
"    </li>",
"    <li>",
"     Holick MF. Biosynthesis, metabolism, and mode of action. In: Endocrinology, DeGroot LJ (Ed), Grune &amp; Stratton, New York 1989. p.902.",
"    </li>",
"    <li>",
"     Holick MF, Krane SM, Potts JT. Calcium, phosphorus, and bone metabolism: Calcium-regulation hormones. In: Harrison's principles of internal medicine, 14th, Fauci AS, Braunwald E, Isselbacher KJ, et al (Eds), McGraw-Hill, New York 1995. p.2214.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/12\">",
"      Holick MF. McCollum Award Lecture, 1994: vitamin D--new horizons for the 21st century. Am J Clin Nutr 1994; 60:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/13\">",
"      Holick MF. Vitamin D and bone health. J Nutr 1996; 126:1159S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/14\">",
"      Kovacs CS, Kronenberg HM. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr Rev 1997; 18:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/15\">",
"      Cole CR, Grant FK, Tangpricha V, et al. 25-hydroxyvitamin D status of healthy, low-income, minority children in Atlanta, Georgia. Pediatrics 2010; 125:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/16\">",
"      Razzaghy-Azar M, Shakiba M. Assessment of vitamin D status in healthy children and adolescents living in Tehran and its relation to iPTH, gender, weight and height. Ann Hum Biol 2010; 37:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/17\">",
"      Mansbach JM, Ginde AA, Camargo CA Jr. Serum 25-hydroxyvitamin D levels among US children aged 1 to 11 years: do children need more vitamin D? Pediatrics 2009; 124:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/18\">",
"      Rovner AJ, O'Brien KO. Hypovitaminosis D among healthy children in the United States: a review of the current evidence. Arch Pediatr Adolesc Med 2008; 162:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/19\">",
"      Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008; 122:398.",
"     </a>",
"    </li>",
"    <li>",
"     Morgan SL, Weinsier RL. Fundamentals of clinical nutrition, Mosby, St. Louis 1998. p.3.",
"    </li>",
"    <li>",
"     Institute of Medicine. Report at a Glance, Report Brief: Dietary Reference Intakes for Calcium and Vitamin D, released 11/30/2010. file://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx (Accessed on December 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/22\">",
"      Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/23\">",
"      Hollis BW, Wagner CL. Assessment of dietary vitamin D requirements during pregnancy and lactation. Am J Clin Nutr 2004; 79:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/24\">",
"      Hollis BW, Wagner CL. Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. Am J Clin Nutr 2004; 80:1752S.",
"     </a>",
"    </li>",
"    <li>",
"     Butte NF,  Lopez-Alarcon  MG, Garza C. Nutrient adequacy of exclusive breastfeeding for the term infant during the first six months of life. World Health Organization, Geneva, 2002. file://whqlibdoc.who.int/publications/9241562110.pdf (Accessed on June 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/26\">",
"      Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982; 1:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39990/abstract/27\">",
"      De S&eacute;vaux RG, Hoitsma AJ, Corstens FH, Wetzels JF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 2002; 13:1608.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board of the Institute of Medicine. Vitamin  D. In: Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, fluoride, National Academies Press, Washington, DC 1997. p.250.",
"    </li>",
"    <li>",
"     file://books.nap.edu/openbook.php?record_id=13050 (Accessed on December 08, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2033 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39990=[""].join("\n");
var outline_f39_3_39990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHEMISTRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ABSORPTION AND METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DEFICIENCY AND RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EXCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2033|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/23/20862\" title=\"figure 1\">",
"      Vit D metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/15/12541\" title=\"table 1\">",
"      Clinical symptoms of selected vitamin deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/31/19967\" title=\"table 2\">",
"      Fat sol vit DRI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38184?source=related_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=related_link\">",
"      Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/62/15331?source=related_link\">",
"      Patient information: Vitamin D deficiency (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/45/10962?source=related_link\">",
"      Patient information: Vitamin D deficiency (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/57/13202?source=related_link\">",
"      Patient information: Vitamin D for babies and children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=related_link\">",
"      Vitamin D and extraskeletal health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_3_39991="Flow CLL";
var content_f39_3_39991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Flow cytometry of chronic lymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunophenotypic analysis of chronic lymphocytic leukemia (CLL) is usually performed using flow cytometry. Typically, the cells express dim CD20, dim CD5, and CD23. This figure displays flow cytometry results for CD5 and CD20 expression. The CLL cells are shown in red and demonstrate weak expression of both CD5 and CD20.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin Lymphomas, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39991=[""].join("\n");
var outline_f39_3_39991=null;
var title_f39_3_39992="Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn";
var content_f39_3_39992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39992/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39992/contributors\">",
"     Ronald J Wong, BA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39992/contributors\">",
"     Vinod K Bhutani, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39992/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39992/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39992/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39992/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/3/39992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all newborn infants develop a total serum or plasma bilirubin (TB) level greater than 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (17",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    which is the upper limit of normal for adults. As the TB increases, it produces neonatal jaundice, the yellowish discoloration of the skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sclerae caused by bilirubin deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperbilirubinemia in infants &ge;35 weeks gestation is defined as a TB &gt;95th percentile on the hour-specific Bhutani nomogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/2\">",
"     2",
"    </a>",
"    ]. Hyperbilirubinemia with a TB &gt;25 to 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (428 to 513",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    is associated with an increased risk for bilirubin-induced neurologic dysfunction (BIND), which occurs when bilirubin crosses the blood-brain barrier and binds to brain tissue. The term \"acute bilirubin encephalopathy\" (ABE) is used to describe the acute manifestations of BIND. The term \"kernicterus\" is used to describe the chronic and permanent sequelae of BIND. Appropriate intervention is important to consider in every infant with severe hyperbilirubinemia. However, even if these infants are adequately treated, long-term neurologic sequelae (kernicterus) can sometimes develop.",
"   </p>",
"   <p>",
"    The pathogenesis and etiology of neonatal unconjugated hyperbilirubinemia is reviewed here. The clinical features, evaluation, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/63/25593?source=see_link\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=see_link\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BILIRUBIN METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the basic steps in bilirubin metabolism is essential to the understanding of the pathogenesis of neonatal hyperbilirubinemia. Bilirubin metabolism is briefly reviewed here and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bilirubin production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilirubin is a product of heme catabolism. Approximately 80 to 90 percent of bilirubin is produced during the breakdown of hemoglobin from red blood cells or from ineffective erythropoiesis. The remaining 10 to 20 percent is derived from the breakdown of other heme-containing proteins, such as cytochromes and catalase.",
"   </p>",
"   <p>",
"    Bilirubin is formed in two steps. The enzyme heme oxygenase (HO), located in the spleen and liver as well as all nucleated cells, catalyzes the breakdown of heme, resulting in the formation of equimolar quantities of carbon monoxide (CO) and biliverdin. Biliverdin then is converted to bilirubin by the enzyme biliverdin reductase. Measurements of CO production, such as end-tidal CO (ETCO) or carboxyhemoglobin (COHb), both corrected for ambient CO (ETCOc and COHbc, respectively), can be used as indices of in vivo bilirubin production. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=see_link&amp;anchor=H20#H20\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'End-tidal carbon monoxide concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bilirubin clearance and excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clearance and excretion of bilirubin occurs in the following steps (",
"    <a class=\"graphic graphic_figure graphicRef52393 \" href=\"mobipreview.htm?30/51/31536\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic uptake &ndash; Circulating bilirubin, which is bound to albumin, is transported to the liver. Bilirubin dissociates from albumin and is taken up by hepatocytes, where it is processed for excretion.",
"     </li>",
"     <li>",
"      Conjugation &ndash; In hepatocytes, uridine diphosphogluconurate glucuronosyltransferase (UGT) catalyzes the conjugation of bilirubin with glucuronic acid, producing bilirubin diglucuronides and, to a lesser degree, bilirubin monoglucuronides. Conjugated bilirubin, which is more water-soluble than unconjugated bilirubin, is excreted in bile.",
"     </li>",
"     <li>",
"      Biliary excretion &ndash; Conjugated bilirubin is secreted into the bile in an active process that depends upon canalicular transporters, and then excreted into the digestive tract (",
"      <a class=\"graphic graphic_figure graphicRef52393 \" href=\"mobipreview.htm?30/51/31536\">",
"       figure 1",
"      </a>",
"      ). Conjugated bilirubin cannot be reabsorbed by the intestinal epithelial cells. It is broken down in the intestine by bacterial enzymes and, in the adult it is reduced to urobilin by bacterial enzymes. But at birth the infant's gut is sterile and, subsequently, infants have far fewer bacteria in the gut, so very little, if any, conjugated bilirubin is reduced to urobilin. Infants have beta-glucuronidase in the intestinal mucosa, which deconjugates the conjugated bilirubin. The unconjugated bilirubin can now be reabsorbed through the intestinal wall and recycled into the circulation, a process known as the \"enterohepatic circulation of bilirubin\".",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NEONATAL JAUNDICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpathologic jaundice is caused by normal neonatal changes in bilirubin metabolism resulting in increased bilirubin production, decreased bilirubin clearance, and increased enterohepatic circulation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In term newborn infants, bilirubin production is two to three times higher than in adults. This occurs because newborns have more red blood cells (hematocrit between 50 to 60 percent) and the cells have a shorter life span (approximately 85 days) than those in adults. The increased turnover of more red blood cells produces more bilirubin.",
"     </li>",
"     <li>",
"      Bilirubin clearance is decreased in newborns, mainly due to the deficiency of the enzyme UGT1A1. UGT activity in term infants at 7 days of age is approximately 1 percent of the adult liver and does not reach adult levels until 14 weeks of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is an increase in the enterohepatic circulation of bilirubin, further increasing the bilirubin load in the infant. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Bilirubin clearance and excretion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These normal physiologic alterations generally result in the mild unconjugated (indirect-reacting) bilirubinemia that occurs in nearly all newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Caucasian and African-American infants, the mean peak TB occurs 48 to 96 hours of age and is 7 to 9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (120 to 154",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      The 95th percentile ranges from 13 to 18",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (222 to 308",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In some Asian infants, mean TB levels can reach 10 to 14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (171 to 239",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      and can occur later, between 72 and 120 hours of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Primary neonatal jaundice resolves within the first one to two weeks after birth.",
"   </p>",
"   <p>",
"    Peak TB is also later in infants born at 35 to 37 weeks gestational age. Physiologic jaundice resolves within the first one to two weeks after birth, usually by the fifth day in Caucasian and African-American infants, and by the 10th day in Asian infants.",
"   </p>",
"   <p>",
"    Differences in TB levels among races may result from specific genetic variations in conjugating ability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, polymorphisms in the UGT1A1 gene, due to differences in the number of thymine-adenine (TA) repeats in the promoter region of the gene, vary among individuals of Asian, African, and Caucasian ancestry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/6\">",
"     6",
"    </a>",
"    ]. These polymorphisms correlate with decreases in UGT1A1 enzyme activity resulting in increased TB levels.",
"   </p>",
"   <p>",
"    Another cause of racial variation in the development of neonatal jaundice results from a common mutation in the UGT1A1 gene at Gly71Arg that occurs in Asians. This mutation leads to an increased incidence of severe neonatal hyperbilirubinemia (approximately 20 percent) in Asians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HYPERBILIRUBINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbilirubinemia (defined as a TB &gt;95th percentile on the hour-specific Bhutani nomogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/2\">",
"     2",
"    </a>",
"    ]) can be caused by certain pathologic conditions or by exaggeration of the mechanisms responsible for neonatal jaundice. Identification of the cause of neonatal hyperbilirubinemia is useful in determining whether therapeutic interventions can prevent severe hyperbilirubinemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following features suggest severe hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jaundice in the first 24 hours (usually caused by increased bilirubin production due to hemolysis)",
"     </li>",
"     <li>",
"      TB greater than the hour-specific 95th percentile (",
"      <a class=\"graphic graphic_figure graphicRef70863 \" href=\"mobipreview.htm?18/51/19263\">",
"       figure 2",
"      </a>",
"      ). The risk for severe hyperbilirubinemia and the threshold for intervention based upon the hour-specific bilirubin value may be determined using the newborn hyperbilirubinemia assessment calculator (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/63/5109?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/63/25593?source=see_link\">",
"       \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rate of TB rise greater than 0.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      per hour",
"     </li>",
"     <li>",
"      Jaundice in a term newborn after 2 weeks of age",
"     </li>",
"     <li>",
"      Direct (conjugated) bilirubin concentration &gt;1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (17",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      if the total bilirubin is &lt;5.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (86",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"      more than 20 percent of the total bilirubin if the total bilirubin is &gt;5.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (86",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/10\">",
"       10",
"      </a>",
"      ]. An increase in direct (conjugated) bilirubin is suggestive of cholestasis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24519?source=see_link\">",
"       \"Approach to neonatal cholestasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CAUSES OF HYPERBILIRUBINEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increased production",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of pathologic indirect hyperbilirubinemia is increased bilirubin production due to hemolytic disease processes that include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/5-7,11-15\">",
"     5-7,11-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isoimmune-mediated hemolysis (eg, ABO or Rh(D) incompatibility). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3912?source=see_link\">",
"       \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27832?source=see_link&amp;anchor=H15#H15\">",
"       \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Hemolytic disease of the fetus and newborn'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inherited red blood cell membrane defects (eg, hereditary spherocytosis and elliptocytosis). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20506?source=see_link\">",
"       \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15623?source=see_link\">",
"       \"Hereditary elliptocytosis: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erythrocyte enzymatic defects (eg, glucose-6-phosphate dehydrogenase (G6PD) deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/16\">",
"       16",
"      </a>",
"      ], pyruvate kinase deficiency, and congenital erythropoietic porphyria). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4505?source=see_link\">",
"       \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27559?source=see_link\">",
"       \"Pyruvate kinase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5801?source=see_link\">",
"       \"Congenital erythropoietic porphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sepsis is a known cause of hemolysis. The mechanism is not known; however, one theory suggests that increased oxidative stress due to sepsis damages neonatal red blood cells that are susceptible to cell injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other causes of increased bilirubin production due to increased red blood cell breakdown include polycythemia or sequestration of blood within a closed space, which occurs in cephalohematoma. Macrosomic infants of diabetic mothers (IDM) also have increased bilirubin production due to either polycythemia or ineffective erythropoiesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36968?source=see_link\">",
"     \"Neonatal polycythemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=see_link\">",
"     \"Infant of a diabetic mother\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Decreased clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited defects in the UGT1A1 gene, which catalyzes the conjugation of bilirubin with glucuronic acid, decrease bilirubin conjugation. This reduces hepatic bilirubin clearance and increases TB levels. These disorders include Crigler-Najjar syndrome types I and II and Gilbert's syndrome, which are briefly summarized below and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6201?source=see_link\">",
"     \"Crigler-Najjar syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Crigler-Najjar syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two variants of Crigler-Najjar syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6201?source=see_link\">",
"     \"Crigler-Najjar syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Crigler-Najjar syndrome type I (CN-I) &ndash; Crigler-Najjar syndrome type I (CN-I) is the most severe form of inherited UGT1A1 disorders. UGT activity is essentially absent, and severe hyperbilirubinemia develops in the first two to three days after birth. Lifelong phototherapy is required to avoid BIND unless liver transplantation is performed. The mode of inheritance is autosomal recessive.",
"     </li>",
"     <li>",
"      Crigler-Najjar syndrome type II &ndash; Crigler-Najjar syndrome type II (CN-II) is less severe than is CN-I. UGT activity in this disorder is low but detectable. Although some affected children develop severe jaundice, the hyperbilirubinemia often responds to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"       phenobarbital",
"      </a>",
"      treatment. CN-II usually is inherited in an autosomal recessive manner, although autosomal dominant transmission occurs in some cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gilbert's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gilbert's syndrome is the most common inherited disorder of bilirubin glucuronidation. It results from a mutation in the promoter region of the UGT1A1 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/17\">",
"     17",
"    </a>",
"    ]. The mutation causes a reduced production of UGT, leading to unconjugated hyperbilirubinemia. Breast milk jaundice during the second week after birth may be due to the concurrent neonatal manifestation of Gilbert&rsquo;s syndrome.",
"   </p>",
"   <p>",
"    In the United States, 9 percent of the population is homozygous and 42 percent heterozygous for the Gilbert's mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/18\">",
"     18",
"    </a>",
"    ]. Newborns who are homozygous for the gene mutation have a higher incidence of jaundice during the first two days after birth than normal infants or those who are heterozygous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/19\">",
"     19",
"    </a>",
"    ]. Similar findings have been noted in other parts of the world, especially Asian countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/8,20\">",
"     8,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Gilbert's genotype is particularly clinically apparent when affected newborns have increased bilirubin production or enhanced enterohepatic circulation. As an example, in one study, infants with the normal Gilbert's genotype did not produce an increase in the incidence of hyperbilirubinemia, 9.7 percent of the deficient infants and 9.9 percent of the G6PD-sufficient normal infants had a TB &ge;15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (257",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/21\">",
"     21",
"    </a>",
"    ]. However, hyperbilirubinemia was more frequent in G6PD-deficient infants who were homozygous or heterozygous for the Gilbert's mutation (50 and 32 percent, respectively). In another study of male infants with G6PD deficiency, mean TB was highest in patients who were homozygotes (11.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [190",
"    <span class=\"nowrap\">",
"     micromol/L]),",
"    </span>",
"    followed by heterozygotes for the Gilbert mutation (9.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [156",
"    <span class=\"nowrap\">",
"     micromol/L]),",
"    </span>",
"    and those without the mutation (8.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [150",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of a usually benign polymorphism of Gilbert's genotype coupled with another factor that increases TB may be the underlying cause of some of the rare cases of infants with extremely high TB levels (&gt;25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [428",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     OATP-2 polymorphism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the polymorphisms of the of the UGT gene discussed above, a study of Taiwanese newborns reported that those with a polymorphic variant of the organic anion transporter protein OATP-2 (also known as OATP-C or solute carrier organic anion transporter 1B1 [SLCO1B1]) were more likely to develop severe hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/24\">",
"     24",
"    </a>",
"    ]. Furthermore, the combination of the OATP-2 polymorphism with a UGT1A1 gene mutation increased this risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of decreased bilirubin clearance include maternal diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/25\">",
"     25",
"    </a>",
"    ], congenital hypothyroidism and galactosemia, although in the latter case, infants typically present with elevated conjugated hyperbilirubinemia. These conditions usually are identified by metabolic screening programs; however, infants may develop severe and prolonged jaundice before screening results become available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30886?source=see_link\">",
"     \"Clinical features and diagnosis of galactosemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Increased enterohepatic circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major causes of increased enterohepatic circulation of bilirubin are breastfeeding failure jaundice, breast milk jaundice, or impaired intestinal motility caused by functional or anatomic obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Breast milk jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast milk jaundice is defined as the persistence of physiologic jaundice beyond the first week of age. It typically begins after the first three to five days of life, peaks within two weeks after birth, and progressively declines to normal levels over 3 to 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/26\">",
"     26",
"    </a>",
"    ]. Breast milk jaundice, a benign condition, needs to be distinguished from breastfeeding failure jaundice that occurs within the first seven days of life, which is caused by decrease intake resulting in excessive weight and fluid loss. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Breastfeeding failure jaundice'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In breast milk jaundice, infants commonly have TB levels &gt;5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (86",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    for several weeks after delivery. Although, the hyperbilirubinemia is generally mild and does not require intervention, it should be monitored to ensure that it remains unconjugated and does not increase. If TB levels begin to increase or there is a significant component of conjugated bilirubin, evaluation for other causes of hyperbilirubinemia should be performed including neonatal cholestasis. If after evaluation, the clinical diagnosis of breast milk jaundice is made, breast feeding can continue with the expectation of resolution by 12 weeks of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=see_link\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24519?source=see_link\">",
"     \"Approach to neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breast milk jaundice appears to be caused by a factor, which has not yet been identified, in human milk that promotes an increase in intestinal absorption of bilirubin. Beta-glucuronidase is one proposed substance as it deconjugates intestinal bilirubin, increasing its ability to be absorbed (ie, increasing enterohepatic circulation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/28\">",
"     28",
"    </a>",
"    ]. Approximately 20 to 40 percent of women have high levels of beta-glucuronidase in their breast milk. Blocking the deconjugation of bilirubin through beta-glucuronidase inhibition may provide a mechanism to reduce intestinal absorption of bilirubin in breastfed infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/29\">",
"     29",
"    </a>",
"    ]. Although some studies have found elevated fecal levels of beta-glucuronidase in breastfed infants with hyperbilirubinemia, this has not been a consistent finding.",
"   </p>",
"   <p>",
"    Beta-glucuronidase inhibitors such as enzymatically-hydrolyzed casein or L-aspartic acid have been used prophylactically in breastfed newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/29\">",
"     29",
"    </a>",
"    ]. However, further studies are needed to determine whether these agents are effective and safe in promoting increased fecal bilirubin excretion, and thereby resulting in lower TB. We do not currently recommend these agents for breast milk jaundice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intestinal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ileus or anatomic causes of intestinal obstruction increase the enterohepatic circulation of bilirubin and result in jaundice. TB levels are frequently higher with small bowel than with large bowel obstruction. As an example, jaundice occurs in 10 to 25 percent of infants with pyloric stenosis when vomiting begins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Breastfeeding failure jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding compared to formula feeding is associated with an increased risk of jaundice and kernicterus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of cases from the Pilot Kernicterus Registry, 59 of 61 infants with kernicterus were breastfed. Of the two infants who were formula-fed, both were found to have glucose-6-phosphate dehydrogenase deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one report, infants who were breastfed compared to bottle-fed infants at day three of life were more likely to have TB concentrations &gt;13",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (222",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      (8.9 versus 2.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, infants fed human milk compared with those fed formula had higher TB on day three of life and lower volumes of stool and urine output during the first week of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary mechanism for the increased likelihood of kernicterus and jaundice with breast versus formula feeding is the failure to successfully initiate breastfeeding rather than a direct effect of breast milk itself, as is seen in breast milk jaundice. A population-based study demonstrated that TB was only marginally higher in successfully breastfed compared to formula-fed infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breastfeeding failure jaundice typically occurs within the first week of life as lactation failure leads to inadequate intake with significant weight and fluid loss resulting in hypovolemia. This causes hyperbilirubinemia (jaundice) and in some cases, hypernatremia defined as a serum sodium &gt;150",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    Decreased intake also causes slower bilirubin elimination and increased enterohepatic circulation that contribute to elevated TB. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8217?source=see_link&amp;anchor=H19#H19\">",
"     \"Initiation of breastfeeding\", section on 'Weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A root cause analysis identified the following as predictors of lactation failure in infants with kernicterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8217?source=see_link\">",
"     \"Initiation of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inadequate education from clinicians and lactation consultants",
"     </li>",
"     <li>",
"      Inadequate documentation of infant latching",
"     </li>",
"     <li>",
"      Inadequate measurement of milk transfer",
"     </li>",
"     <li>",
"      Inadequate recording of urine output and stool pattern changes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, maternal breastfeeding complications, such as engorgement, cracked nipples, and fatigue, and neonatal factors, such as ineffective suck, may not be properly addressed prior to hospital discharge and result in ineffective breastfeeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17658?source=see_link\">",
"     \"Common problems of breastfeeding and weaning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although late preterm infant (defined as gestational age between 34 weeks, and 36 weeks and 6 days) are usually able to breastfeed, they are more likely to experience difficulty in establishing successful breastfeeding than term infants. Late preterm infants may not fully empty the breast because of increased sleepiness, fatigue,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    difficulty maintaining a latch because their oro-buccal coordination and swallowing mechanisms are not fully matured. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/12/36040?source=see_link&amp;anchor=H16#H16\">",
"     \"Breastfeeding the preterm infant\", section on 'Late preterm infants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of successful breastfeeding, one of the mainstays of preventing hyperbilirubinemia, has become an increasing problem due to shortened postpartum length of stay for newborn infants and their mothers. Postnatal educational and support, and care should be provided to the infant-mother dyad during the birth hospitalization and after discharge. The overall approach is briefly summarized here and is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42616?source=see_link\">",
"     \"Breastfeeding: Parental education and support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8217?source=see_link\">",
"     \"Initiation of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the first postpartum week while breastfeeding is being established, mothers should nurse whenever the infant shows signs of hunger or when four hours have elapsed since the last feeding. This will usually result in 8 to 12 feedings in 24 hours, which is usually sufficient to prevent significant hyperbilirubinemia that requires intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During the birth hospitalization, monitoring and assessment of breastfeeding are crucial. Problems identified in the hospital should be addressed at that time, and a documented plan for management after discharge should be communicated to both the parents and primary care provider.",
"     </li>",
"     <li>",
"      At discharge, a primary care appointment should be scheduled so that the infant-mother dyad is evaluated 24 to 48 after discharge and post-discharge lactation resources provided.",
"     </li>",
"     <li>",
"      At the follow-up appointment, supplementation with banked human milk or commercial infant formula is recommended when the infant has lost more than 7 percent of",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      birth weight, exhibits signs of dehydration (eg, decreased urine output), stool output is less than three small stools a day, and mother's milk supply remains limited. Glucose water or sterile water feedings should not be used, as they do not provide adequate nutrition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Severe hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although genetic factors may contribute to an increase in TB, clinical factors are the major contributors to the pathogenesis of severe hyperbilirubinemia defined as a TB &gt;95th percentile. This was illustrated in a case control study of term infants that compared genetic and clinical factors between infants with TB levels &gt;95th percentile and those with TB levels &lt;40th percentile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39992/abstract/15\">",
"     15",
"    </a>",
"    ]. There were no differences in the frequency of G6PD, UGT1A1, and SCLO1B1 genetic variants between the two groups. Among the group with severe hyperbilirubinemia, the most common cause of an elevated TB was hemolysis due to ABO incompatibility (31 percent) followed by breastfeeding failure (22 percent), although no cause was identified in 39 percent of the cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/45/16083?source=see_link\">",
"       \"Patient information: Jaundice in newborn infants (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total serum or plasma bilirubin (TB) levels &gt;1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (17",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      occur in almost all term and near-term newborn infants. Infants with severe hyperbilirubinemia (TB &gt;25 to 30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [428 to 513",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      are at risk for bilirubin-induced neurologic dysfunction (BIND), presenting acutely as acute bilirubin encephalopathy (ABE) and, if inadequately treated, long-term neurologic sequelae or kernicterus.",
"     </li>",
"     <li>",
"      Neonatal jaundice is primarily caused by normal neonatal alterations in bilirubin metabolism including increased bilirubin production, decreased bilirubin clearance, and increased enterohepatic circulation. These alterations generally result in mild unconjugated (indirect-reacting) hyperbilirubinemia with peak TB of 7 to 9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (120 to 154",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      in Caucasian and African-American infants and higher values in Asian infants, 10 to 14",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (171 to 239",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Neonatal jaundice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperbilirubinemia is caused by exaggeration of mechanisms that cause neonatal jaundice or by pathologic conditions that increase bilirubin production, decrease bilirubin clearance, or increase the enterohepatic circulation. Identification of the cause of neonatal hyperbilirubinemia is useful in determining whether therapeutic interventions can prevent severe hyperbilirubinemia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hyperbilirubinemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/59/21434?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Prevention of hyperbilirubinemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The following clinical findings are predictors for hyperbilirubinemia:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Jaundice in the first 24 hours of life.",
"     </li>",
"     <li>",
"      TB greater than the hour-specific 95th percentile (",
"      <a class=\"graphic graphic_figure graphicRef70863 \" href=\"mobipreview.htm?18/51/19263\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Conjugated bilirubin concentration &gt;1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (17",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      if the total bilirubin is &lt;5.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (86",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      or more than 20 percent of the total bilirubin if the total bilirubin is &gt;5.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (86",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      Conjugated bilirubinemia suggests neonatal cholestasis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24519?source=see_link\">",
"       \"Approach to neonatal cholestasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rate of TB rise greater than 0.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      per hour.",
"     </li>",
"     <li>",
"      Jaundice in a term newborn after 2 weeks of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes of hyperbilirubinemia can be classified by pathogenesis as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increased production &ndash; Hemolytic disease, polycythemia, and sequestration of blood within a closed space increase bilirubin production because of increased red cell breakdown. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Increased production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased clearance &ndash; Inherited defects in uridine diphosphogluconurate glucuronosyl transferase (UGT), such as Crigler-Najjar syndrome types I and II and Gilbert's syndrome. In addition, metabolic disorders, such as congenital hypothyroidism, galactosemia, and infants of diabetic mothers, can decrease bilirubin clearance. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Decreased clearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased enterohepatic circulation of bilirubin",
"     </li>",
"     <li>",
"      Breast milk jaundice, and impaired intestinal motility caused by functional or anatomic obstruction increase enterohepatic circulation of bilirubin. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Increased enterohepatic circulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Breastfeeding failure jaundice'",
"      </a>",
"      above.)",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/1\">",
"      Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001; 344:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/2\">",
"      Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999; 103:6.",
"     </a>",
"    </li>",
"    <li>",
"     Maisels MJ. Neonatal hyperbilirubinemia. In: Care of the High-Risk Neonate, 5th ed, Klaus MH, Fanaroff AA (Eds), WB Saunders, Philadelphia 2001. p.324.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/4\">",
"      Kawade N, Onishi S. The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver. Biochem J 1981; 196:257.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan M, Wong RJ, Sibley E, Stevenson DK. Neonatal jaundice and liver disease. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 9th ed, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St. Louis 2011. Vol 2, p.1443.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/6\">",
"      Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998; 95:8170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/7\">",
"      Akaba K, Kimura T, Sasaki A, et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 1998; 46:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/8\">",
"      Long J, Zhang S, Fang X, et al. Neonatal hyperbilirubinemia and Gly71Arg mutation of UGT1A1 gene: a Chinese case-control study followed by systematic review of existing evidence. Acta Paediatr 2011; 100:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/9\">",
"      American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/10\">",
"      Moyer V, Freese DK, Whitington PF, et al. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/11\">",
"      MacDonald MG. Hidden risks: early discharge and bilirubin toxicity due to glucose 6-phosphate dehydrogenase deficiency. Pediatrics 1995; 96:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/12\">",
"      Slusher TM, Vreman HJ, McLaren DW, et al. Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. J Pediatr 1995; 126:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/13\">",
"      Johnson JD, Angelus P, Aldrich M, Skipper BJ. Exaggerated jaundice in Navajo neonates. The role of bilirubin production. Am J Dis Child 1986; 140:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/14\">",
"      Fischer AF, Nakamura H, Uetani Y, et al. Comparison of bilirubin production in Japanese and Caucasian infants. J Pediatr Gastroenterol Nutr 1988; 7:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/15\">",
"      Watchko JF, Lin Z, Clark RH, et al. Complex multifactorial nature of significant hyperbilirubinemia in neonates. Pediatrics 2009; 124:e868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/16\">",
"      Riskin A, Gery N, Kugelman A, et al. Glucose-6-phosphate dehydrogenase deficiency and borderline deficiency: association with neonatal hyperbilirubinemia. J Pediatr 2012; 161:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/17\">",
"      Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/18\">",
"      Kadakol A, Sappal BS, Ghosh SS, et al. Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus. J Med Genet 2001; 38:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/19\">",
"      Bancroft JD, Kreamer B, Gourley GR. Gilbert syndrome accelerates development of neonatal jaundice. J Pediatr 1998; 132:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/20\">",
"      Chang PF, Lin YC, Liu K, et al. Prolonged unconjugated hyperbiliriubinemia in breast-fed male infants with a mutation of uridine diphosphate-glucuronosyl transferase. J Pediatr 2009; 155:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/21\">",
"      Kaplan M, Renbaum P, Levy-Lahad E, et al. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci U S A 1997; 94:12128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/22\">",
"      Kaplan M, Renbaum P, Vreman HJ, et al. (TA)n UGT 1A1 promoter polymorphism: a crucial factor in the pathophysiology of jaundice in G-6-PD deficient neonates. Pediatr Res 2007; 61:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/23\">",
"      Watchko JF. Vigintiphobia revisited. Pediatrics 2005; 115:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/24\">",
"      Huang MJ, Kua KE, Teng HC, et al. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 2004; 56:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/25\">",
"      Stevenson DK, Ostrander CR, Hopper AO, et al. Pulmonary excretion of carbon monoxide as an index of bilirubin production. IIa. Evidence for possible delayed clearance of bilirubin in infants of diabetic mothers. J Pediatr 1981; 98:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/26\">",
"      Grunebaum E, Amir J, Merlob P, et al. Breast mild jaundice: natural history, familial incidence and late neurodevelopmental outcome of the infant. Eur J Pediatr 1991; 150:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/27\">",
"      Preer GL, Philipp BL. Understanding and managing breast milk jaundice. Arch Dis Child Fetal Neonatal Ed 2011; 96:F461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/28\">",
"      Gourley GR, Arend RA. beta-Glucuronidase and hyperbilirubinaemia in breast-fed and formula-fed babies. Lancet 1986; 1:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/29\">",
"      Gourley GR, Li Z, Kreamer BL, Kosorok MR. A controlled, randomized, double-blind trial of prophylaxis against jaundice among breastfed newborns. Pediatrics 2005; 116:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/30\">",
"      Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr 2002; 140:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/31\">",
"      Maisels MJ, Gifford K. Normal serum bilirubin levels in the newborn and the effect of breast-feeding. Pediatrics 1986; 78:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/32\">",
"      Gourley GR, Kreamer B, Arend R. The effect of diet on feces and jaundice during the first 3 weeks of life. Gastroenterology 1992; 103:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39992/abstract/33\">",
"      Johnson L, Bhutani VK, Karp K, et al. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J Perinatol 2009; 29 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care, 6th ed, Lemnos JA, Lockwood CL (Eds), American Academy of Pediatrics, Elk Grove Village 2008.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5020 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FC043B0C43-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39992=[""].join("\n");
var outline_f39_3_39992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BILIRUBIN METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bilirubin production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bilirubin clearance and excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NEONATAL JAUNDICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HYPERBILIRUBINEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CAUSES OF HYPERBILIRUBINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increased production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Decreased clearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Crigler-Najjar syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gilbert's syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - OATP-2 polymorphism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Increased enterohepatic circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Breast milk jaundice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intestinal obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Breastfeeding failure jaundice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Severe hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5020\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5020|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/51/31536\" title=\"figure 1\">",
"      Bilirubin in hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/51/19263\" title=\"figure 2\">",
"      Nomogram of hour-specific total bilirubin in term infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/63/5109?source=related_link\" title=\"calculator 1\">",
"      Calculator: Newborn hyperbilirubinemia assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24519?source=related_link\">",
"      Approach to neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27943?source=related_link\">",
"      Bilirubin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/12/36040?source=related_link\">",
"      Breastfeeding the preterm infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42616?source=related_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/50/16169?source=related_link\">",
"      Causes of neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30886?source=related_link\">",
"      Clinical features and diagnosis of galactosemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/63/25593?source=related_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5801?source=related_link\">",
"      Congenital erythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6201?source=related_link\">",
"      Crigler-Najjar syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=related_link\">",
"      Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3912?source=related_link\">",
"      Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15623?source=related_link\">",
"      Hereditary elliptocytosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20506?source=related_link\">",
"      Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8217?source=related_link\">",
"      Initiation of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36968?source=related_link\">",
"      Neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/45/16083?source=related_link\">",
"      Patient information: Jaundice in newborn infants (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27559?source=related_link\">",
"      Pyruvate kinase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27832?source=related_link\">",
"      Red cell transfusion in infants and children: Selection of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_3_39993="Lymphocytic colitis Light";
var content_f39_3_39993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1108px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphocytic colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a colonic biopsy from a patient with lymphocytic colitis shows intraepithelial and lamina propria lymphocytic infiltrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Normal colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 172px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39993=[""].join("\n");
var outline_f39_3_39993=null;
var title_f39_3_39994="Juvenile idiopathic arthritis: Epidemiology and immunopathogenesis";
var content_f39_3_39994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Juvenile idiopathic arthritis: Epidemiology and immunopathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39994/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39994/contributors\">",
"     Alexei A Grom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39994/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39994/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/3/39994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/3/39994/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/3/39994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile idiopathic arthritis (JIA) is a chronic idiopathic inflammatory disorder primarily involving joints. The epidemiology and immunopathogenesis of JIA are reviewed here. Diagnostic criteria and nomenclature of JIA are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35717?source=see_link\">",
"     \"Classification of juvenile arthritis (JRA/JIA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4186997\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The older terms juvenile rheumatoid arthritis (JRA, used commonly in the United States) and juvenile chronic arthritis (JCA, preferred in Europe), have been replaced by the term juvenile idiopathic arthritis (JIA). JIA incorporates all of what was called JRA in the past, and also includes all other forms of \"idiopathic\" arthritis in childhood. The term JRA will still be used to describe the general patient population in older studies, since JRA is a less inclusive term than JIA (the term JIA will be used for these older studies if a specific subgroup is specified, eg systemic onset JIA). However, most clinicians assume that the results of these earlier studies of JRA are generally applicable to all the categories included in JIA, although the precise numbers will be somewhat different. The JIA nomenclature should be regarded as a \"work in progress\" that will be refined as the genetic and pathophysiologic understanding of arthritis improves. All of the discussion of epidemiology and pathogenesis that follows is complicated by the fact that JIA is not a single disease, but several different diseases. While there are elements common to all of these diseases, some forms of JIA, such as the HLA-B27-associated diseases and systemic onset JIA, are clearly distinct entities with differing etiologies and pathogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overall incidence and prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of standard diagnostic criteria has complicated epidemiologic studies. When the revised American College of Rheumatology (ACR, formerly the ARA) classification criteria were applied to the Rochester Epidemiology Program Project database, an incidence of 13.9 cases of juvenile rheumatoid arthritis (JRA) per 100,000 per year was reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/1\">",
"     1",
"    </a>",
"    ]. A follow-up study, utilizing the same database, noted a decrease in incidence over a subsequent decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of other population studies are presented in the table [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/3-7\">",
"     3-7",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef78901 \" href=\"mobipreview.htm?10/13/10459\">",
"     table 1",
"    </a>",
"    ). In the Rochester study, the prevalence rate for JRA was 94 patients per 100,000 children on January 1, 1980, and 86 on January 1, 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/2\">",
"     2",
"    </a>",
"    ]. An extrapolation to the entire United States population under 16 years of age in the year 2000 suggests that there must be 70,000 to 100,000 cases of JRA (active and inactive). However, the population in the Rochester study was predominantly Caucasian. The actual prevalence in the total United States population is probably much lower (15,000 to 36,000 in some estimates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/8\">",
"     8",
"    </a>",
"    ]) because JRA appears to be less common in African-American and Asian populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ethnic differences in prevalence have also been noted in other populations. As examples, the prevalence of JRA is less in blacks than in those of Indian ancestry among South African children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/10\">",
"     10",
"    </a>",
"    ] and is higher in the native population than among Caucasians among Canadian children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in disease onset between ethnic groups have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/12\">",
"     12",
"    </a>",
"    ]. African-American children are more likely to have a polyarticular onset than Caucasian children, who most often have a pauciarticular onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/13\">",
"     13",
"    </a>",
"    ]. Among Japanese children, systemic disease is more common than the pauciarticular form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/14\">",
"     14",
"    </a>",
"    ]. Genetic factors are likely to contribute to these differences. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Age of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series from the United States, the peak incidence of JRA occurred at one to three years, with a preponderance of girls in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/15\">",
"     15",
"    </a>",
"    ]. A second, less prominent peak was noted between ages 8 to 10 years; this peak included more boys with pauciarticular JIA. Other investigators have found a mean age of onset of approximately six years for both systemic and polyarticular disease; pauciarticular disease began at a mean age of approximately 4 years in girls and 10 years in boys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gender differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most published series, the female:male ratio ranges from 2:1 to 3:1, although equal sex ratios have been described among Indian and black South African children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/10\">",
"     10",
"    </a>",
"    ]. These ratios depend upon the age at onset and the type of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/17\">",
"     17",
"    </a>",
"    ]. As an example, pauciarticular JIA affecting children under eight years old may have a female preponderance as high as 8:1, especially if iridocyclitis is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In contrast, late-onset HLA-B27-related disease occurs more commonly in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Systemic onset JIA shows little or no discrimination between sexes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Secular and seasonal variations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial variations in JIA occurrence over extended (secular trends) and shorter (seasonal) periods have been noted in some populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. The possibility of an etiologic link was suggested by a report from the United Kingdom in which an influenza virus epidemic occurred prior to an \"outbreak\" of JIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/23\">",
"     23",
"    </a>",
"    ]. The strongest seasonal variations have been observed with systemic onset JIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], although this appears to be true only in some geographic regions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis and etiology of JIA are unclear. As with most autoimmune disorders, interactions among genetic factors, immune mechanisms, and environmental exposures are thought to contribute in most cases:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Familial predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patterns of inheritance consistent with Mendelian or monogenic inheritance have not been observed in JIA. The level of risk to family members of a proband appears to be only mildly increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], and families with multiple affected members are uncommon. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, the JRA Affected Sib Pairs Research Registry in Cincinnati estimated the total number of affected sib pairs at 300 in a population of approximately 250 million [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/28\">",
"       28",
"      </a>",
"      ]. Almost 80 percent of the pairs and 100 percent of twin pairs were concordant for disease type. Among twins, disease onset was separated by a mean of approximately three months. In a subsequent study that included an additional 94 affected pairs, the mean difference in age of onset of non twin pairs was approximately three years and concordance of disease type was 73 percent for the two cohorts combined (120 of 164 non twin affected sib pairs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Europe, only 12 affected sib-pairs were found among over 3000 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anecdotal evidence suggests that families with JRA probands have an increased risk of other nonrheumatic autoimmune diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Predisposing MHC genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple HLA loci are associated with the development of JIA, with specific disease subtypes being linked to specific HLA alleles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/27,33\">",
"     27,33",
"    </a>",
"    ]. Genes that do not encode classic HLA proteins, but lie within the major histocompatibility complex (MHC) may also predispose to JIA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Early-onset pauciarticular JIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early-onset pauciarticular JIA, which has a relatively high concordance among siblings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/28\">",
"     28",
"    </a>",
"    ], constitute the subtype with the most distinctive HLA associations. Correlations with various HLA class II DR and DP alleles include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HLA-DR8 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HLA-DR11 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HLA-DR13 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HLA-DPw2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DNA sequence-dependent methodologies have defined more precisely the HLA alleles associated with pauciarticular JIA. Disease susceptibility correlates with particular alleles of each serologically or cellularly defined specificity, such as HLA-DRB1*0801 of DR8 and HLA-DPB1*0201 of DPw2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/33\">",
"     33",
"    </a>",
"    ]. Although most associations are with HLA class II, a consistent increase in risk with the HLA class I A2 allele has been reported in girls with early-onset pauciarticular JIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to these findings, some HLA class II alleles occur with decreased frequency in affected children, suggesting a protective effect. Examples include HLA-DR4 and HLA-DR7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determination of HLA specificities using DNA-based methodologies has also better defined the genetic markers of disease outcome in early-onset pauciarticular JIA. Haplotypes carrying HLA-DRB*0801, HLA-DRB*1301, and HLA-DP*0201 alleles appear to predispose to pauciarticular JIA in general. In contrast, other alleles may contribute to the risk for other clinical manifestations. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HLA-DRB1*1104 predisposes to eye disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HLA-DQA1*0101 predisposes to evolution from pauciarticular to polyarticular, erosive disease, but is associated with a reduced risk of eye disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HLA-DRB1*0101 has been associated with polyarticular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether the HLA-DQA*0101 or the HLA-DRB*0101 allele is a better marker for the haplotype is uncertain, but there are data that are compatible with either possibility.",
"   </p>",
"   <p>",
"    The fact that HLA genes from four loci (HLA-A, HLA-DR, HLA-DQ, and HLA-DP) are involved in inherited predisposition to pauciarticular JIA raises the possibility that these genes make up a potential susceptibility haplotype. However, the absence of linkage disequilibrium between these genes indicates that there are independent genetic effects at three loci. This is illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef72340 \" href=\"mobipreview.htm?34/59/35772\">",
"     table 2",
"    </a>",
"    ), which demonstrates the odds ratio obtained by the cumulative addition of risk factors. Such interactions have been demonstrated in other populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a significant proportion of patients with early-onset pauciarticular JIA, especially those with uveitis, the development of the disease may be associated with the presence of two susceptibility alleles of either the HLA-DR or HLA-DQ loci. Patients who are heterozygous for",
"    <span class=\"nowrap\">",
"     HLA-DR5/HLA-DR8",
"    </span>",
"    have a particularly increased risk for developing eye disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/47\">",
"     47",
"    </a>",
"    ]. An HLA-DP gene and the class I HLA-A2 gene also contribute, appearing as independent risk factors. Class II gene homozygosity is not increased in the pauciarticular JIA patient population, suggesting that a dosage effect of any individual gene does not increase risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other types",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLA associations with clinical forms other than early-onset pauciarticular JIA are less strong. In addition to the previously mentioned increased risk of late onset pauciarticular JIA associated with HLA-B27 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], the following associations have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyarticular onset, rheumatoid factor (RF)-negative JIA susceptibility with HLA-DPw3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RF-positive, polyarticular JIA has the same HLA-DR4 associations as does adult RA: HLA-DRB1*0401 and HLA-DRB1*0101 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=see_link\">",
"       \"HLA and other susceptibility genes in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic onset JIA with HLA-DR4 in northern, but not southern European populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     HLA-DR1/DR4 shared epitope hypothesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA in adults is associated with the presence of the DNA sequence common to HLA-DR1 and some HLA-DR4 specificities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. However, the shared epitope hypothesis as applied to adults is not useful for pauciarticular JIA, in which HLA-DR4 is protective and HLA-DR1 haplotypes predispose to a polyarticular outcome. Similarly, patients with seronegative polyarticular JIA do not carry the appropriate epitopes. The only JIA group in which the shared epitope hypothesis may hold is in older children with polyarticular disease who are IgM RF-positive. These patients have the childhood equivalent of adult RA; they represent fewer than 10 percent of all patients with JIA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=see_link&amp;anchor=H3#H3\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\", section on 'Individual alleles and the shared epitope'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Age-specific effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is new evidence that some genes operative in JIA appear to have a \"window-of-effect\" during which time they may contribute risk of disease, but be neutral or even protective at other times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/52\">",
"     52",
"    </a>",
"    ]. This appears to be particularly true in the pauciarticular groups, in which HLA-related risks clearly differ with age. For example, fifty percent of children carrying at least one of the susceptibility MHC alleles have disease onset prior to their third birthday, suggesting that the period of susceptibility to early-onset pauciarticular JIA is limited to the first years of life. In contrast, HLA-B27 and DR-4 appear to be associated with the protection against early-onset pauciarticular JIA early in life, but with the increased risk for other forms of JIA later in childhood (",
"    <a class=\"graphic graphic_figure graphicRef79342 \" href=\"mobipreview.htm?35/6/35950\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Predisposing non-HLA genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing evidence supports the concept that the occurrence of JIA and its phenotype is determined by complex genetic traits with \"genetic interplay\" between HLA and non-HLA predisposing alleles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/53\">",
"     53",
"    </a>",
"    ]. The spectrum of non-HLA genes that may be associated with JIA is expanding rapidly, as illustrated in the table [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/19,36,54-66\">",
"     19,36,54-66",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef79960 \" href=\"mobipreview.htm?41/13/42203\">",
"     table 3",
"    </a>",
"    ). However, their contribution to the risk of JIA appears to be less significant than that of HLA genes, and their effects may not be specific to JIA. In general, the odds ratios are low, and distinguishing between founder effects (the incomplete mixing of genetically disparate populations) and associations that relate to pathogenesis has been difficult. Reproducible associations with odds-ratios greater than two have been noted with interleukin-6 (IL-6) and macrophage migration inhibitory factor (MIF) promoter polymorphisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/67\">",
"     67",
"    </a>",
"    ]. The IL-6 promoter (-174G) allele is significantly associated with systemic onset disease in children older than the age of five years but not in younger children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of genetic markers, such as microsatellite polymorphisms, suggests the presence of other, as yet unknown genes, which are associated with JIA. As an example, the marker D6S265*5 which is in proximity to, but distinct from, the HLA-A locus, is more commonly found in Norwegian children with seronegative forms of JIA than controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial genome wide scanning, using polymorphic markers on all the chromosomes, in 121 families with a pair of affected children has confirmed the linkage of JIA to the HLA region on chromosome 6 and identified several other sites of interest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/70\">",
"     70",
"    </a>",
"    ]. Evidence for linkage to sites on chromosome 1, 19, and 20 were noted. When affected children were stratified by the type of disease onset, evidence of linkage was found at different chromosomal locations (eg, early onset polyarticular and pauciarticular disease with chromosomes 7 and 19, respectively), and when children carrying the HLA-DR8 allele were selected, strong evidence of linkage to a site on chromosome 2 was noted.",
"   </p>",
"   <p>",
"    Additional loci and genes associated with JIA have been identified in genome-wide association studies (GWAS) of rheumatoid arthritis, including IL-2 receptor alpha (",
"    <em>",
"     IL2RA",
"    </em>",
"    ), protein tyrosine phosphatase nonreceptor-type 2 (",
"    <em>",
"     PTPN2",
"    </em>",
"    ),",
"    <em>",
"     PTPN22",
"    </em>",
"    , signal transducer and activator of transcription 4 (",
"    <em>",
"     STAT4",
"    </em>",
"    ), angiopoietin 1 (",
"    <em>",
"     ANGPT1",
"    </em>",
"    ), and component of oligomeric golgi complex 6 (",
"    <em>",
"     COG6",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. The latter study also found associations with loci at 3q13 and 10q21 that may be unique to JIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although at least some genetic component is evident in all clinical forms of JIA, the environmental component appears to be stronger for some forms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/73\">",
"     73",
"    </a>",
"    ]. Potential environmental influences that may improve or worsen disease include infection, breastfeeding, maternal smoking, and vitamin",
"    <span class=\"nowrap\">",
"     D/sun",
"    </span>",
"    exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An infectious etiology has been suspected for a long time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/75\">",
"     75",
"    </a>",
"    ]. However, classical epidemiologic studies have not generally shown clustering of JIA that would imply a definite infectious etiology, although some seasonality in systemic onset disease has been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In addition, changes in the incidence of JIA over time may reflect an environmental or infectious rather than a genetic effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Several potential pathogens have been proposed but none have been definitely shown to be casual. The following are of interest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rubella virus has been implicated, and a small proportion of individuals who received rubella immunizations develop arthritis similar to that of pauciarticular JIA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=see_link&amp;anchor=H6#H6\">",
"       \"Specific viruses that cause arthritis\", section on 'Rubella and rubella vaccine virus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An Epstein-Barr virus protein has sequence similarities to HLA-DR8, DR11, and DPw2, all of which are associated with pauciarticular JIA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/78\">",
"       78",
"      </a>",
"      ]. This and the finding of cross reactive T cell mediated cytotoxicity stimulated by HLA and viral derived peptides suggests a role for molecular mimicry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chlamydia has been identified in the joints of some children with arthritis, although the significance of this in the context of JIA is uncertain. The clinical presentation of chlamydial arthritis can be similar to JIA, including the development of iridocyclitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Influenza A infection in pregnancy was associated with the subsequent development of polyarticular JIA in childhood in a study from South Wales [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An evaluation of long-term trends in Canada found that Mycoplasma pneumoniae infections had incidence peaks which coincided with incidence peaks for JRA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/6\">",
"       6",
"      </a>",
"      ]. Peaks in JRA incidence over years of observation have been noted in other studies but have not been correlated with specific infectious agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recovery of parvovirus B19 DNA from synovial fluid or serum was higher in 74 patients with various types of JIA than in children without arthritis (35 versus 7 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/81\">",
"       81",
"      </a>",
"      ]. There was little difference in the rates of prior infection with parvovirus B1 (as estimated by the prevalence of IgG antibodies to viral proteins (62 versus 52 percent, respectively)).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HLA-B27 associated forms of JIA can be triggered by bacterial infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/82\">",
"     82",
"    </a>",
"    ], as is the case with HLA-B27-associated disease in adults. An immunodominant epitope of E. coli heat shock proteins is a potential target in HLA-B27 positive JIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PATHOBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical manifestation of JIA is persistent joint swelling that results from the combination of synovial fluid accumulation and synovial thickening. Such swelling may cause deformities of affected joints due to stretching of periarticular ligaments and tendons. In addition, enzymes released by inflammatory cells within the synovium or synovial fluid may result in degradation of the collagen and proteoglycan matrix of the articular cartilage. Activation of osteoclasts resulting from the production of cytokines by cells within the mass of inflammatory tissue is probably the final pathway of juxtaarticular bone demineralization and bone erosions.",
"   </p>",
"   <p>",
"    While some mechanisms of disease are likely shared by children with JIA and adults with RA, there may be some that are unique to childhood disease. The pathobiology of RA in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3754?source=see_link\">",
"     \"Synovial pathology in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Synovial fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial fluid in affected joints is increased in amount and decreased in viscosity. Various inflammatory cells are found in the fluid, including neutrophils, plasma cells, dendritic cells, and T cells expressing markers of activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/84\">",
"     84",
"    </a>",
"    ]. Mediators of inflammation such as cytokines and cleavage products of the complement system are also abundant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Synovial tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the hallmarks of the pathology of both JIA and RA is the tumor-like expansion of inflamed synovial tissue, or pannus, which causes much of the joint damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. As the disease progresses, pannus spreads over the synovial space and adheres to intraarticular cartilage. It is in the areas of pannus-cartilage junction where the cartilage eventually degrades.",
"   </p>",
"   <p>",
"    Pannus results from the proliferation of synoviocytes and invasion of the synovial tissue by inflammatory cells recruited from the peripheral circulation. Mitotic figures are rarely seen in synovial histopathology, suggesting that ongoing recruitment of inflammatory cells from peripheral circulation is a major pathway of pannus expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/88\">",
"     88",
"    </a>",
"    ]. Pannus growth is also supported by extensive formation of new blood vessels that provide both a source of nutrients for growing pannus and access for inflammatory cells to infiltrate the synovium.",
"   </p>",
"   <p>",
"    The increased angiogenic activity appears to be mediated by growth factors derived from monocytic cells recruited to the synovium in patients with JIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. These factors include vascular endothelial growth factors (VEGF), angiopoietin 1 (Ang 1), and osteopontin. In one study, expression of VEGF and Ang and their receptors correlated with the inflammatory activity in the tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/89\">",
"     89",
"    </a>",
"    ]. Another study showed a strong correlation between increased serum levels of VEGF and disease activity in polyarticular JIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cellular infiltrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light and electron microscopic studies of the synovium in JIA reveal prominent infiltration with lymphocytes, plasma cells, and macrophages as well as proliferation of fibroblast- and macrophage-like synoviocytes. Infiltration with inflammatory cells is inhomogeneous: lightly infiltrated areas alternate with areas of dense cell aggregates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inflammatory cell aggregates are usually seen around or near blood vessels and are comprised of clusters of CD4 positive cells surrounded by a mantle of mixed CD4 and CD8 positive cells and B cells. In one small series of newly diagnosed untreated patients, those with polyarthritis had significantly higher numbers of CD4 and CD8 positive T cells and B cells than patients with oligoarthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/92\">",
"     92",
"    </a>",
"    ]. Patients with persistent oligoarthritis had fewer CD3 and CD4 positive T cells and B cells than those who went on to develop extended oligoarthritis. CD68 positive cells of",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    lineage are numerous and are typically found in the cell aggregates. This pattern of findings resembles that of classic delayed-type hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/93\">",
"     93",
"    </a>",
"    ]. In general, tissues from patients with the polyarticular form of JIA appear to have somewhat larger mononuclear cell foci as compared with pauciarticular JIA patients. However, the tissues cannot be reliably distinguished solely on this basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/94\">",
"     94",
"    </a>",
"    ]. The meaning of these findings in relation to disease pathogenesis remains unclear.",
"   </p>",
"   <p>",
"    Dendritic cells appear in increased numbers within the synovial membrane and fluid. Dendritic cells from the synovial compartment are larger than most of those from peripheral blood and have a more extensive Golgi complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/86\">",
"     86",
"    </a>",
"    ]. They are often found near T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/95\">",
"     95",
"    </a>",
"    ]. A distinctive feature of such synovial dendritic cells is their high level of HLA-DQ and -DR expression.",
"   </p>",
"   <p>",
"    Dendritic cells are particularly potent antigen presenting cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/96\">",
"     96",
"    </a>",
"    ]. Since their only known function is to present antigens, it is reasonable to believe that antigen presentation is taking place in inflamed synovium. This notion is supported by the demonstration that dendritic cells from joints of some patients with JIA stimulate autologous lymphocytes in a mixed lymphocyte reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the T cells infiltrating synovium are of a memory phenotype. T cell activation levels vary among different areas in synovium. Most interleukin (IL)-2 receptor-positive cells are found in the \"mantle\" surrounding the inflammatory cell aggregates or in interaggregate areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/9\">",
"     9",
"    </a>",
"    ]. DNA-synthesizing T cell blasts represent no more than 5 percent of all synovial compartment mononuclear cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/13\">",
"     13",
"    </a>",
"    ], suggesting that most of these cells are recruited from the peripheral circulation. Among the small proportion of radiolabeled blast cells, CD4+ lymphocytes are the dominant cell population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Recruitment of cells into synovium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltration into the synovium depends upon an interplay of vascular factors, cytokines, adhesion molecules, and chemokines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Vascular factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mononuclear cell aggregates are found predominantly around blood vessels, particularly postcapillary venules that have distinct morphology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/86\">",
"     86",
"    </a>",
"    ]. These venules are lined by tall, metabolically active endothelial cells that express high levels of adhesion molecules, features similar to those observed in venules of lymphoid organs. Some of the postcapillary venules in lymphoid organs are specialized to facilitate the transendothelial migration of circulating lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/88,99\">",
"     88,99",
"    </a>",
"    ]. These specialized high endothelial venules (HEV) may play a similar role in JIA synovium. As an example, CD4+, HLA-DR+ lymphocytes from peripheral blood of children with JIA adhere to human umbilical vein endothelial cells that have been activated by tumor necrosis factor (TNF)-alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the abundance of TNF-alpha in JRA synovial tissues and the high levels of the p55 TNF receptor on the synovial endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/101\">",
"     101",
"    </a>",
"    ], it is likely that TNF-alpha plays a pivotal role in the enhancement of inflammatory cell trafficking into inflamed synovium. IL-15 is another cytokine that enhances the transendothelial migration of lymphocytes to RA synovium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/102\">",
"     102",
"    </a>",
"    ]. IL-15 appears to be one of the most highly expressed cytokines in JRA synovium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macrophage migration inhibitory factor (MIF) may also play a role in JIA. Both serum and synovial fluid levels of this cytokine may be elevated in children with systemic onset disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/104\">",
"     104",
"    </a>",
"    ]. Other evidence for a contribution of MIF in this subset is the correlation between increased disease severity, as estimated from swollen joint counts and duration of corticosteroid therapy, and the presence of a single nucleotide polymorphism in the promoter (noncoding) region of the MIF gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/105,106\">",
"     105,106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Adhesion molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trafficking into synovium may also be enhanced by overexpression on lymphocytes of very late activation antigen (VLA-1), a surface protein from the integrin family of adhesion molecules that mediates leukocyte adhesion to matrix proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/107\">",
"     107",
"    </a>",
"    ]. The recruitment of proinflammatory cells into synovium does not appear to be random. Selection of predominantly Th1 lymphocytes may be dependent upon various chemokines and be both antigen-specific and antigen-nonspecific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/108,109\">",
"     108,109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     T cell contribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell receptor-alpha-beta-T cells are the predominant cell population in the JIA synovium and exhibit phenotypic and functional characteristics of cells that have undergone prior activation in vivo. These characteristics include expression of IL-2 receptors (CD25) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/110\">",
"     110",
"    </a>",
"    ], early activation antigen CD69, CD45RO (memory phenotype), VLA-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/107\">",
"     107",
"    </a>",
"    ], and HLA class II antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/84,111\">",
"     84,111",
"    </a>",
"    ]. These activated effector T cells have impaired sensitivity to immunoregulation by regulatory T cells (CD4+CD25+FoxP3+ Tregs) in synovial fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A theory that such activation might be induced by an autoantigen located in the inflamed joints prompted a search for clonally expanded synovial T cell populations, an approach that had been successfully utilized in experimental allergic encephalomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/113\">",
"     113",
"    </a>",
"    ]. In this model, a known autoantigen (eg, myelin basic protein) stimulates expansion of T cells with receptor specificity for this particular antigen. Furthermore, clonally expanded T cells utilize a limited number of V-beta segments in their TCRs. It was anticipated that, if detected in the JIA synovium, such populations might provide a clue to the identification of the antigens driving the immune response in JIA.",
"   </p>",
"   <p>",
"    Clonal expansion of alpha-beta-T cells in both CD4+ and CD8+ populations can be detected in the synovium of the vast majority of JRA patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/114-117\">",
"     114-117",
"    </a>",
"    ]. Identical clones with the same receptor specificity are present in multiple joints of the same individual and persist over a long period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/115,117\">",
"     115,117",
"    </a>",
"    ]. Some clones can be detected in peripheral blood as well, although there is preferential accumulation of these clonally expanded populations in inflamed synovial tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/115,116\">",
"     115,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings were thought to be consistent with the concept of persistent antigenic stimulation of T cells in the synovial compartment of JIA patients. However, the discovery of similar clonally expanded CD8+ populations in peripheral blood of healthy adults (usually older than 35 years of age) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/118\">",
"     118",
"    </a>",
"    ] made some investigators question this concept.",
"   </p>",
"   <p>",
"    Further studies were focused on the analysis of the T cell receptor (TCR) complementarity determining region-3 (CDR3), the site of specific interaction of the TCR with unique peptide-HLA complexes. It was anticipated that expansion of structurally identical clones would be indicative of an ongoing antigen-driven immune response in the joint. Since the CDR3 region is encoded by the variable diversity joining (V-D-J) segments, several studies were carried out to determine whether oligoclonal T cell populations preferentially utilized particular V-alpha or V-beta chain TCR segments. Initially, fewer V-beta families were found in fresh T cells from the synovial fluid than from the peripheral blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/114\">",
"     114",
"    </a>",
"    ]. These differences were more obvious when IL-2R+ T-cells were isolated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/114\">",
"     114",
"    </a>",
"    ]. Restricted usage of V-alpha segments by synovial fluid T cells was also seen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A more comprehensive study of synovial fluid samples obtained from 36 patients with different forms of JRA, revealed that the vast majority of JRA patients had multiple synovial T cell clones utilizing a wide variety of different TCR V-beta segments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/116\">",
"     116",
"    </a>",
"    ]. However, some differences in patterns of TCR V-beta utilization between clinical subtypes of JRA were noted, suggesting that different antigens might be involved in different clinical forms of JRA.",
"   </p>",
"   <p>",
"    Subsequently, extensive DNA sequencing efforts showed that, despite the wide diversity of CDR3 motifs, certain similarities between multiple synovial T cell clones derived from an individual patient, could be found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/119\">",
"     119",
"    </a>",
"    ]. These data provided indirect support for the concept that the persistent synovial inflammation in JIA is antigen-driven. However, the wide variety of both V-alpha and V-beta segments and CDR3 motifs utilized by clonally expanded T cell populations precludes their use as potential targets for specific immunotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Gamma-delta-T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clonal analysis of JRA synovial T cells responding to IL-2 revealed the presence of a distinct T cell population with a CD3+ CD4-, CD8- phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/110\">",
"     110",
"    </a>",
"    ]. These cells have gamma-delta (instead of alpha-beta) T cell receptors and comprise about 5 to 10 percent of T cells infiltrating the JRA synovial membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/120-122\">",
"     120-122",
"    </a>",
"    ]. In most cases, gamma-delta T cells are clustered in lymphoid follicle-like structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/122\">",
"     122",
"    </a>",
"    ]. In approximately 30 percent of patients with JRA, the proportions of gamma-delta T cells were increased in synovial fluid relative to peripheral blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/123\">",
"     123",
"    </a>",
"    ]. A high proportion of synovial gamma-delta T cells express CD25, CD69, and HLA-DR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the specificity and function of human gamma-delta T cells are unknown, at least some of these cells, including those in JRA synovial fluid, appear to respond to mycobacterial antigens and stress proteins (in particular heat shock protein 65, hsp65) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/83,124,125\">",
"     83,124,125",
"    </a>",
"    ]. Heat shock proteins are constitutively expressed in practically all organisms, and increased synthesis can be induced by a variety of stress conditions including inflammation. Utilizing monoclonal antibodies that recognize human hsp60, high levels of expression were demonstrated within synovial lining cells in JRA synovial tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6118351\">",
"    <span class=\"h3\">",
"     HSP-related T-cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a high degree of homology between bacterial and mammalian Hep2 derived heat shock proteins (HSP). During infection, the synthesis of HSP is elevated in both the microorganism and host cells. If cross-reactivity occurs between these, it can be inferred that the immune response to HSP would be potentially autoreactive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/127\">",
"     127",
"    </a>",
"    ]. On the other hand, HSP have been shown to stimulate local expansion of T cells secreting antiinflammatory cytokines such as IL-4 or IL-10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/128,129\">",
"     128,129",
"    </a>",
"    ]. These T cells appear to have a phenotype of so called immunoregulatory T cells that appear to provide protection against autoimmunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/130\">",
"     130",
"    </a>",
"    ]. Indeed, an inverse relationship may hold between high immune responses to human hsp60 and the severity of arthritis in patients with JIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/129,131\">",
"     129,131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This is illustrated by the following studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first study, 13 of15 patients with pauciarticular JIA had peripheral blood T-cells that demonstrated reactivity to HSP 60 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/132\">",
"       132",
"      </a>",
"      ]. Only 1 of 20 patients with polyarticular JIA had a similar finding. HSP reactivity was associated with disease remission by 12 weeks.",
"     </li>",
"     <li>",
"      In contrast, a study of 57 patients with pauciarticular or polyarticular JIA demonstrated an enhanced proliferative response of peripheral blood T-cells when exposed to five of eight selected HSP epitopes. This response was absent in both of the control groups (healthy children and children with type 1 diabetes). The relative response of T regulatory and T-helper cells was also measured by comparing cytokine production of interleukin 10 (immunosuppressive cytokine) to interferon gamma (proinflammatory cytokine). Only patients with active pauciarticular JIA produced increased levels of interleukin 10 compared to interferon gamma. These results suggest that in patients with active pauciarticular JIA there is a greater response in the T regulatory cells than in T helper cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One interpretation of these data is that upregulation of the T regulatory cells in patients with pauciarticular JIA decreases inflammation leading to less severe disease in these patients compared to those with polyarticular JIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. The data also suggest that increased T regulatory cell activity might contribute to better clinical outcomes with early remission of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/132,134\">",
"     132,134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     T cell derived cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults with RA, T cell derived cytokines are usually undetectable despite heavy T cell infiltration of the synovium. In contrast, T cells in JIA appear to be more actively producing cytokines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Th1 cytokines such as interferon-gamma (IFN-gamma) or tumor necrosis factor-beta (TNF-beta), are found in most of the synovial tissue and fluid samples of children with JRA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/85,135\">",
"     85,135",
"    </a>",
"    ]. Increased TNF-beta expression correlates with the occurrence of lymphocytic aggregates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/101\">",
"     101",
"    </a>",
"    ]. The in vitro production of cytokines by T cell clones derived from synovial fluids of pauciarticular JIA were of",
"    <span class=\"nowrap\">",
"     Th1/Th0",
"    </span>",
"    type in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/136\">",
"     136",
"    </a>",
"    ]. Thus, a Th1 cytokine response may be disease-promoting. Consistent with this notion, one study showed that higher levels of IFN-&gamma; and a strong IFN-induced transcriptional signature in synovial fluid mononuclear cells were predictive of progression from oligoarticular to polyarticular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Th2 cytokines, such as IL-4 and IL-10, may be produced as well. IL-4 has mainly been demonstrated in tissue and fluid samples obtained from patients with more restricted disease, particularly pauciarticular JIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/135\">",
"     135",
"    </a>",
"    ]. IL-10 is more consistently found in JRA tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/135\">",
"     135",
"    </a>",
"    ]. Preliminary evidence suggests that at least some of these cytokines are derived from the immunoregulatory T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/130,138\">",
"     130,138",
"    </a>",
"    ] which are found in the CD25+ T cell population in both peripheral blood and synovial compartments.",
"   </p>",
"   <p>",
"    T cells infiltrating the inflamed synovium in children with JIA may have a skewed cytokine phenotype, which may be due to selective recruitment of cells expressing chemokine receptors characteristic of Th1 cells. This hypothesis is supported by the demonstration of enrichment of synovial fluid lymphocytes for T cells expressing chemokine receptors CCR5, and CXCR3, that are markers for the Th1 phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/139,140\">",
"     139,140",
"    </a>",
"    ]. Enrichment of synovial fluid CCR4-bearing T cells, when compared to similar cells in peripheral blood, has also been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    JIA synovial tissues are also enriched by chemokines capable of stimulating CCR5 and CXCR3 receptors (eg, interferon inducible protein-10 (IP-10), and RANTES) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/142\">",
"     142",
"    </a>",
"    ]. I-309, a chemokine that upregulates IFN-gamma production, is also abundant. As discussed earlier, heat shock proteins may stimulate regulatory T cell activity.",
"   </p>",
"   <p>",
"    Results from one study suggest that the highly proinflammatory Th17 cells contribute to joint pathology in JIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/143\">",
"     143",
"    </a>",
"    ]. IL-17+ T cells were increased in the joints of children with JIA compared with levels in the blood of JIA patients and controls and were also demonstrated in synovial tissue. IL-17+ T cell numbers were higher in patients with extended oligoarthritis, compared with patients with persistent oligoarthritis. Within the joint, there was an inverse relationship between IL-17+ T cells and FoxP3+ Treg cells. A higher proportion of Th17 cells is also seen in the peripheral blood of patients with systemic JIA compared with normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Natural killer cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural killer (NK) cells in JIA have been assessed in several studies, with somewhat contradictory results. No significant differences in the distribution of cells bearing CD16+, a surface marker for cytotoxic T lymphocytes was noted in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/107\">",
"     107",
"    </a>",
"    ]. However, decreased NK cell numbers and an inverse correlation between disease activity and NK cell content has been described by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/145\">",
"     145",
"    </a>",
"    ]. Profoundly decreased NK cytolytic activity often associated with abnormal levels of perforin expression may be a distinguishing feature of the systemic form of JIA that puts these patients at risk for the development of macrophage activation syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/146\">",
"     146",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Macrophage activation syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Macrophages/fibroblasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased numbers of macrophages, dendritic cells, and synoviocytes of both fibroblast-like and macrophage-like phenotype are typical features of JIA synovium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/86\">",
"     86",
"    </a>",
"    ]. The abundance of cytokines secreted by these cells (such as IL-1, IL-6, IL-12 and TNF-alpha) provides further evidence for a major role in perpetuation of the synovial inflammation.",
"   </p>",
"   <p>",
"    Evidence of the importance of inflammatory mediators released from such cells includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High spontaneous production of IL-1 by mononuclear cells derived from peripheral blood of JRA patients and abundance of IL-1 producing macrophages in inflamed JRA synovium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/147\">",
"       147",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A correlation between levels of IL-6 expression in the serum, the extent of joint involvement, and degree of thrombocytosis in systemic onset JIA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/148\">",
"       148",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum from patients with systemic onset JIA induced the transcription of IL-1 in healthy peripheral blood mononuclear cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevation of IL-12 in the serum and TNF-alpha, TNF-beta, and IL-6 in synovial fluids of a large proportion of JRA patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/85,101\">",
"       85,101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased circulating levels of IL-18 in children with systemic onset disease were not seen in other JIA subtypes or Kawasaki disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/150\">",
"       150",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Role of TNF-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of JRA synovial tissue samples, cells staining for TNF-alpha are found within dense cellular aggregates and in the \"mantle\" of cells surrounding the aggregates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/101\">",
"     101",
"    </a>",
"    ]. The pattern of distribution of TNF-alpha staining is similar in nature to the pattern observed with CD68 staining. The level of expression of TNF-alpha correlates closely with the degree of inflammatory infiltration of synovia.",
"   </p>",
"   <p>",
"    High levels of TNF expression are associated with wide distribution of TNF receptors in the vast majority of tissues. As an example, staining with antibodies specific for the p55 and p75 TNF-receptors revealed that cells with diverse morphology expressed TNF receptors on their surfaces. Higher numbers of positive cells were observed in the areas of cellular aggregates adjacent to synovial venules, with the most intense staining seen on the endothelial cells lining the synovial blood vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/101\">",
"     101",
"    </a>",
"    ]. Serum levels of the soluble forms of both the p55 and p75 TNF-receptors are elevated in the majority of children with active systemic onset JIA, but only in minority of those with polyarticular or pauciarticular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activated lymphocytes from peripheral blood of children with JRA adhere to vascular endothelial cells stimulated with TNF-alpha in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/100\">",
"     100",
"    </a>",
"    ]. In vivo, this would be expected to lead to the extravasation of such cells and their accumulation at the site of inflammation. These observations suggest that one of the mechanisms by which TNF-alpha amplifies inflammation in JIA is its ability to promote trafficking of the inflammatory cells from peripheral circulation into synovium.",
"   </p>",
"   <p>",
"    The proinflammatory role of TNF-alpha in rheumatoid disease does not appear to be limited to only synovium. TNF-alpha is a major proinflammatory cytokine with both local and systemic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/152\">",
"     152",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At low concentrations, it acts locally, mostly as a paracrine and autocrine regulator of leukocytes and vascular endothelial cells. These actions contribute to the accumulation of inflammatory cells at local site of inflammation.",
"     </li>",
"     <li>",
"      When production of TNF-alpha is increased significantly, it is released into peripheral circulation causing a number of systemic effects. As an example, TNF-alpha acts on hypothalamic regulatory systems to induce fever and stimulate hepatocytes to produce proteins that constitute the acute phase response. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38569?source=see_link\">",
"       \"Acute phase reactants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When TNF-alpha is produced at high levels over a long period of time, it also suppresses the bone marrow and may cause metabolic alterations leading to cachexia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although similar symptoms and signs are often observed in JIA, particularly in the systemic form, it is not clear to which extent they can be attributed to TNF-alpha. The beneficial clinical experience with anti-TNF-alpha treatment strategies supports a critical role of TNF-alpha in both local and systemic features of pauci- and polyarticular JIA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24983?source=see_link\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5274?source=see_link&amp;anchor=H15849649#H15849649\">",
"     \"Systemic onset juvenile idiopathic arthritis: Treatment\", section on 'Anticytokine therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surprisingly, the same strategy appears to be less effective in the systemic form of JIA. Preliminary clinical experience, however, suggests that patients with systemic JIA may show a much better response to therapy directed toward IL-1 or IL-6. In fact, good clinical response to the inhibition of IL-6",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IL-1 in systemic JIA is similar to that seen in autoinflammatory diseases with a known genetic cause, such as neonatal onset multisystem inflammatory disease, in which the inflammatory response is triggered by the abnormalities in the innate immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/149\">",
"     149",
"    </a>",
"    ]. It has been suggested that the role of the adaptive immune response in systemic JIA may be rather limited compared to the other clinical forms of JIA. In contrast, the contribution of the innate immunity may be much more prominent, and systemic JIA should be viewed as an autoinflammatory syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=see_link&amp;anchor=H7#H7\">",
"     \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Neonatal onset multisystem inflammatory disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5274?source=see_link&amp;anchor=H15849649#H15849649\">",
"     \"Systemic onset juvenile idiopathic arthritis: Treatment\", section on 'Anticytokine therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Macrophage activation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive expansion of macrophages exhibiting hemophagocytic activity is the central feature of so-called \"macrophage activation syndrome\" (MAS), occasionally seen in patients with predominantly systemic onset JIA. The expansion of macrophages in this condition is associated with the uncontrolled proliferation of activated CD8+T cells. Clinically, MAS shares strong similarities with familial hemophagocytic lymphohistiocytosis (FHLH), a usually fatal heritable disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/23/39285?source=see_link&amp;anchor=H401611#H401611\">",
"     \"Systemic onset juvenile idiopathic arthritis: Course, prognosis, and complications\", section on 'Macrophage activation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Neutrophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numbers of circulating neutrophils may be very high in patients with systemic onset JIA and these cells may contribute to the amplification of the inflammatory response in this form of JIA. Neutrophil gene profiling in polyarticular JIA suggests an important role for neutrophils in disease pathogenesis of this subtype as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/153\">",
"     153",
"    </a>",
"    ]. Evidence of the importance of inflammatory mediators released from neutrophils includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevation of serum levels of a pair of calcium-binding S100 molecules (the myeloid-related proteins 8 and 14) by 120-fold and approximately 12-fold from children with systemic onset disease when compared to healthy children or those with other inflammatory diseases or infections, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/154\">",
"       154",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased serum levels of the calcium binding protein S100A12 (also called p6 or calgranulin C), a ligand for the receptor for advanced glycation end products (RAGE) and a mediator of inflammation are often present in untreated patients; average levels are much higher in those with systemic onset disease than in children with polyarticular or oligoarticular disease (mean serum concentrations of 3,700",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      versus 395 and 325",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/155\">",
"       155",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     B cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although T cells are usually more numerous in inflamed synovial tissue, B cell activity appears to be enhanced in both peripheral blood and the synovial compartment. Synovial tissue specimens from JIA patients have significant numbers of immunoglobulin-synthesizing cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/95\">",
"     95",
"    </a>",
"    ]. These cells tend to be focally aggregated. An increased number of B cells spontaneously producing immunoglobulins are also seen in the peripheral blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/156,157\">",
"     156,157",
"    </a>",
"    ]. In addition, memory B cells in the synovium of JIA patients express costimulatory molecules",
"    <span class=\"nowrap\">",
"     (CD80/CD86)",
"    </span>",
"    and may function as antigen presenting cells and activate T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased expression of genes related to B cells and decreased expression of genes related to cells of the myeloid compartment is seen in patients with oligoarticular JIA who had disease onset before age six years compared with those with a later age of onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/159\">",
"     159",
"    </a>",
"    ]. These findings suggest that oligoarticular JIA with onset before six years of age may ultimately be determined to be a distinct disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Immunoglobulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum levels of immunoglobulins are elevated in a large proportion of patients with JRA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/160,161\">",
"     160,161",
"    </a>",
"    ]. In one series, for example, 37 percent of patients with JRA exhibited hyperglobulinemia in at least one immunoglobulin class, and elevation of globulins correlated with the activity of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/161\">",
"     161",
"    </a>",
"    ]. Differences in immunoglobulin levels among different JIA clinical subgroups were also noted: children with polyarticular and systemic disease had mean immunoglobulin levels that were higher than those with pauciarticular JIA. Elevated IgA levels were associated with the appearance of cartilage erosions.",
"   </p>",
"   <p>",
"    Conversely, hypoglobulinemia has also been associated with JRA, and a selective decrease in serum IgA concentrations has been described in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/161,162\">",
"     161,162",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Rheumatoid factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid factors (RFs) are only rarely detected in patients with JIA by the classic Rose-Waller reaction or latex-fixation method; the probability of RF-positivity increases with the child's age and the duration of the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42648?source=see_link\">",
"     \"Origin and utility of measurement of rheumatoid factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allen and Kunkel demonstrated a so-called hidden RF, defined as IgM 19S antiglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/163\">",
"     163",
"    </a>",
"    ]. This antiglobulin is \"hidden\" because of its occupied binding sites. Gel filtration at acid pH dissociates IgM from IgG and allows IgM RF to fix complement in the hemolytic assay. Hidden RFs have been correlated with clinically active disease in approximately two-thirds of patients with JRA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/164,165\">",
"     164,165",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Antinuclear antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of antinuclear antibodies (ANAs) in patients with JRA varies from 4 to 88 percent depending upon the clinical subtype and the laboratory technique used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/166\">",
"     166",
"    </a>",
"    ]. ANAs are uncommon in systemic-onset disease, but are present in more than one-half of children with pauciarticular JIA. ANAs are occasionally found in patients with polyarticular disease, most often in those who are RF positive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who are ANA-positive carry an especially high risk of chronic anterior uveitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/166,167\">",
"     166,167",
"    </a>",
"    ]. Local synthesis of ANA in the eyes of patients with chronic iridocyclitis has been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/168\">",
"     168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specificity of these antibodies remains to be determined. Some studies indicate that ANAs in JRA are directed against a ribonucleoprotein that requires both RNA and protein components for antigenic integrity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/169\">",
"     169",
"    </a>",
"    ]. Others dispute this and find that ANA specificity profiles are highly individual and do not correlate with disease subtype or activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/170\">",
"     170",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies to many antigens typical for other rheumatic diseases, eg, the extractable nuclear protein, centromere proteins, topoisomerase (Scl-70), Ro, La, and double stranded DNA, are generally absent in JIA. Antibodies to the 45 kDa DEK nuclear antigen, a putative oncoprotein, have been associated with the pauciarticular type of JIA, particularly in patients with a history of iridocyclitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/171\">",
"     171",
"    </a>",
"    ]. However, these antibodies are present in other rheumatic diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/172\">",
"     172",
"    </a>",
"    ]. Anticollagen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/173\">",
"     173",
"    </a>",
"    ], antiretinal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/174-176\">",
"     174-176",
"    </a>",
"    ], and anti-T cell antibodies have been described, but their relevance to the pathogenesis of JIA is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/177-179\">",
"     177-179",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Immune complexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal antibody production and defects in clearance by the reticuloendothelial system may result in an increased concentration of circulating immune complexes in serum and synovial fluid.",
"   </p>",
"   <p>",
"    Attempts at quantitating immune complexes in serum have yielded conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using a C1q binding assay, 22 percent of patients with JRA have elevated levels of circulating immune complexes, and the concentration of circulating immune complexes may correlate with the severity of the disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/180\">",
"       180",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using the polyethylene glycol precipitation method, circulating immune complexes were found in the serum of only 1 out of 13 children with JRA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/181\">",
"       181",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using four different techniques, elevated levels of circulating immune complexes were demonstrated in 79 percent of patients with JRA by at least one method [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/182\">",
"       182",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Findings in synovial fluid have also been inconsistent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using the C1q binding assay, elevated levels of immune complexes were found in joint fluid from some children but the results varied substantially among patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/183\">",
"       183",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using the Raji cell method, normal levels of circulating immune complexes have been found in synovial fluids of patients with pauciarticular JIA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/133\">",
"       133",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A general impression is that circulating immune complexes may contribute to the perpetuation of chronic inflammation in JIA, but do not play a major role in its pathogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Complement activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite these conflicting results, many investigators think that deposition of circulating immune complexes in synovial compartments may result in complement system activation, which in turn causes tissue damage. Some evidence to support this hypothesis has been obtained.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, complement degradation products C3c and C3d were elevated in the serum of 7 of 10 patients with active systemic disease, in 16 of 29 with active polyarthritis, in 7 of 20 with active pauciarthritis, but in only 2 of 20 with inactive disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/184\">",
"       184",
"      </a>",
"      ]. C3c and C3d were not increased in synovial fluid. Elevated serum C3d has also been described in other studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/183\">",
"       183",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic, and to a lesser degree, polyarticular subgroups may have elevations of both",
"      <span class=\"nowrap\">",
"       C4d/C4",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       C3d/C3",
"      </span>",
"      ratios, while only the C3d level may be increased in pauciarticular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/185\">",
"       185",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The complement activation cascade (C1-C5) participates in inflammatory reactions mostly by releasing anaphylatoxins, while the terminal cascade results in the formation of the cytolytic macromolecular complex. The entire cascade is involved in the activation process both in peripheral blood and the synovial compartment in patients with JRA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/186\">",
"     186",
"    </a>",
"    ]. Weak staining for deposits of C3b, C3dg, and the membrane attack complex has also been noted. However, no association was noted between clinical activity and the degree of complement activation. This may in part be due to complement activation by C-reactive protein, a process that is not antigen specific, rather than by immune complexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/186\">",
"     186",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Systemic onset JIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data suggest that the underlying pathogenesis of systemic onset JIA is based upon an uncontrolled innate immune system that results in an autoinflammatory disease. In this disease, there is activation of the vascular endothelium with expression of leucocyte adhesion molecules (E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1), subsequent recruitment of neutrophils, and monocytes, and secretion of proinflammatory cytokines (TNF-alpha, IL-1, and IL-6) and S100 proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/3/39994/abstract/187\">",
"     187",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Recruitment of cells into synovium'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H28\">",
"     'Macrophages/fibroblasts'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H31\">",
"     'Neutrophils'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29719575\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lack of standard diagnostic criteria for juvenile idiopathic arthritis (JIA, which includes the previous grouping of juvenile rheumatoid arthritis [JRA] or juvenile chronic arthritis [JCA]) has complicated epidemiologic studies, including the determination of incidence and prevalence (",
"      <a class=\"graphic graphic_table graphicRef78901 \" href=\"mobipreview.htm?10/13/10459\">",
"       table 1",
"      </a>",
"      ). JIA appears to be less common in African-American and Asian populations in the United States. In most populations, the female to male ratio ranges from 2:1 to 3:1. However, these ratios depend upon the age at onset and the type of the disease. The peak incidence is one to three years of age, although this varies depending upon gender and type of disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis and etiology of JIA are unclear. As with most autoimmune disorders, interactions among genetic factors, immune mechanisms, and environmental exposures are thought to contribute in most cases. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patterns of inheritance consistent with Mendelian or monogenic inheritance have not been observed in JIA. The level of risk to family members of a proband appears to be only mildly increased in most cases. Multiple HLA loci are associated with the development of JIA, with specific disease subtypes being linked to specific HLA alleles. Patients with early-onset pauciarticular JIA, which has a relatively high concordance among siblings, constitute the subtype with the most distinctive HLA associations. Some genes operative in JIA appear to have a \"window-of-effect\" during which time they may contribute risk of disease, but be neutral or even protective at other times. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Predisposing MHC genes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major clinical manifestation of JIA is persistent joint swelling that results from the combination of synovial fluid accumulation and synovial thickening. Such swelling may cause deformities of affected joints due to stretching of periarticular ligaments and tendons. In addition, enzymes released by inflammatory cells within the synovium or synovial fluid may result in degradation of the collagen and proteoglycan matrix of the articular cartilage. Activation of osteoclasts resulting from the production of cytokines by cells within the mass of inflammatory tissue is probably the final pathway of juxtaarticular bone demineralization and bone erosions. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pathobiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One of the pathologic hallmarks of JIA is the tumor-like expansion of inflamed synovial tissue, or pannus, which causes much of the joint damage. Pannus results from the proliferation of synoviocytes and invasion of the synovial tissue by inflammatory cells, including lymphocytes, macrophages, and dendritic cells, recruited from the peripheral circulation. Infiltration into the synovium depends upon the interplay of vascular factors, cytokines, adhesion molecules, and chemokines. Various inflammatory cells are also found in the synovial fluid. As the disease progresses, pannus spreads over the synovial space and adheres to intraarticular cartilage. It is in the areas of pannus-cartilage junction where the cartilage eventually degrades. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pathobiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8605940\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of David N Glass, who passed away in November 2012. UpToDate wishes to acknowledge his dedicated work on this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/1\">",
"      Towner SR, Michet CJ Jr, O'Fallon WM, Nelson AM. The epidemiology of juvenile arthritis in Rochester, Minnesota 1960-1979. Arthritis Rheum 1983; 26:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/2\">",
"      Peterson LS, Mason T, Nelson AM, et al. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993. Is the epidemiology changing? Arthritis Rheum 1996; 39:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/3\">",
"      Laaksonen AL. A prognostic study of juvenile rheumatoid arthritis. Analysis of 544 cases. Acta Paediatr Scand 1966; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/4\">",
"      Kunnamo I, Kallio P, Pelkonen P. Incidence of arthritis in urban Finnish children. A prospective study. Arthritis Rheum 1986; 29:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/5\">",
"      G&auml;re BA, Fasth A. Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study. Pediatrics 1992; 90:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/6\">",
"      Oen K, Fast M, Postl B. Epidemiology of juvenile rheumatoid arthritis in Manitoba, Canada, 1975-92: cycles in incidence. J Rheumatol 1995; 22:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/7\">",
"      Symmons DP, Jones M, Osborne J, et al. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 1996; 23:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/8\">",
"      Gewanter HL, Baum J. The frequency of juvenile arthritis. J Rheumatol 1989; 16:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/9\">",
"      Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/10\">",
"      Haffejee IE, Raga J, Coovadia HM. Juvenile chronic arthritis in black and Indian South African children. S Afr Med J 1984; 65:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/11\">",
"      Hill R. Juvenile arthritis in various racial groups in British Columbia. Arthritis Rheum 1977; 20:S162 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/12\">",
"      Graham TB, Glass DN. Juvenile rheumatoid arthritis: ethnic differences in diagnostic types. J Rheumatol 1997; 24:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/13\">",
"      Schwartz MM, Simpson P, Kerr KL, Jarvis JN. Juvenile rheumatoid arthritis in African Americans. J Rheumatol 1997; 24:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/14\">",
"      Fujikawa S, Okuni M. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of a nationwide retrospective survey in Japan. Acta Paediatr Jpn 1997; 39:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/15\">",
"      Sullivan DB, Cassidy JT, Petty RE. Pathogenic implications of age of onset in juvenile rheumatoid arthritis. Arthritis Rheum 1975; 18:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/16\">",
"      Schaller JG. Juvenile rheumatoid arthritis: Series 1. Arthritis Rheum 1977; 20:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/17\">",
"      Van Kerckhove C, Balakrishnan K, Levinson JE, et al. HLA and altered sex ratios in juvenile rheumatoid arthritis sibships. Hum Immunol 1988; 22:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/18\">",
"      Schaller J, Kupfer C, Wedgwood RJ. Iridocyclitis in juvenile rheumatoid arthritis. Pediatrics 1969; 44:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/19\">",
"      Cassidy JT, Sullivan DB, Petty RE. Clinical patterns of chronic iridocyclitis in children with juvenile rheumatoid arthritis. Arthritis Rheum 1977; 20:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/20\">",
"      Aaron S, Fraser PA, Jackson JM, et al. Sex ratio and sibship size in juvenile rheumatoid arthritis kindreds. Arthritis Rheum 1985; 28:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/21\">",
"      Rachelefsky GS, Terasaki PI, Katz R, Stiehm ER. Increased prevalence of W27 in juvenile rheumatoid arthritis. N Engl J Med 1974; 290:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/22\">",
"      Schaller JG, Ochs HD, Thomas ED, et al. Histocompatibility antigens in childhood-onset arthritis. J Pediatr 1976; 88:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/23\">",
"      Pritchard MH, Matthews N, Munro J. Antibodies to influenza A in a cluster of children with juvenile chronic arthritis. Br J Rheumatol 1988; 27:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/24\">",
"      Lindsley CB. Seasonal variation in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 1987; 30:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/25\">",
"      Feldman BM, Birdi N, Boone JE, et al. Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J Pediatr 1996; 129:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/26\">",
"      Ansell BM, Bywaters EG, Lawrence JS. Familial aggregation and twin studies in Still's disease. Juvenile chronic polyarthritis. Rheumatology 1969; 2:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/27\">",
"      Rossen RD, Brewer EJ, Sharp RM, et al. Familial rheumatoid arthritis: linkage of HLA to disease susceptibility locus in four families where proband presented with juvenile rheumatoid arthritis. J Clin Invest 1980; 65:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/28\">",
"      Moroldo MB, Tague BL, Shear ES, et al. Juvenile rheumatoid arthritis in affected sibpairs. Arthritis Rheum 1997; 40:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/29\">",
"      Moroldo MB, Chaudhari M, Shear E, et al. Juvenile rheumatoid arthritis affected sibpairs: extent of clinical phenotype concordance. Arthritis Rheum 2004; 50:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/30\">",
"      Clemens LE, Albert E, Ansell BM. Sibling pairs affected by chronic arthritis of childhood: evidence for a genetic predisposition. J Rheumatol 1985; 12:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/31\">",
"      Rudolf MC, Genel M, Tamborlane WV Jr, Dwyer JM. Juvenile rheumatoid arthritis in children with diabetes mellitus. J Pediatr 1981; 99:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/32\">",
"      Firooz A, Mazhar A, Ahmed AR. Prevalence of autoimmune diseases in the family members of patients with pemphigus vulgaris. J Am Acad Dermatol 1994; 31:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/33\">",
"      Nepom BS, Glass DN. Juvenile rheumatoid arthritis and HLA: report of the Park City III workshop. J Rheumatol Suppl 1992; 33:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/34\">",
"      Stastny P, Fink CW. Different HLA-D associations in adult and juvenile rheumatoid arthritis. J Clin Invest 1979; 63:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/35\">",
"      Van Kerckhove C, Melin-Aldana H, Elma MS, et al. A distinct HLA-DRw8 haplotype characterizes patients with juvenile rheumatoid arthritis. Immunogenetics 1990; 32:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/36\">",
"      Glass D, Litvin D, Wallace K, et al. Early-onset pauciarticular juvenile rheumatoid arthritis associated with human leukocyte antigen-DRw5, iritis, and antinuclear antibody. J Clin Invest 1980; 66:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/37\">",
"      Howard JF, Sigsbee A, Glass DN. HLA genetics and inherited predisposition to JRA. J Rheumatol 1985; 12:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/38\">",
"      F&oslash;rre O, Dobloug JH, H&oslash;yeraal HM, Thorsby E. HLA antigens in juvenile arthritis. Genetic basis for the different subtypes. Arthritis Rheum 1983; 26:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/39\">",
"      Reekers P, Schretlen ED, van de Putte LB. Increase of HLA-\"DRw6\" in patients with juvenile chronic arthritis. Tissue Antigens 1983; 22:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/40\">",
"      Hoffman RW, Shaw S, Francis LC, et al. HLA-DP antigens in patients with pauciarticular juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/41\">",
"      Odum N, Morling N, Friis J, et al. Increased frequency of HLA-DPw2 in pauciarticular onset juvenile chronic arthritis. Tissue Antigens 1986; 28:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/42\">",
"      Oen K, Petty RE, Schroeder ML. An association between HLA-A2 and juvenile rheumatoid arthritis in girls. J Rheumatol 1982; 9:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/43\">",
"      Melin-Aldana H, Giannini EH, Taylor J, et al. Human leukocyte antigen-DRB1*1104 in the chronic iridocyclitis of pauciarticular juvenile rheumatoid arthritis. J Pediatr 1992; 121:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/44\">",
"      van Kerckhove C, Luyrink L, Taylor J, et al. HLA-DQA1*0101 haplotypes and disease outcome in early onset pauciarticular juvenile rheumatoid arthritis. J Rheumatol 1991; 18:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/45\">",
"      Ploski R, Vinje O, R&oslash;nningen KS, et al. HLA class II alleles and heterogeneity of juvenile rheumatoid arthritis. DRB1*0101 may define a novel subset of the disease. Arthritis Rheum 1993; 36:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/46\">",
"      Paul C, Schoenwald U, Truckenbrodt H, et al. HLA-DP/DR interaction in early onset pauciarticular juvenile chronic arthritis. Immunogenetics 1993; 37:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/47\">",
"      Hall PJ, Burman SJ, Laurent MR, et al. Genetic susceptibility to early onset pauciarticular juvenile chronic arthritis: a study of HLA and complement markers in 158 British patients. Ann Rheum Dis 1986; 45:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/48\">",
"      Fernandez-Vi&ntilde;a MA, Fink CW, Stastny P. HLA antigens in juvenile arthritis. Pauciarticular and polyarticular juvenile arthritis are immunogenetically distinct. Arthritis Rheum 1990; 33:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/49\">",
"      Nepom BS, Nepom GT, Mickelson E, et al. Specific HLA-DR4-associated histocompatibility molecules characterize patients with seropositive juvenile rheumatoid arthritis. J Clin Invest 1984; 74:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/50\">",
"      Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/51\">",
"      Willkens RF, Nepom GT, Marks CR, et al. Association of HLA-Dw16 with rheumatoid arthritis in Yakima Indians. Further evidence for the \"shared epitope\" hypothesis. Arthritis Rheum 1991; 34:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/52\">",
"      Murray KJ, Moroldo MB, Donnelly P, et al. Age-specific effects of juvenile rheumatoid arthritis-associated HLA alleles. Arthritis Rheum 1999; 42:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/53\">",
"      Grom AA, von Knorre C, Murray KJ, et al. T-cell receptor BV6S1 null alleles and HLA-DR1 haplotypes in polyarticular outcome juvenile rheumatoid arthritis. Hum Immunol 1996; 45:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/54\">",
"      McLaughlin JF, Schaller J, Wedgwood RJ. Arthritis and immunodeficiency. J Pediatr 1972; 81:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/55\">",
"      McDowell TL, Symons JA, Ploski R, et al. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995; 38:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/56\">",
"      Date Y, Seki N, Kamizono S, et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes. Arthritis Rheum 1999; 42:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/57\">",
"      Maksymowych WP, Gabriel CA, Luyrink L, et al. Polymorphism in a T-cell receptor variable gene is associated with susceptibility to a juvenile rheumatoid arthritis subset. Immunogenetics 1992; 35:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/58\">",
"      Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/59\">",
"      Crawley E, Kay R, Sillibourne J, et al. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999; 42:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/60\">",
"      Sullivan KE, McDonald-McGinn DM, Driscoll DA, et al. Juvenile rheumatoid arthritis-like polyarthritis in chromosome 22q11.2 deletion syndrome (DiGeorge anomalad/velocardiofacial syndrome/conotruncal anomaly face syndrome). Arthritis Rheum 1997; 40:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/61\">",
"      Donn RP, Davies EJ, Holt PL, et al. Increased frequency of TAP2B in early onset pauciarticular juvenile chronic arthritis. Ann Rheum Dis 1994; 53:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/62\">",
"      Pryhuber KG, Murray KJ, Donnelly P, et al. Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis. J Rheumatol 1996; 23:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/63\">",
"      Donn RP, Shelley E, Ollier WE, et al. A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001; 44:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/64\">",
"      Donn R, Alourfi Z, De Benedetti F, et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/65\">",
"      Zeggini E, Thomson W, Kwiatkowski D, et al. Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis. Arthritis Rheum 2002; 46:3304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/66\">",
"      Hinks A, Barton A, John S, et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum 2005; 52:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/67\">",
"      Rosen P, Thompson S, Glass D. Non-HLA gene polymorphisms in juvenile rheumatoid arthritis. Clin Exp Rheumatol 2003; 21:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/68\">",
"      Ogilvie EM, Fife MS, Thompson SD, et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 2003; 48:3202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/69\">",
"      Smerdel A, Lie BA, Ploski R, et al. A gene in the telomeric HLA complex distinct from HLA-A is involved in predisposition to juvenile idiopathic arthritis. Arthritis Rheum 2002; 46:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/70\">",
"      Thompson SD, Moroldo MB, Guyer L, et al. A genome-wide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage. Arthritis Rheum 2004; 50:2920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/71\">",
"      Hinks A, Cobb J, Sudman M, et al. Investigation of rheumatoid arthritis susceptibility loci in juvenile idiopathic arthritis confirms high degree of overlap. Ann Rheum Dis 2012; 71:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/72\">",
"      Thompson SD, Marion MC, Sudman M, et al. Genome-wide association analysis of juvenile idiopathic arthritis identifies a new susceptibility locus at chromosomal region 3q13. Arthritis Rheum 2012; 64:2781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/73\">",
"      Murray K, Thompson SD, Glass DN. Pathogenesis of juvenile chronic arthritis: genetic and environmental factors. Arch Dis Child 1997; 77:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/74\">",
"      Ellis JA, Munro JE, Ponsonby AL. Possible environmental determinants of juvenile idiopathic arthritis. Rheumatology (Oxford) 2010; 49:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/75\">",
"      Inman RD. The role of infection in chronic arthritis. J Rheumatol Suppl 1992; 33:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/76\">",
"      Ogra PL, Chiba Y, Ogra SS, et al. Rubella-virus infection in juvenile rheumatoid arthritis. Lancet 1975; 1:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/77\">",
"      Chantler JK, Tingle AJ, Petty RE. Persistent rubella virus infection associated with chronic arthritis in children. N Engl J Med 1985; 313:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/78\">",
"      Albani S. Infection and molecular mimicry in autoimmune diseases of childhood. Clin Exp Rheumatol 1994; 12 Suppl 10:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/79\">",
"      Massa M, Mazzoli F, Pignatti P, et al. Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum 2002; 46:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/80\">",
"      Maximov AA, Shaikov AV, Lovell DJ, et al. Chlamydial associated syndrome of arthritis and eye involvement in young children. J Rheumatol 1992; 19:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/81\">",
"      Lehmann HW, Kn&ouml;ll A, K&uuml;ster RM, Modrow S. Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood. Arthritis Rheum 2003; 48:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/82\">",
"      Sieper J, Braun J, D&ouml;ring E, et al. Aetiological role of bacteria associated with reactive arthritis in pauciarticular juvenile chronic arthritis. Ann Rheum Dis 1992; 51:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/83\">",
"      Life P, Hassell A, Williams K, et al. Responses to gram negative enteric bacterial antigens by synovial T cells from patients with juvenile chronic arthritis: recognition of heat shock protein HSP60. J Rheumatol 1993; 20:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/84\">",
"      F&oslash;rre O, Dobloug JH, Natvig JB. Augmented numbers of HLA-DR-positive T lymphocytes in the synovial fluid and synovial tissue of patients with rheumatoid arthritis and juvenile rheumatoid arthritis: in vivo-activated T lymphocytes are potent stimulators in the mixed lymphocyte reaction. Scand J Immunol 1982; 15:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/85\">",
"      Eberhard BA, Laxer RM, Andersson U, Silverman ED. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol 1994; 96:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/86\">",
"      Wynne-Roberts CR, Anderson CH, Turano AM, Baron M. Light- and electron-microscopic findings of juvenile rheumatoid arthritis synovium: comparison with normal juvenile synovium. Semin Arthritis Rheum 1978; 7:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/87\">",
"      Wynne-Roberts CR, Anderson C. Light- and electron-microscopic studies of normal juvenile human synovium. Semin Arthritis Rheum 1978; 7:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/88\">",
"      Ziff M. Role of the endothelium in chronic inflammatory synovitis. Arthritis Rheum 1991; 34:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/89\">",
"      Scola MP, Imagawa T, Boivin GP, et al. Expression of angiogenic factors in juvenile rheumatoid arthritis: correlation with revascularization of human synovium engrafted into SCID mice. Arthritis Rheum 2001; 44:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/90\">",
"      Maeno N, Takei S, Imanaka H, et al. Increased circulating vascular endothelial growth factor is correlated with disease activity in polyarticular juvenile rheumatoid arthritis. J Rheumatol 1999; 26:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/91\">",
"      Bosco MC, Delfino S, Ferlito F, et al. The hypoxic synovial environment regulates expression of vascular endothelial growth factor and osteopontin in juvenile idiopathic arthritis. J Rheumatol 2009; 36:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/92\">",
"      Finnegan S, Clarke S, Gibson D, et al. Synovial membrane immunohistology in early untreated juvenile idiopathic arthritis: differences between clinical subgroups. Ann Rheum Dis 2011; 70:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/93\">",
"      Klareskog L, Forsum U, Scheynius A, et al. Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci U S A 1982; 79:3632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/94\">",
"      Murray KJ, Luyrink L, Grom AA, et al. Immunohistological characteristics of T cell infiltrates in different forms of childhood onset chronic arthritis. J Rheumatol 1996; 23:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/95\">",
"      Lindblad S, Klareskog L, Hedfors E, et al. Phenotypic characterization of synovial tissue cells in situ in different types of synovitis. Arthritis Rheum 1983; 26:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/96\">",
"      Nunez G, Ball EJ, Stastny P. Antigen presentation by adherent cells from human peripheral blood. Correlation between T-cell activation and expression of HLA-DQ and -DR antigens. Hum Immunol 1987; 19:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/97\">",
"      Harding B, Knight SC. The distribution of dendritic cells in the synovial fluids of patients with arthritis. Clin Exp Immunol 1986; 63:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/98\">",
"      Bergroth V, Konttinen YT, Pelkonen P, et al. Synovial fluid lymphocytes in different subtypes of juvenile rheumatoid arthritis. Arthritis Rheum 1988; 31:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/99\">",
"      Jalkanen S, Steere AC, Fox RI, Butcher EC. A distinct endothelial cell recognition system that controls lymphocyte traffic into inflamed synovium. Science 1986; 233:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/100\">",
"      Oen K, Danell G, Stewart S, et al. Adhesion of peripheral blood lymphocytes of children with arthritis to human umbilical vein endothelial cells. Clin Exp Immunol 1994; 95:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/101\">",
"      Grom AA, Murray KJ, Luyrink L, et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/102\">",
"      Oppenheimer-Marks N, Brezinschek RI, Mohamadzadeh M, et al. Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells In vitro and in the SCID mouse-human rheumatoid arthritis model In vivo. J Clin Invest 1998; 101:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/103\">",
"      Scola MP, Thompson SD, Brunner HI, et al. Interferon-gamma:interleukin 4 ratios and associated type 1 cytokine expression in juvenile rheumatoid arthritis synovial tissue. J Rheumatol 2002; 29:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/104\">",
"      Meazza C, Travaglino P, Pignatti P, et al. Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/105\">",
"      De Benedetti F, Meazza C, Vivarelli M, et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003; 48:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/106\">",
"      Donn R, Alourfi Z, Zeggini E, et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 2004; 50:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/107\">",
"      Odum N, Morling N, Platz P, et al. Increased prevalence of late stage T cell activation antigen (VLA-1) in active juvenile chronic arthritis. Ann Rheum Dis 1987; 46:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/108\">",
"      Wedderburn LR, Woo P. Type 1 and type 2 immune responses in children: their relevance in juvenile arthritis. Springer Semin Immunopathol 1999; 21:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/109\">",
"      Issekutz AC, Quinn PJ, Lang B, et al. Coexpression of chemokine receptors CCR5, CXCR3, and CCR4 and ligands for P- and E-selectin on T lymphocytes of patients with juvenile idiopathic arthritis. Arthritis Rheum 2011; 63:3467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/110\">",
"      De Maria A, Malnati M, Moretta A, et al. CD3+4-8-WT31-(T cell receptor gamma+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysis. Eur J Immunol 1987; 17:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/111\">",
"      F&oslash;rre O, Thoen J, Dobloug JH, et al. Detection of T-lymphocyte subpopulation in the peripheral blood and the synovium of patients with rheumatoid arthritis and juvenile rheumatoid arthritis using monoclonal antibodies. Scand J Immunol 1982; 15:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/112\">",
"      Haufe S, Haug M, Schepp C, et al. Impaired suppression of synovial fluid CD4+CD25- T cells from patients with juvenile idiopathic arthritis by CD4+CD25+ Treg cells. Arthritis Rheum 2011; 63:3153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/113\">",
"      Gold DP, Offner H, Sun D, et al. Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3. J Exp Med 1991; 174:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/114\">",
"      Sioud M, Kjeldsen-Kragh J, Suleyman S, et al. Limited heterogeneity of T cell receptor variable region gene usage in juvenile rheumatoid arthritis synovial T cells. Eur J Immunol 1992; 22:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/115\">",
"      Grom AA, Thompson SD, Luyrink L, et al. Dominant T-cell-receptor beta chain variable region V beta 14+ clones in juvenile rheumatoid arthritis. Proc Natl Acad Sci U S A 1993; 90:11104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/116\">",
"      Thompson SD, Grom AA, Bailey S, et al. Patterns of T lymphocyte clonal expansion in HLA-typed patients with juvenile rheumatoid arthritis. J Rheumatol 1995; 22:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/117\">",
"      Wedderburn LR, Maini MK, Patel A, et al. Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood. Int Immunol 1999; 11:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/118\">",
"      Hingorani R, Choi IH, Akolkar P, et al. Clonal predominance of T cell receptors within the CD8+ CD45RO+ subset in normal human subjects. J Immunol 1993; 151:5762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/119\">",
"      Thompson SD, Murray KJ, Grom AA, et al. Comparative sequence analysis of the human T cell receptor beta chain in juvenile rheumatoid arthritis and juvenile spondylarthropathies: evidence for antigenic selection of T cells in the synovium. Arthritis Rheum 1998; 41:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/120\">",
"      Sioud M, F&oslash;rre O, Natvig JB. T cell receptor delta diversity of freshly isolated T lymphocytes in rheumatoid synovitis. Eur J Immunol 1991; 21:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/121\">",
"      Kjeldsen-Kragh J, Quayle A, Kalvenes C, et al. T gamma delta cells in juvenile rheumatoid arthritis and rheumatoid arthritis. In the juvenile rheumatoid arthritis synovium the T gamma delta cells express activation antigens and are predominantly V delta 1+, and a significant proportion of these patients have elevated percentages of T gamma delta cells. Scand J Immunol 1990; 32:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/122\">",
"      Shen Y, Li S, Quayle AJ, et al. TCR gamma/delta+ cell subsets in the synovial membranes of patients with rheumatoid arthritis and juvenile rheumatoid arthritis. Scand J Immunol 1992; 36:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/123\">",
"      Kjeldsen-Kragh J, Quayle AJ, Vinje O, et al. A high proportion of the V delta 1+ synovial fluid gamma delta T cells in juvenile rheumatoid arthritis patients express the very early activation marker CD69, but carry the high molecular weight isoform of the leucocyte common antigen (CD45RA). Clin Exp Immunol 1993; 91:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/124\">",
"      Born WK, O'Brien RL, Modlin RL. Antigen specificity of gamma delta T lymphocytes. FASEB J 1991; 5:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/125\">",
"      S&ouml;derstr&ouml;m K, Halapi E, Nilsson E, et al. Synovial cells responding to a 65-kDa mycobacterial heat shock protein have a high proportion of a TcR gamma delta subtype uncommon in peripheral blood. Scand J Immunol 1990; 32:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/126\">",
"      De Graeff-Meeder ER, van der Zee R, Rijkers GT, et al. Recognition of human 60 kD heat shock protein by mononuclear cells from patients with juvenile chronic arthritis. Lancet 1991; 337:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/127\">",
"      Gaston JS. Heat shock proteins and arthritis--new readers start here. Autoimmunity 1997; 26:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/128\">",
"      Quayle AJ, Chomarat P, Miossec P, et al. Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0-like) cytokine patterns. Scand J Immunol 1993; 38:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/129\">",
"      de Kleer IM, Kamphuis SM, Rijkers GT, et al. The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. Arthritis Rheum 2003; 48:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/130\">",
"      de Kleer IM, Wedderburn LR, Taams LS, et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004; 172:6435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/131\">",
"      de Graeff-Meeder ER, van Eden W, Rijkers GT, et al. Juvenile chronic arthritis: T cell reactivity to human HSP60 in patients with a favorable course of arthritis. J Clin Invest 1995; 95:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/132\">",
"      Prakken AB, van Eden W, Rijkers GT, et al. Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. Arthritis Rheum 1996; 39:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/133\">",
"      Kamphuis S, Kuis W, de Jager W, et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 2005; 366:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/134\">",
"      Lehman TJ. Juvenile idiopathic arthritis and HSP60 vaccination: selective down-regulation? Lancet 2005; 366:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/135\">",
"      Murray KJ, Grom AA, Thompson SD, et al. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 1998; 25:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/136\">",
"      Gattorno M, Facchetti P, Ghiotto F, et al. Synovial fluid T cell clones from oligoarticular juvenile arthritis patients display a prevalent Th1/Th0-type pattern of cytokine secretion irrespective of immunophenotype. Clin Exp Immunol 1997; 109:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/137\">",
"      Hunter PJ, Nistala K, Jina N, et al. Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis Rheum 2010; 62:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/138\">",
"      Patel A, Varsani H, Wederburn LR. The hyporesponsiveness of synovial T cells in juvenile idiopathic arthritis is a property of CD4+CD25+ T cells: evidence for regulatory T cells in juvenile arthritis. Rheumatology (Oxford) 2003; 42:S11 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/139\">",
"      Wedderburn LR, Robinson N, Patel A, et al. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 2000; 43:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/140\">",
"      Thompson SD, Luyrink L, Passo MH, et al. Comparison of the beta-chemokine receptors CCR4 and CCR5 expression on T-cells in paired synovial fluid and peripheral blood from juvenile rheumatopid arthritis patients. Arthritis Rheum 1999; 42:S185 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/141\">",
"      Thompson SD, Luyrink LK, Graham TB, et al. Chemokine receptor CCR4 on CD4+ T cells in juvenile rheumatoid arthritis synovial fluid defines a subset of cells with increased IL-4:IFN-gamma mRNA ratios. J Immunol 2001; 166:6899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/142\">",
"      Scola MP, Thompson SD, Tsoras M, et al. JRA synovial tissues: Abundance of macrophage products including IL-15 and the chemokines MCP-1, IL-8, and MIP-1alpha. Arthritis Rheum 1999; 42:S394 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/143\">",
"      Nistala K, Moncrieffe H, Newton KR, et al. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008; 58:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/144\">",
"      Omoyinmi E, Hamaoui R, Pesenacker A, et al. Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2012; 51:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/145\">",
"      Dobloug JH, F&oslash;rre O, Kvien TK, et al. Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis. Ann Rheum Dis 1982; 41:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/146\">",
"      Villanueva J, Lee S, Giannini EH, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7:R30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/147\">",
"      Martini A, Ravelli A, Notarangelo LD, et al. Enhanced interleukin 1 and depressed interleukin 2 production in juvenile arthritis. J Rheumatol 1986; 13:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/148\">",
"      de Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/149\">",
"      Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/150\">",
"      Maeno N, Takei S, Nomura Y, et al. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum 2002; 46:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/151\">",
"      Muzaffer MA, Dayer JM, Feldman BM, et al. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. J Rheumatol 2002; 29:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/152\">",
"      Beutler B. TNF, immunity and inflammatory disease: lessons of the past decade. J Investig Med 1995; 43:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/153\">",
"      Jarvis JN, Jiang K, Frank MB, et al. Gene expression profiling in neutrophils from children with polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2009; 60:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/154\">",
"      Frosch M, Vogl T, Seeliger S, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2003; 48:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/155\">",
"      Foell D, Wittkowski H, Hammerschmidt I, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 2004; 50:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/156\">",
"      Tsokos GC, Mavridis A, Inghirami G, et al. Cellular immunity in patients with systemic juvenile rheumatoid arthritis. Clin Immunol Immunopathol 1987; 42:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/157\">",
"      Tsokos GC, Inghirami G, Pillemer SR, et al. Immunoregulatory aberrations in patients with polyarticular juvenile rheumatoid arthritis. Clin Immunol Immunopathol 1988; 47:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/158\">",
"      Morbach H, Wiegering V, Richl P, et al. Activated memory B cells may function as antigen-presenting cells in the joints of children with juvenile idiopathic arthritis. Arthritis Rheum 2011; 63:3458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/159\">",
"      Barnes MG, Grom AA, Thompson SD, et al. Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum 2010; 62:3249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/160\">",
"      Lipnick RN, Tsokos GC. Immune abnormalities in the pathogenesis of juvenile rheumatoid arthritis. Clin Exp Rheumatol 1990; 8:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/161\">",
"      Cassidy JT, Petty RE, Sullivan DB. Abnormalities in the distribution of serum immunoglobulin concentrations in juvenile rheumatoid arthritis. J Clin Invest 1973; 52:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/162\">",
"      Pelkonen P, Savilahti E, M&auml;kel&auml; AL. Persistent and transient IgA deficiency in juvenile rheumatoid arthritis. Scand J Rheumatol 1983; 12:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/163\">",
"      Allen JC, Kunkel HG. Hidden rheumatoid factors with specificity for native gammaglobulins. Arthritis Rheum 1966; 9:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/164\">",
"      Moore T, Dorner RW, Zuckner J. Hidden rheumatoid factor in seronegative juvenile rheumatoid arthritis. Ann Rheum Dis 1974; 33:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/165\">",
"      Moore TL, Zuckner J, Baldassare AR, et al. Complement-fixing hidden rheumatoid factor in juvenile rheumatoid arthritis. Arthritis Rheum 1978; 21:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/166\">",
"      Schaller JG, Johnson GD, Holborow EJ, et al. The association of antinuclear antibodies with the chronic iridocyclitis of juvenile rheumatoid arthritis (Still's disease). Arthritis Rheum 1974; 17:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/167\">",
"      Leak AM, Ansell BM, Burman SJ. Antinuclear antibody studies in juvenile chronic arthritis. Arch Dis Child 1986; 61:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/168\">",
"      Rahi AH, Kanski JJ, Fielder A. Immunoglobulins and antinuclear antibodies in aqueous humour from patients with juvenile \"rheumatoid\" arthritis (Still's disease). Trans Ophthalmol Soc U K 1977; 97:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/169\">",
"      Saulsbury FT. Antibody to ribonucleoprotein in pauciarticular juvenile rheumatoid arthritis. J Rheumatol 1988; 15:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/170\">",
"      Szer W, Sierakowska H, Szer IS. Antinuclear antibody profile in juvenile rheumatoid arthritis. J Rheumatol 1991; 18:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/171\">",
"      Murray KJ, Szer W, Grom AA, et al. Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoid arthritis and iridocyclitis: selective association with MHC gene. J Rheumatol 1997; 24:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/172\">",
"      Dong X, Wang J, Kabir FN, et al. Autoantibodies to DEK oncoprotein in human inflammatory disease. Arthritis Rheum 2000; 43:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/173\">",
"      Rosenberg AM, Hunt DW, Petty RE. Antibodies to native and denatured type II collagen in children with rheumatic diseases. J Rheumatol 1984; 11:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/174\">",
"      Godfrey WA, Lindsley CB, Cuppage FE. Localization of IgM in plasma cells in the iris of a patient with iridocyclitis and juvenile rheumatoid arthritis. Arthritis Rheum 1981; 24:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/175\">",
"      Petty RE, Hunt DW, Rollins DF, et al. Immunity to soluble retinal antigen in patients with uveitis accompanying juvenile rheumatoid arthritis. Arthritis Rheum 1987; 30:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/176\">",
"      Uchiyama RC, Osborn TG, Moore TL. Antibodies to iris and retina detected in sera from patients with juvenile rheumatoid arthritis with iridocyclitis by indirect immunofluorescence studies on human eye tissue. J Rheumatol 1989; 16:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/177\">",
"      Borel Y, Morimoto C, Cairns L, et al. Anti-T cell antibody in juvenile rheumatoid arthritis. J Rheumatol 1984; 11:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/178\">",
"      Strelkauskas AJ, Schauf V, Wilson BS, et al. Isolation and characterization of naturally occurring subclasses of human peripheral blood T cells with regulatory functions. J Immunol 1978; 120:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/179\">",
"      Barron KS, Lewis DE, Brewer EJ, et al. Cytotoxic anti-T cell antibodies in children with juvenile rheumatoid arthritis. Arthritis Rheum 1984; 27:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/180\">",
"      Rossen RD, Brewer EJ, Person DA, et al. Circulating immune complexes and antinuclear antibodies in juvenile rheumatoid arthritis. Arthritis Rheum 1977; 20:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/181\">",
"      Balogh Z, Mer&eacute;tey K, Falus A, Bozs&oacute;ky S. Serological abnormalities in juvenile chronic arthritis: a review of 46 cases. Ann Rheum Dis 1980; 39:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/182\">",
"      Moore TL, Sheridan PW, Traycoff RB, et al. Immune complexes in juvenile rheumatoid arthritis: a comparison of four methods. J Rheumatol 1982; 9:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/183\">",
"      Miller JJ 3rd, Olds LC, Huene DB. Complement activation products and factors influencing phagocyte migration in synovial fluids from children with chronic arthritis. Clin Exp Rheumatol 1986; 4:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/184\">",
"      Miller JJ 3rd, Hsu YP, Moss R, et al. The immunologic and clinical associations of the split products of C3 in plasma in juvenile rheumatoid arthritis. Arthritis Rheum 1979; 22:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/185\">",
"      Miller JJ 3rd, Olds LC, Silverman ED, et al. Different patterns of C3 and C4 activation in the varied types of juvenile arthritis. Pediatr Res 1986; 20:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/186\">",
"      Mollnes TE, Paus A. Complement activation in synovial fluid and tissue from patients with juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/3/39994/abstract/187\">",
"      Frosch M, Roth J. New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment. Rheumatology (Oxford) 2008; 47:121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6429 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39994=[""].join("\n");
var outline_f39_3_39994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29719575\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4186997\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overall incidence and prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Age of onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gender differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Secular and seasonal variations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Familial predisposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Predisposing MHC genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Early-onset pauciarticular JIA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other types",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - HLA-DR1/DR4 shared epitope hypothesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Age-specific effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Predisposing non-HLA genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PATHOBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Synovial fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Synovial tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cellular infiltrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Recruitment of cells into synovium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Vascular factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cytokines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Adhesion molecules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      T cell contribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Gamma-delta-T cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6118351\">",
"      - HSP-related T-cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - T cell derived cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Natural killer cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Macrophages/fibroblasts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Role of TNF-alpha",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Macrophage activation syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Neutrophils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      B cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Rheumatoid factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Immune complexes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Complement activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Systemic onset JIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29719575\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8605940\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6429\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6429|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/6/35950\" title=\"figure 1\">",
"      HLA-DR4 prevalence by age JRA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6429|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/13/10459\" title=\"table 1\">",
"      Incidence childhood arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/59/35772\" title=\"table 2\">",
"      Polygenic risk in JIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/13/42203\" title=\"table 3\">",
"      Non-MHC genes and JIA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35717?source=related_link\">",
"      Classification of juvenile arthritis (JRA/JIA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42648?source=related_link\">",
"      Origin and utility of measurement of rheumatoid factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3754?source=related_link\">",
"      Synovial pathology in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/23/39285?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Course, prognosis, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5274?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=related_link\">",
"      T cell receptor genetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_3_39995="Water contaminants in HD";
var content_f39_3_39995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Water contaminants and resulting symptoms among hemodialysis patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Contaminant",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms of toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aluminum",
"       </td>",
"       <td>",
"        Neurological deterioration, encephalopathy, bone disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteria and endotoxin",
"       </td>",
"       <td>",
"        Pyrogenic reaction, such as hypotension, fever, nausea and vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium",
"       </td>",
"       <td>",
"        Nausea and vomiting, muscle weakness, hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloramine",
"       </td>",
"       <td>",
"        Hemolysis, anemia, methemoglobinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copper",
"       </td>",
"       <td>",
"        Nausea, chills, hemolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoride",
"       </td>",
"       <td>",
"        Bone disease (chronic exposure); pruritus, chest pain, nausea, cardiac arrest (acute exposure to high concentrations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead",
"       </td>",
"       <td>",
"        Abdominal pain, muscle weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium",
"       </td>",
"       <td>",
"        Nausea and vomiting, muscle weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrates",
"       </td>",
"       <td>",
"        Nausea and vomiting, hypotension, methemoglobinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium",
"       </td>",
"       <td>",
"        Hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfate",
"       </td>",
"       <td>",
"        Nausea and vomiting, metabolic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc",
"       </td>",
"       <td>",
"        Anemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39995=[""].join("\n");
var outline_f39_3_39995=null;
var title_f39_3_39996="Bacteria sepsis term infant";
var content_f39_3_39996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common bacterial agents causing neonatal sepsis in term infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"70%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"15%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Bacterial species",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Frequency of isolation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Early-onset",
"       </td>",
"       <td class=\"subtitle2\">",
"        Late-onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group B",
"        <em>",
"         Streptococcus",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Escherichia coli",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"       <td class=\"centered\">",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Klebsiella",
"        </em>",
"        spp.",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Enterobacter",
"        </em>",
"        spp.",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Listeria monocytogenes",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other enteric gram-negatives",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-enteric gram-negatives*",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viridans streptococci",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Citrobacter",
"        </em>",
"        spp.",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Salmonella",
"        </em>",
"        spp.",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulase-negative staphylococci",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Enterococcus",
"        </em>",
"        spp.",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    +++: commonly associated; ++: frequently associated; +: occasionally associated; 0: rarely associated.",
"    <div class=\"footnotes\">",
"     * Includes nontypable",
"     <em>",
"      Hemophilus influenzae",
"     </em>",
"     and",
"     <em>",
"      Neisseria meningitidis",
"     </em>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Edwards MS, Baker CJ. Bacterial infections in the neonate. In: Principles and Practice of Pediatric Infectious Disease, 4th ed, Long SS, Pickering LK, Prober CG. Elsevier Saunders, Philadelphia 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39996=[""].join("\n");
var outline_f39_3_39996=null;
var title_f39_3_39997="Viral gastroenteritis sxs";
var content_f39_3_39997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effect of age and presenting symptoms upon rate of detected rotavirus excretion among hospitalized children, during one year of study",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Presenting symptoms*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"10\" rowspan=\"1\">",
"        Percent&bull;",
"rotavirus-positive in age group, months (number tested)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Total number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        0-2",
"       </td>",
"       <td class=\"subtitle2\">",
"        3-5",
"       </td>",
"       <td class=\"subtitle2\">",
"        6-8",
"       </td>",
"       <td class=\"subtitle2\">",
"        9-11",
"       </td>",
"       <td class=\"subtitle2\">",
"        12-17",
"       </td>",
"       <td class=\"subtitle2\">",
"        18-23",
"       </td>",
"       <td class=\"subtitle2\">",
"        24-35",
"       </td>",
"       <td class=\"subtitle2\">",
"        36-47",
"       </td>",
"       <td class=\"subtitle2\">",
"        48-60",
"       </td>",
"       <td class=\"subtitle2\">",
"        All",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D V F",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        296",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D V",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        138",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D F",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        177",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V F",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        F",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        236",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All",
"       </td>",
"       <td>",
"        11 (395)",
"       </td>",
"       <td>",
"        16 (113)",
"       </td>",
"       <td>",
"        25 (97)",
"       </td>",
"       <td>",
"        41 (93)",
"       </td>",
"       <td>",
"        40 (132)",
"       </td>",
"       <td>",
"        40 (62)",
"       </td>",
"       <td>",
"        33 (96)",
"       </td>",
"       <td>",
"        26 (49)",
"       </td>",
"       <td>",
"        19 (26)",
"       </td>",
"       <td>",
"        24 (1063)",
"       </td>",
"       <td>",
"        1063",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any diarrhea&Delta;",
"       </td>",
"       <td>",
"        14 (196)",
"       </td>",
"       <td>",
"        23 (79)",
"       </td>",
"       <td>",
"        31 (75)",
"       </td>",
"       <td>",
"        51 (72)",
"       </td>",
"       <td>",
"        48 (105)",
"       </td>",
"       <td>",
"        53 (47)",
"       </td>",
"       <td>",
"        45 (62)",
"       </td>",
"       <td>",
"        33 (33)",
"       </td>",
"       <td>",
"        25 (16)",
"       </td>",
"       <td>",
"        33 (685)",
"       </td>",
"       <td>",
"        685",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any vomiting&Delta;",
"       </td>",
"       <td>",
"        16 (143)",
"       </td>",
"       <td>",
"        22 (55)",
"       </td>",
"       <td>",
"        43 (47)",
"       </td>",
"       <td>",
"        58 (64)",
"       </td>",
"       <td>",
"        56 (88)",
"       </td>",
"       <td>",
"        54 (46)",
"       </td>",
"       <td>",
"        39 (75)",
"       </td>",
"       <td>",
"        32 (37)",
"       </td>",
"       <td>",
"        24 (21)",
"       </td>",
"       <td>",
"        37 (576)",
"       </td>",
"       <td>",
"        576",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any fever&Delta;",
"       </td>",
"       <td>",
"        10 (327)",
"       </td>",
"       <td>",
"        19 (79)",
"       </td>",
"       <td>",
"        26 (65)",
"       </td>",
"       <td>",
"        46 (69)",
"       </td>",
"       <td>",
"        45 (94)",
"       </td>",
"       <td>",
"        43 (47)",
"       </td>",
"       <td>",
"        39 (66)",
"       </td>",
"       <td>",
"        24 (33)",
"       </td>",
"       <td>",
"        19 (16)",
"       </td>",
"       <td>",
"        25 (796)",
"       </td>",
"       <td>",
"        796",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * D: diarrhea; V: vomiting; F: fever.",
"     <br>",
"      &bull; Variability of trends within a row or column in part represents effect of small cell numbers.",
"      <br>",
"       &Delta; Symptom alone or in any combination of the three presenting symptoms.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39997=[""].join("\n");
var outline_f39_3_39997=null;
var title_f39_3_39998="Boutonniere finger PI";
var content_f39_3_39998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Boutonniere deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A &ldquo;boutonniere deformity&rdquo; is a finger injury that makes the finger joint nearest the finger tip stay straight, and the finger joint in the middle of the finger stay bent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39998=[""].join("\n");
var outline_f39_3_39998=null;
var title_f39_3_39999="Cervical osteoarthritis xray";
var content_f39_3_39999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical osteoarthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 337px; height: 524px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a lateral x-ray from a 77-year-old who complained of neck stiffness. He denied radicular symptoms or loss of strength in the upper extremities. Neck rotation measured 60 to 65 degrees (30 percent loss) with end point stiffness. The Spurling maneuver was normal as was the neurologic examination. The lateral film demonstrates osteoarthritis. There is exaggerated cervical lordosis and the disk spaces are uniformly narrowed and irregular. The facet joints are hypertrophic, sclerotic, but without ankylosis. The posterior aspects of the vertebral bodies are hypertrophic and sclerotic. These are the joints of Luschka, unique to the cervical vertebrae. Bony osteophytes at the joints of Luschka are responsible for the foraminal encroachment of cervical radiculopathy caused by osteoarthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_3_39999=[""].join("\n");
var outline_f39_3_39999=null;
